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A B S T R A C T
Background
Gestational diabetes (GDM) is glucose intolerance, first recognised in pregnancy and usually resolving after birth. GDM is associated
with both short- and long-term adverse effects for themother and her infant. Lifestyle interventions are the primary therapeutic strategy
for many women with GDM.
Objectives
To evaluate the effects of combined lifestyle interventions with or without pharmacotherapy in treating women with gestational diabetes.
Search methods
We searched the Pregnancy and Childbirth Group’s Trials Register (14 May 2016), ClinicalTrials.gov, WHO International Clinical
Trials Registry Platform (ICTRP) (14th May 2016) and reference lists of retrieved studies.
Selection criteria
We included only randomised controlled trials comparing a lifestyle intervention with usual care or another intervention for the
treatment of pregnant women with GDM. Quasi-randomised trials were excluded. Cross-over trials were not eligible for inclusion.
Women with pre-existing type 1 or type 2 diabetes were excluded.
Data collection and analysis
We used standard methodological procedures expected by the Cochrane Collaboration. All selection of studies, data extraction was
conducted independently by two review authors.
Main results
Fifteen trials (in 45 reports) are included in this review (4501 women, 3768 infants). None of the trials were funded by a conditional
grant from a pharmaceutical company. The lifestyle interventions included a wide variety of components such as education, diet, exercise
and self-monitoring of blood glucose. The control group included usual antenatal care or diet alone. Using GRADE methodology, the
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quality of the evidence ranged from high to very low quality. The main reasons for downgrading evidence were inconsistency and risk
of bias. We summarised the following data from the important outcomes of this review.
Lifestyle intervention versus control group
For the mother:
There was no clear evidence of a difference between lifestyle intervention and control groups for the risk of hypertensive disorders
of pregnancy (pre-eclampsia) (average risk ratio (RR) 0.70; 95% confidence interval (CI) 0.40 to 1.22; four trials, 2796 women; I
2 = 79%, Tau2 = 0.23; low-quality evidence); caesarean section (average RR 0.90; 95% CI 0.78 to 1.05; 10 trials, 3545 women; I2 =
48%, Tau2 = 0.02; low-quality evidence); development of type 2 diabetes(up to a maximum of 10 years follow-up) (RR 0.98, 95%
CI 0.54 to 1.76; two trials, 486 women; I2 = 16%; low-quality evidence); perineal trauma/tearing (RR 1.04, 95% CI 0.93 to 1.18;
one trial, n = 1000 women; moderate-quality evidence) or induction of labour (average RR 1.20, 95% CI 0.99 to 1.46; four trials, n =
2699 women; I2 = 37%; high-quality evidence).
More women in the lifestyle intervention group hadmet postpartum weight goals one year after birth than in the control group (RR
1.75, 95% CI 1.05 to 2.90; 156 women; one trial, low-quality evidence). Lifestyle interventions were associated with a decrease in the
risk of postnatal depression compared with the control group (RR 0.49, 95% CI 0.31 to 0.78; one trial, n = 573 women; low-quality
evidence).
For the infant/child/adult:
Lifestyle interventions were associated with a reduction in the risk of being born large-for-gestational age (LGA) (RR 0.60, 95% CI
0.50 to 0.71; six trials, 2994 infants; I2 = 4%; moderate-quality evidence). Birthweight and the incidence of macrosomia were lower in
the lifestyle intervention group.
Exposure to the lifestyle interventionwas associatedwith decreasedneonatal fatmass comparedwith the control group (mean difference
(MD) -37.30 g, 95% CI -63.97 to -10.63; one trial, 958 infants; low-quality evidence). In childhood, there was no clear evidence of a
difference between groups for body mass index (BMI) ≥ 85th percentile (RR 0.91, 95% CI 0.75 to 1.11; three trials, 767 children; I
2 = 4%; moderate-quality evidence).
There was no clear evidence of a difference between lifestyle intervention and control groups for the risk of perinatal death (RR 0.09,
95% CI 0.01 to 1.70; two trials, 1988 infants; low-quality evidence). Of 1988 infants, only five events were reported in total in the
control group and there were no events in the lifestyle group. There was no clear evidence of a difference between lifestyle intervention
and control groups for a composite of serious infant outcome/s (average RR 0.57, 95% CI 0.21 to 1.55; two trials, 1930 infants; I
2 = 82%, Tau2 = 0.44; very low-quality evidence) or neonatal hypoglycaemia (average RR 0.99, 95% CI 0.65 to 1.52; six trials, 3000
infants; I2 = 48%, Tau2 = 0.12; moderate-quality evidence).
Diabetes and adiposity in adulthood and neurosensory disability in later childhoodwere not prespecified or reported as outcomes
for any of the trials included in this review.
Authors’ conclusions
Lifestyle interventions are the primary therapeutic strategy for women with GDM. Women receiving lifestyle interventions were less
likely to have postnatal depression and were more likely to achieve postpartum weight goals. Exposure to lifestyle interventions was
associated with a decreased risk of the baby being born LGA and decreased neonatal adiposity. Long-term maternal and childhood/
adulthood outcomes were poorly reported.
The value of lifestyle interventions in low-and middle-income countries or for different ethnicities remains unclear. The longer-term
benefits or harms of lifestyle interventions remains unclear due to limited reporting.
The contribution of individual components of lifestyle interventions could not be assessed. Ten per cent of participants also received
some form of pharmacological therapy. Lifestyle interventions are useful as the primary therapeutic strategy andmost commonly include
healthy eating, physical activity and self-monitoring of blood glucose concentrations.
Future research could focus onwhich specific interventions aremost useful (as the sole interventionwithout pharmacological treatment),
which health professionals should give them and the optimal format for providing the information. Evaluation of long-term outcomes
for the mother and her child should be a priority when planning future trials. There has been no in-depth exploration of the costs
‘saved’ from reduction in risk of LGA/macrosomia and potential longer-term risks for the infants.
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P L A I N L A N G U A G E S U M M A R Y
Lifestyle interventions for treating women with gestational diabetes (or diabetes in pregnancy)
What is the issue?
Gestational diabetes (GDM), is a glucose intolerance leading to high blood glucose levels that is first recognised during pregnancy
and which usually normalises after giving birth. Diabetes during pregnancy has been linked to many short-term and long-term health
problems for the mother and her baby. The main way to treat GDM is through lifestyle changes such as diet, exercise and checking
blood glucose levels.
Why is this important?
Women with GDM have an increased risk of developing high blood pressure during pregnancy (pre-eclampsia) and are more likely to
have their labour induced. The babies of women with GDM are more likely to be large when born and this can be linked to babies
having birth trauma (bones broken or nerves damaged during the birth) and the need for giving birth by caesarean section. Lifestyle
interventions that include two or more components of dietary advice, physical activity, education, and self-monitoring of blood glucose
are the first-line treatment for most women diagnosed with GDM. Interventions such as healthy eating and physical activity aim to
help women maintain their blood glucose levels within a target range and to improve health outcomes for the mother and baby.
What evidence did we find?
We searched the literature (May 2016) for controlled trials comparing lifestyle intervention with a control group of women receiving
usual care or another intervention. Fifteen randomised controlled trials (45 publications) are included in this review, involving 4501
women and 3768 infants. None of the trials were funded by a conditional grant from a pharmaceutical company.
For the baby, lifestyle interventions were associated with a reduction in the risk of being born large-for-gestational age (six trials,
2994 infants). The number of babies with birthweight over 4000 g (macrosomia) was lower with the lifestyle intervention, with no
clear difference in the number of newborn babies experiencing low blood glucose levels (six trials, 3000 infants). The evidence was of
moderate quality for these findings. Birthweight was also lower in the lifestyle intervention group.
For the mothers, introducing lifestyle interventions made no clear difference in the number of women with pregnancy-induced high
blood pressure (four trials, 2796 women) or having a caesarean section (10 trials, 3545 women) based on low-quality evidence or
on induction of labour (four trials, 2699 women, high-quality evidence). Similar numbers of women experienced perineal trauma or
tearing (one trial, 1000 women) or developed type 2 diabetes at a maximum of 10 years after giving birth (two trials, 486 women).
These findings were supported by low- to moderate-quality evidence.
More women in the lifestyle group had met their weight goals one year after giving birth, and lifestyle interventions were associated
with a decrease in the risk of depression after birth, from single trials. These findings were supported by low quality evidence.
What does this mean?
Lifestyle interventions provide benefits to women with GDM and their babies. The interventions are useful as the primary therapeutic
strategy and generally include, as a minimum, healthy eating, physical activity and self-monitoring of blood sugar levels.
Furture research could focus on the effective components of lifestyle interventions and the use of lifestyle interventions as the sole
intervention without pharmacological treatment. Future studies also need to consider long-term outcomes for the mother and her child
as a priority when planning future trials.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Lifestyle intervent ions versus usual care or diet alone for the treatment of women with gestat ional diabetes
Patient or population: Women with gestat ional diabetes
Settings: UK, Italy, Australia, Canada, United Arab Emirates, China
Intervention: Lifestyle intervent ion
Comparison: Usual care or diet alone
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with usual care/
control
Risk with lifestyle in-
tervention
Hypertensive disorders
of pregnancy (pre-
eclampsia)
129 per 1000 90 per 1000
(51 to 157)
RR 0.70
(0.40 to 1.22)
2796
(4 RCTs)
⊕⊕©©
LOW 1
Perineal trauma/ tear 498 per 1000 518 per 1000
(463 to 588)
RR 1.04
(0.93 to 1.18)
1000
(1 RCT)
⊕⊕⊕©
MODERATE 5
Caesarean sect ion 380 per 1000 342 per 1000
(296 to 399)
RR 0.90
(0.78 to 1.05)
3545
(10 RCTs)
⊕⊕©©
LOW 23
Induct ion of labour 211 per 1000 252 per 1000
(220 to 285)
RR 1.20
(0.99 to 1.46)
2699
(4 RCTs)
⊕⊕⊕⊕
HIGH
Postnatal depression 169 per 1000 83 per 1000
(53 to 132)
RR 0.49
(0.31 to 0.78)
573
(1 RCT)
⊕⊕©©
LOW 57
Postnatal weight reten-
t ion or return to pre-
pregnancy weight
214 per 1000 375 per 1000
(225 to 621)
RR 1.75
(1.05 to 2.90)
156
(1 RCT)
⊕⊕©©
LOW 56
These data refer to
women meeting post-
partum weight goals at
12 months postpartum
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Development of type 2
diabetes (follow-up)
83 per 1000 81 per 1000
(45 to 146)
RR 0.98
(0.54 to 1.76)
486
(2 RCTs)
⊕⊕©©
LOW 47
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Evidence of inconsistency with I2 > 70%, downgraded 2 levels
2 Evidence of select ive report ing in more than half of the trials report ing this outcome - downgraded 1 level
3 Evidence of inconsistency with I2 = > 50% but < 70%, downgraded 1 level
4 Evidence of risk of bias with one of the two studies not blinding part icipants/ researchers, downgraded 1 level
5 Imprecision - Evidence is based on a single trial, downgraded 1 level
6 Evidence of risk of bias - Allocat ion concealment unclear and no blinding of part icipants/ researchers, downgraded 1 level
7 Evidence of risk of bias - attrit ion bias, downgraded 1 level
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B A C K G R O U N D
The original review on Treatments for gestational diabetes (Alwan
2009) has been split into three new reviews due to the complexity
of the included interventions. The following new review protocols
are published.
Lifestyle interventions for the treatment of women with gestational
diabetes (this review) (Brown 2015)
Oral anti-diabetic pharmacological therapies for the treatment of
women with gestational diabetes (Brown 2015b)
Insulin for the treatment of women with gestational diabetes (Brown
2016)
There will be similarities in the background, methods and out-
comes between these three systematic reviews. Portions of the
methods section of this protocol are based on a standard template
used by the Cochrane Pregnancy and Childbirth Review Group.
Description of the condition
Gestational diabetes mellitus (GDM), often referred to as gesta-
tional diabetes can be defined as ’glucose intolerance or hyper-
glycaemia (high blood glucose concentration) with onset or first
recognition during pregnancy’ (WHO 1999). GDM occurs when
the body is unable to make enough insulin to meet the extra needs
in pregnancy. The high blood sugars associated with GDM will
usually return to normal after the birth of the baby. However, there
is currently no universally accepted diagnostic criteria (ACOG
2013; Coustan 2010; HAPO 2008; Hoffman 1998; IADPSG
2010; Metzger 1998; NICE 2015). GDM may include previ-
ously undetected glucose intolerance (IADPSG 2010; Nankervis
2014; WHO 2013). In an attempt to distinguish women with
diabetes mellitus in pregnancy from women with gestational di-
abetes, WHO 2013 provides separate diagnostic criteria. Some
countries such as New Zealand have recommended early screen-
ing in the first trimester using glycated or glycosylated haemoglo-
bin - HbA1C (glycated or glycosylated haemoglobin is a form of
haemoglobin measured primarily to identify the average plasma
glucose concentration over a period of time), with the aim that
more women with overt diabetes will be diagnosed and treated
appropriately (Ministry of Health 2014 - NewZealand). It should
be noted that this screening is not used globally.
GDM is one of the most common pregnancy complications and
the prevalence is rising worldwide with 1% to 36% of pregnan-
cies being affected (Bottalico 2007; Cundy 2014; Duran 2014;
Ferrara 2007; Kleinwechter 2014; NICE 2015; Tran 2013). The
prevalence of GDM is likely to continue to increase along with
the increasing prevalence of maternal obesity and associated type
2 diabetes mellitus (Bottalico 2007; Mulla 2010).
Screening and diagnosis of GDM
There are global variations in screening forGDMwith some coun-
tries, such as the UK, using an assessment of risk for GDM based
on maternal characteristics (NICE 2015), some countries, such as
the USA, use either an assessment based on maternal risk factors
or a 50 g oral glucose challenge test. In New Zealand all women
with an HbA1c value in the normal range at the time of booking
are offered the 50 g oral glucose challenge test at 24 to 28 weeks’
gestation (Ministry of Health 2014).
Diagnosis of GDM is usually based on either a 75 g two-hour
oral glucose tolerance test (OGTT) or a 100 g three-hour OGTT
(ADA2013; IADPSG2010;Nankervis 2014;NICE 2015;WHO
1999; WHO 2013). Recommendations regarding diagnostic cri-
teria vary nationally and internationally (Table 1), and these diag-
nostic criteria have changed over time, sometimes due to changing
understanding about the effects of hyperglycaemia on pregnancy
and infant outcomes (Coustan 2010), but also because of a lack of
evidence clearly demonstrating the clinical and cost-effectiveness
of one criterion over another.
The Hyperglycaemia and Adverse Pregnancy Outcomes (HAPO)
study (HAPO 2008) was a large, international observational study
that reported graded linear associations in the odds of several
GDM-associated adverse outcomes and glucose concentrations at
OGTT, with no clear threshold identified at which risk increased
substantially. The International Association of the Diabetes and
Pregnancy StudyGroups (IADPSG) recommended diagnostic cri-
teria using data from the HAPO study (IADPSG 2010) (Table 1).
Applying the IADPSG criteria in most health environments will
increase the number of women diagnosed with GDM. A study
conducted inVietnam showed that depending on the criteria used,
the diagnosis of GDM varied between 5.9% (American Diabetes
Association - ADA), 20.4% (IADPSG), 20.8% (Australasian Di-
abetes in Pregnancy Society - ADIPS), and up to 24.3% (World
HealthOrganization -WHO) (Tran 2013). A Bulgarian study also
reported differences in prevalence based on the different diagnostic
criteria used ranging from 10.8% (European Association for the
Study of Diabetes - EASD), 13.5% (ADA), 16.2% (New Zealand
Society for the Study of Diabetes - NZSSD), 17.1% (WHO),
21.2% (ADIPS), 31.6% (IADPSG) (Boyadzhieva 2012).
Pathophysiology of GDM
Normal pregnancy is associated with significant changes in ma-
ternal metabolism (Lain 2007). In early pregnancy, oestrogen and
progesterone stimulate maternal beta-cell hyperplasia and insulin
secretion, which promotes maternal nutrient storage (adipose and
hepatic glycogen) to support later fetal growth. At this stage, in-
sulin sensitivity is maintained or may even increase. However, as
pregnancy progresses, whole-body insulin sensitivity steadily de-
creases, such that by the third trimester it is reduced by almost half
(Barbour 2007). Several factors contribute to this, including pla-
cental hormones (human placental lactogen and placental growth
6Lifestyle interventions for the treatment of women with gestational diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
hormone), cytokines released from adipocytes (e.g. IL-6, TNF-
alpha), increased free fatty acids and lower adiponectin concen-
trations (Clapp 2006; Devlieger 2008). This results in decreased
post-prandial peripheral glucose disposal by up to 40% to 60%
(Barbour 2007). Because glucose is transported across the placenta
to the fetus by facilitated diffusion, this state of physiological in-
sulin resistance promotes fetal glucose uptake, a principal oxida-
tive fuel and carbon source for the growing fetus. In normal preg-
nancy, maternal glycaemia is maintained by a significant increase
in insulin secretion of up to 200% to 250% (Barbour 2007; Lain
2007; Suman Rao 2013).
Women who develop GDM have greater reductions in insulin
sensitivity in pregnancy and are unable to increase insulin secre-
tion sufficiently to maintain euglycaemia, especially after meals.
Glucose intolerance results from both reduced insulin action in
skeletal muscle, leading to decreased peripheral glucose disposal,
and in the liver, resulting in inadequate suppression of endogenous
glucose production. GDM is associated with impaired insulin sig-
nalling, with disruption of several components of the signalling
cascade. Subclinical inflammation (TNF-alpha) and decreased se-
cretion of adiponectin from adipocytes contribute to altered in-
sulin signalling in women with GDM (Barbour 2007). The net ef-
fect in skeletal muscle is reduced insulin-mediated glucose uptake
due to decrease translocation of the glucose transporter GLUT4
to the cell membrane.
In GDM, the steeper maternal-fetal glucose gradient, especially
post-prandial, leads to increased fetal glucose uptake, which stimu-
lates fetal insulin secretion. Insulin is a key fetal anabolic hormone
and hyperinsulinaemia promotes fetal overgrowth, especially of
fat, leading to large-for-gestational age (LGA) infants, macrosomia
(larger than average baby), and possible organ damage (Catalano
2003; Ju 2008; Metzger 2008; Reece 2009).
Women with GDM have increased circulating inflammatory cy-
tokines and lower adiponectin concentrations which can lead to
insulin resistance in adipose tissue, which in turn results in in-
creased lipolysis and fatty acid concentrations. Placental transfer
of free fatty acids contributes to increased fetal adiposity, indepen-
dent of glucose uptake (Knopp 1985). Thus, even women with
well-controlled GDM still have an increased risk of fetal macro-
somia (Langer 2005).
Risk factors associated with GDM
A variety of factors have been associated with an increased risk of
developing GDM. Non-modifiable risk factors include advanced
maternal age (Chamberlain 2013; Morisset 2010), high parity,
non-Caucasian race or ethnicity (in particular SouthAsian,Middle
Eastern), family history of diabetes mellitus, maternal high or low
birthweight, polycystic ovarian syndrome (Cypryk 2008; Petry
2010; Solomon 1997), a history of having a previous macrosomic
infant (birthweight 4000 g ormore) and previous history of GDM
(Petry 2010).
Modifiable risk factors include physical inactivity (Chasan-Taber
2008), having a low-fibre and high-glycaemic load diet (Zhang
2006), maternal overweight (body mass index (BMI) equal to
or greater than 25 kg/m²) or obesity (BMI equal to or greater
than 30 kg/m²) (Kim 2010a), and excessive weight gain during
pregnancy, especially for those who are already overweight or obese
(Hedderson 2010).
Clinical outcomes for women with pregnancy
hyperglycaemia
Adverse outcomes have been consistently reported at higher rates
inwomen diagnosedwithGDM, and their infants, comparedwith
women without GDM (Crowther 2005; Landon 2009; Metzger
2008; Reece 2009).
Women with GDM have an increased risk of developing pre-
eclampsia, are more likely to have their labour induced (Anderberg
2010; Crowther 2005; Ju 2008; Landon 2009; Metzger 2008),
and to give birth by caesarean section (Landon 2009; Metzger
2008). The incidence of uterine rupture, shoulder dystocia and
perineal lacerations is increased in women with GDM due to the
increased likelihood of having a LGAormacrosomic baby (Jastrow
2010).Women who have experiencedGDM are at a greater risk of
metabolic dysfunction in later life (Shah 2008; Vohr 2008), with
a crude cumulative incidence of type 2 diabetes of 10% to 20%
within 10 years (Bellamy 2009; Kim 2002), but up to 50% when
adjusted for retention and length of follow-up (Kim 2002).
Neonatal, infant and later outcomes related to
pregnancy hyperglycaemia
A significant adverse health outcome for babies born to mothers
with GDM is being born LGA or macrosomic (Catalano 2003;
Crowther 2005; Landon 2009;Metzger 2008; Reece 2009), which
increases the risk of birth injury, including shoulder dystocia, peri-
natal asphyxia, bone fractures and nerve palsies (Esakoff 2009;
Henriksen 2008; Langer 2005;Metzger 2008).Other adverse out-
comes which are increased for babies born to women with GDM
include respiratory distress syndrome, hypoglycaemia (which if
prolonged can cause brain injury), hyperbilirubinaemia, hyper-
trophic cardiomyopathy, hypocalcaemia, hypomagnesaemia, poly-
cythaemia and admission to the neonatal nursery (Metzger 2008;
Reece 2009).
Babies born to women with GDM, compared with babies born
to women without GDM, have significantly greater skinfold mea-
sures and fat mass (Catalano 2003), have greater adiposity (Pettitt
1985; Pettitt 1993), and are more likely to develop early over-
weight or obesity, type 2 diabetes (Hillier 2007; Pettitt 1993;
Whincup 2008), and metabolic syndrome in childhood, adoles-
cence or adulthood. Metabolic syndrome is a cluster of risk factors
defined by the occurrence of three of the following: obesity, hy-
pertension, hypertriglyceridaemia and low concentration of high-
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density lipoprotein (HDL) cholesterol (Guerrero-Romero 2010;
Harder 2009).
The development of the metabolic syndrome during childhood is
a risk factor for the development of adult type 2 diabetes at 25
to 30 years of age (Morrison 2008). These health problems repeat
across generations (Dabelea 2005; Mulla 2010) and are important
from a public health perspective, because with each generation the
prevalence of diabetes increases.
Description of the intervention
GDM management aims to optimise glycaemic control and con-
sequently improve pregnancy outcomes (Kim 2010b). Providing
dietary and lifestyle advice is usually recommended as the primary
therapeutic strategy for women with GDM (ACOG 2013; ADA
2015a; Hoffman 1998; NICE 2015). If diet and lifestyle man-
agement alone are insufficient to achieve targets for maternal gly-
caemic control, insulin therapy or oral anti-diabetic pharmacolog-
ical therapies such as glibenclamide and metformin can be added
(ACOG 2013; ADA 2013; Hoffman 1998; NICE 2015; Silva
2010; Simmons 2004). As part of GDM management, maternal
glucose monitoring and ultrasonography are advised to monitor
the effectiveness of treatment and to guide care for birth (ACOG
2013; Hoffman 1998; NICE 2015). However, treatment recom-
mendations differ across countries, for example, serial ultrasonog-
raphy is not recommended to guide treatment management in the
New Zealand Ministry of Health guidelines (Ministry of Health
2014).
Dietary intervention for managing GDM
Diet therapy is the primary strategy for managing GDM. Elevated
blood glucose concentrations, in particular elevations in post-
prandial glucose are associated with adverse pregnancy outcomes
in GDM (de Veciana 1995). The role of different dietary inter-
ventions for treatment of women with GDM, assessed by head-to-
head trials, has been described in the Cochrane systematic review
by Han 2013 and will not be included in this systematic review.
Carbohydrate-containing foods are important sources of energy,
vitamins, minerals and fibre and are the main nutrient affecting
blood glucose concentrations (Reader 2007). Blood glucose con-
centrations are affected by both total amount and type of carbohy-
drates consumed (Reader 2007). Glycaemic index (GI) is a rank-
ing of the effects of carbohydrates on blood glucose concentra-
tions (Jenkins 1981). Foods with a low GI (less than 55) produce
a lower post-prandial glucose elevation and area under the glu-
cose curve; foods with a high GI (more than 70) produce a rapid
increase in post-prandial blood glucose concentrations (Jenkins
1981). Outside of pregnancy, consumption of low-GI diets by
people with diabetes seems to help lower glycated or glycosylated
haemoglobin - HbA1C (Thomas 2010). Use of low-GI diets in
GDM management seems to be beneficial in reducing the need
for insulin, though the evidence is limited (Moses 2009). Polyun-
saturated fatty acids may be protective against impaired glucose
tolerance, while saturated fatty acids can increase glucose and in-
sulin concentrations in women with GDM (Ilic 1999). Reducing
blood lipid concentrations may improve glycaemic control and
pregnancy outcomes in GDM (Barrett 2014). However, the spe-
cific amount and sources of fat that are beneficial for GDMman-
agement are not clear (Kim 2010b). Therefore, recommendations
on the fat intake for women with GDM have not yet been pro-
mulgated (ACOG 2013; Hoffman 1998; Metzger 2007; (New
Zealand) Ministry of Health 2014; NICE 2015). Recommenda-
tions on the intake of other nutrients for women with GDM are
usually based on the general recommendations for people with
diabetes mellitus outside pregnancy (Cheung 2009).
Physical activity during pregnancy for managing GDM
The role of supplementary physical activity interventions for the
management of glycaemic control inwomenwith diabetes in preg-
nancy (including GDM) was one of the comparisons described in
the Cochrane review by Ceysens 2006. In non-pregnant women
with type 2 diabetes, physical activity (in addition to diet and in-
sulin) helped tonormalise blood glucose levels (Tuomilehto 2001).
Caution is required when generalising this evidence to pregnant
women, but it potentially suggests that during pregnancy mild
exercise could reduce the risk of complications related to high
blood glucose and high insulin levels, includingmacrosomia, birth
trauma, respiratory distress, neonatal hypoglycaemia and hypocal-
caemia. Exercise interventions alone for treating women with ges-
tational diabetes will not be included in this systematic review.
Appropriate weight gain during pregnancy
Interventions for preventing excessive weight gain in pregnancy
(diet or exercise or both) have been described in the Cochrane
systematic review by Muktabhant 2015, which included 65 ran-
domised controlled trials, of which seven recruited women who
were at high risk of gestational diabetes. Given the high prevalence
of overweight and obesity in women with GDM, dietary interven-
tions for appropriate pregnancy weight gain are routinely included
as a part of nutritional management of GDM (Kim 2010b). Small
reductions in weight improve glycaemic control (ACOG 2005),
but the implications in pregnancy for the mother and fetus are
unclear.
In 2009, the American Institute of Medicine updated their guide-
lines for weight gain during pregnancy. Guidance is stratified by
pre-pregnancy BMI, i.e. women with a pre-pregnancy BMI be-
tween 25 kg/m² and 29.9 kg/m² should aim for 6.8 kg to 11.4 kg
weight gain and those with pre-pregnancy BMI of 30 kg/m² or
more should aim for 5 kg to 9 kg weight gain (IOM 2009). How-
ever, the degree of energy restriction for pre-pregnancy overweight
and obese women to achieve these weight gain goals is unknown
and based on observational data (Kim 2010b).
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Dietary interventions provided for women with GDM should
ensure adequate nutrients for normal fetal growth and maternal
health, but not induce weight loss or excessive weight gain during
pregnancy; themain aim however is to promote optimal glycaemic
control (ACOG 2013; Hoffman 1998; Metzger 2007; NICE
2015).
Combined dietary intervention and physical activity
during pregnancy for managing GDM
Some interventions may involve a combination of dietary and
physical activity modalities. Regular physical activity may help
normalise maternal blood glucose for pregnant women with ges-
tational diabetes and in combination with dietary interventions
may reduce the need for oral anti-diabetic agents or insulin. As
women with gestational diabetes are at increased risk of develop-
ing type 2 diabetes in the future, regular physical activity may also
help reduce the risk of this long-term complications (Tuomilehto
2011).
Other interventions during pregnancy for managing
GDM
There may be other interventions, including psychological ap-
proaches that could be used independently or alongside physical
activity or dietary modalities such as mindfulness eating, yoga or
spiritual support.
How the intervention might work
Role of diet
A carbohydrate-controlled diet (with carbohydrates distributed
evenly throughout the day) that provides adequate nutrition,
alongside glycaemic control and avoids ketonuria (ketones are pro-
duced when stored fat is utilised to produce energy in the absence
of glucose) is thought to be optimal to reduce complications asso-
ciatedwith gestational diabetes (Dornhorst 2002).Other elements
of diet such as fat and fibre are also thought to influence maternal
blood glucose concentrations (Zhang 2006). Excess fetal growth
is most effectively limited by normal post-prandial maternal glu-
cose concentrations (de Veciana 1995; Dornhorst 2002; Harmon
2011; Rowan 2011; Weisz 2005). Dietary advice in the second
trimester, when insulin resistance is increasing, may help reduce
the risk of adverse outcomes associated with GDM (Dornhorst
2002).
Role of physical activity
Insulin sensitivity in skeletal muscle is related to the degree of
physical activity, and therefore, physical activity interventions may
improve insulin sensitivity and glucose control in individuals with
diabetes (Asano 2014).
Glucose enters skeletal muscle cells via facilitated diffusion
through a glucose transporter (GLUT4). Peripheral clearance of
glucose in skeletalmuscle depends onbloodflow tomuscle, expres-
sion of GLUT4 transporters and intracellular utilisation of glucose
through glycolysis and glycogenesis. Translocation of the GLUT4
transporter is induced by insulin and insulin-independent mecha-
nisms (Richter 2001). Exercise increases glucose uptake in skeletal
muscle (Asano 2014), and improves glucose homeostasis and in-
sulin sensitivity in skeletal muscle. Exercise potentiates most of the
insulin-mediated post-receptor events that lead to an increased ex-
pression of GLUT4, and GLUT4 translocation from intracellular
stores to the muscle membrane. These exercise-induced improve-
ments in glucose uptake, however, are not limited to changes in
GLUT4 expression. The improvements in insulin sensitivity after
regular exercise may be related to changes in expression and/or ac-
tivity of proteins involved in insulin signal transduction in skeletal
muscle. As such, the enhanced glucose uptake in skeletal muscle
attributed to exercise might be related to an increased expression
and activity of key proteins for insulin signalling such as insulin
receptor, insulin receptor substrate, and phosphatidylinositol 3-
kinase (Chibalin 2000; Dela 1993; Hjeltnes 1998). Physical ac-
tivity improves blood supply to the active skeletal muscles (Jensen
2004), counteracts the ability of lipids to induce insulin resistance
(Schenk 2005), and modifies the hormonal regulation of hepatic
glucose output. These exercise-induced alterations in muscle glu-
cose handling explain most of the insulin-sensitising and diabetes-
preventing effects of exercise, and partly explain why the many
defects of insulin action observed in type 2 diabetes and insulin
resistance are reversed by the effects of exercise (Zierath 2002).
Self-monitoring of blood glucose
Self-monitoring of blood glucose is performed by most women
with GDM. Evidence has suggested that self-monitoring between
four and seven times per day (including fasting and post-prandial
measurements) can contribute to improvedmaternal and perinatal
outcomes (ADA 2015a), and is likely to be most effective when
combined with effective treatment.
Why it is important to do this review
GDM affects a significant proportion of pregnant women and
the prevalence is increasing worldwide (Bottalico 2007; Dabelea
2005; Mulla 2010). GDM is associated with an increased risk of
a range of adverse pregnancy outcomes and these adverse health
outcomes repeat across generations (Metzger 2008; Mulla 2010),
which has important implications for the future. Providing dietary
and lifestyle advice is usually recommended as the primary ther-
apeutic strategy for women with GDM (ACOG 2013; Hoffman
1998; (New Zealand) Ministry of Health 2014; NICE 2015).
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Two other Cochrane reviews cover comparisons of individual
lifestyle components (diet and exercise) ’Different types of dietary
advice for women with gestational diabetes mellitus’ (Han 2013).
This review examined the effects of two or more modalities of di-
etary interventions compared with each other for treating women
with GDM, i.e. standard dietary advice compared with individ-
ualised dietary advice, individual dietary education sessions com-
pared with group dietary education sessions, single dietary coun-
selling session compared with multiple dietary counselling ses-
sions. ’Exercise for diabetic pregnant women’ (Ceysens 2006). This
review evaluated the effects of physical activity interventions with
or without dietary interventions compared with no additional
physical activity intervention for women with diabetes in preg-
nancy and the trials included in the review recruited women with
gestational diabetes.
This review focuses on the potential effectiveness of multi-com-
ponent lifestyle interventions.
O B J E C T I V E S
To evaluate the effects of combined lifestyle interventions with
or without pharmacotherapy in treating women with gestational
diabetes.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included published or unpublished randomised controlled tri-
als in full text or abstract format. If identified, we planned to in-
clude cluster-randomised trials. Quasi-randomised trials were ex-
cluded. Cross-over trials were not eligible for inclusion. Confer-
ence abstracts were handled in the same way as full-text publica-
tions.
Types of participants
Participants were pregnant women diagnosed with gestational di-
abetes (diagnosis as defined by the individual trial). Women with
known type 1 or type 2 diabetes were excluded.
Types of interventions
We included randomised trials comparing lifestyle interventions
(as defined by trialists) with:
• expectant management, standard care;
• other lifestyle intervention or combination of lifestyle
interventions not described below.
The aim of the interventions was to maintain maternal glycaemic
targets during pregnancy in women with gestational diabetes.
Lifestyle interventions could include a combination of at least two
or more of the following interventions:
• diet;
• physical activity;
• education;
• behavioural change techniques;
• regimens of self-monitoring of blood glucose;
• other intervention not previously specified.
These interventions may or may not require adjunctive pharma-
cotherapy (oral anti-diabetic pharmacological therapies, insulin)
used to treat women with gestational diabetes.
Interventions examining the comparison of different dietary inter-
ventions or the effects of exercise alone are not be included in this
review as they are already included in other Cochrane systematic
reviews (Han 2013 and Ceysens 2006, respectively).
Types of outcome measures
The following standardised outcomes have been developed
through a process involving authors of Cochrane reviews for treat-
ment interventions for women with gestational diabetes mellitus
(GDM).
Primary outcomes
Maternal
• Hypertensive disorders of pregnancy (including pre-
eclampsia, pregnancy-induced hypertension, eclampsia as
defined by trialists)
• Caesarean section
• Development of type 2 diabetes
Neonatal
• Perinatal (fetal and neonatal death) and later infant
mortality
• Large-for-gestational age (LGA) (as defined by trialists)
• Death or serious morbidity composite (variously defined by
trials, e.g. perinatal or infant death, shoulder dystocia, bone
fracture or nerve palsy)
• Neurosensory disability in later childhood (as defined by
trialists)
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Secondary outcomes
Maternal
• Use of additional pharmacotherapy
• Maternal hypoglycaemia (as defined by trialists)
• Glycaemic control during/end of treatment (as defined by
trialists)
• Weight gain in pregnancy
• Adherence to the intervention
• Induction of labour
• Placental abruption
• Postpartum haemorrhage (as defined by trialists)
• Postpartum infection
• Perineal trauma/tear
• Breastfeeding at discharge, six weeks postpartum, six
months or longer
• Maternal mortality
• Sense of well-being and quality of life
• Behavioural changes associated with the intervention
• Views of the intervention
• Relevant biomarker changes associated with the
intervention (including adiponectin, free fatty acids,
triglycerides, high-density lipoproteins (HDL), low-density
lipoproteins (LDL), insulin)
Long-term outcomes for mother
• Postnatal depression
• Body mass index (BMI)
• Postnatal weight retention or return to pre-pregnancy
weight
• Type 1 diabetes
• Impaired glucose tolerance
• Subsequent gestational diabetes
• Cardiovascular health (as defined by trialists including
blood pressure, hypertension, cardiovascular disease, metabolic
syndrome)
Fetal/neonatal outcomes
• Stillbirth
• Neonatal death
• Macrosomia (greater than 4000 g; or as defined by
individual study)
• Small-for-gestational (SGA) age (as defined by trialists)
• Birth trauma (shoulder dystocia, bone fracture, nerve palsy)
• Gestational age at birth
• Preterm birth (< 37 weeks’ gestation; and < 32 weeks’
gestation)
• Five-minute Apgar less than seven
• Birthweight and z score
• Head circumference and z score
• Length and z score
• Ponderal index
• Adiposity (including skinfold thickness measurements
(mm); fat mass as defined by trialists)
• Neonatal hypoglycaemia (as defined by trialists)
• Respiratory distress syndrome
• Neonatal jaundice (hyperbilirubinaemia) (as defined by
trialists)
• Hypocalcaemia (as defined by trialists)
• Polycythaemia (as defined by trialists)
• Relevant biomarker changes associated with the
intervention (including insulin, cord c-peptide)
Later infant/childhood outcomes
• Weight and z score
• Height and z score
• Head circumference and z score
• Adiposity (including BMI, skinfold thickness, fat mass)
• Educational attainment
• Blood pressure
• Type 1 diabetes
• Type 2 diabetes
• Impaired glucose tolerance
• Dyslipidaemia or metabolic syndrome
Child as an adult outcomes
• Weight
• Height
• Adiposity (including BMI, skinfold thickness, fat mass)
• Employment, education and social status/achievement
• Dyslipidaemia or metabolic syndrome
• Type 1 diabetes
• Type 2 diabetes
• Impaired glucose tolerance
• Cardiovascular health (as defined by trialists including
blood pressure, hypertension, cardiovascular disease, metabolic
syndrome)
Health service use
• Number of antenatal visits or admissions
• Number of hospital or health professional visits (including
midwife, obstetrician, physician, dietician, diabetic nurse)
• Admission to neonatal intensive care unit/nursery
• Duration of stay in neonatal intensive care unit or special
care baby unit
• Length of antenatal stay
• Length of postnatal stay (maternal)
• Length of postnatal stay (baby)
• Cost of maternal care
• Cost of offspring care
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• Costs associated with the intervention
• Costs to families associated with the management provided
• Cost of dietary monitoring (e.g. diet journals, dietician,
nurse visits, etc)
• Costs to families - change of diet, extra antenatal visits
• Extra use of healthcare services (consultations, blood
glucose monitoring, length and number of antenatal visits)
• Women’s view of treatment advice
Search methods for identification of studies
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Electronic searches
We searched Cochrane Pregnancy and Childbirth’s Trials Register
by contacting their Information Specialist (14 May 2016).
The Register is a database containing over 23,000 reports of con-
trolled trials in the field of pregnancy and childbirth. For full search
methods used to populate Pregnancy andChildbirth’s Trials Regis-
ter including the detailed search strategies for CENTRAL, MED-
LINE, Embase and CINAHL; the list of handsearched journals
and conference proceedings, and the list of journals reviewed via
the current awareness service, please follow this link to the edi-
torial information about the Cochrane Pregnancy and Childbirth
in the Cochrane Library and select the ‘Specialized Register ’ sec-
tion from the options on the left side of the screen.
Briefly, Cochrane Pregnancy and Childbirth’s Trials Register is
maintained by their Information Specialist and contains trials
identified from:
1. monthly searches of the Cochrane Central Register of
Controlled Trials (CENTRAL);
2. weekly searches of MEDLINE (Ovid);
3. weekly searches of Embase (Ovid);
4. monthly searches of CINAHL (EBSCO);
5. handsearches of 30 journals and the proceedings of major
conferences;
6. weekly current awareness alerts for a further 44 journals
plus monthly BioMed Central email alerts.
Search results are screened by two people and the full text of all
relevant trial reports identified through the searching activities de-
scribed above is reviewed. Based on the intervention described,
each trial report is assigned a number that corresponds to a spe-
cific Pregnancy and Childbirth review topic (or topics), and is
then added to the Register. The Information Specialist searches
the Register for each review using this topic number rather than
keywords. This results in a more specific search set which has
been fully accounted for in the relevant review sections (Included
studies; Excluded studies; Studies awaiting classification; Ongoing
studies).
In addition, we searched ClinicalTrials.gov and the WHO Inter-
national Clinical Trials Registry Platform (ICTRP) (14May 2016)
for unpublished, planned and ongoing trial reports. The search
terms we used are given in (Appendix 1).
Searching other resources
We searched the reference lists of retrieved studies. We did not
apply any language or date restrictions.
Data collection and analysis
The followingmethods section of this review is based on a standard
template used by Cochrane Pregnancy and Childbirth.
Selection of studies
Two review authors independently assessed for inclusion all the
potential studies we identified as a result of the search strategy.
We resolved any disagreement through discussion or, if required,
consulted a third person.
We created a study flow diagram tomap out the number of records
identified, included and excluded.
Data extraction and management
Wedesigned a form to extract data. For eligible studies, two review
authors extracted the data using the agreed form. We resolved dis-
crepancies through discussion or, if required, we consulted a third
person. We entered data into Review Manager software (RevMan
2014) and checked for accuracy. When information regarding any
of the above was unclear, we attempted to contact authors of the
original reports to provide further details.
Assessment of risk of bias in included studies
Two review authors independently assessed risk of bias for each
randomised study using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We resolved any disagreement by discussion or by involving a third
assessor. For cluster-randomised trials, we planned to refer to the
Handbook sections 16.3.2 and 16.4.3 for assessing bias. No clus-
ter-randomised trials were identified in this version of the review.
(1) Random sequence generation (checking for possible
selection bias)
We described for each included study the method used to generate
the allocation sequence in sufficient detail to allow an assessment
of whether it should produce comparable groups.
We assessed the method as:
• low risk of bias (any truly random process, e.g. random
number table; computer random number generator);
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• high risk of bias (any non-random process, e.g. odd or even
date of birth; hospital or clinic record number);
• unclear risk of bias.
(2) Allocation concealment (checking for possible selection
bias)
We described for each included study the method used to con-
ceal allocation to interventions prior to assignment and will assess
whether intervention allocation could have been foreseen in ad-
vance of, or during recruitment, or changed after assignment.
We assessed the methods as:
• low risk of bias (e.g. telephone or central randomisation;
consecutively numbered sealed opaque envelopes);
• high risk of bias (open random allocation; unsealed or non-
opaque envelopes, alternation; date of birth);
• unclear risk of bias.
(3.1) Blinding of participants and personnel (checking for
possible performance bias)
We described for each included study the methods used, if any, to
blind study participants and personnel from knowledge of which
intervention a participant received. We considered that studies
were at low risk of bias if theywere blinded, or if we judged that the
lack of blinding was unlikely to affect results. We assessed blinding
separately for different outcomes or classes of outcomes.
We assessed the methods as:
• low, high or unclear risk of bias for participants;
• low, high or unclear risk of bias for personnel.
(3.2) Blinding of outcome assessment (checking for possible
detection bias)
We described for each included study the methods used, if any, to
blind outcome assessors from knowledge of which intervention a
participant received. We assessed blinding separately for different
outcomes or classes of outcomes.
We assessed methods used to blind outcome assessment as:
• low, high or unclear risk of bias.
(4) Incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data)
We described for each included study, and for each outcome or
class of outcomes, the completeness of data including attrition and
exclusions from the analysis. We stated whether attrition and ex-
clusions were reported and the numbers included in the analysis at
each stage (compared with the total randomised participants), rea-
sons for attrition or exclusion where reported, and whether miss-
ing data were balanced across groups or were related to outcomes.
Where sufficient information was reported, or could be supplied
by the trial authors, we re-included missing data in the analyses
which we undertook.
We assessed methods as:
• low risk of bias (e.g. no missing outcome data; missing
outcome data balanced across groups);
• high risk of bias (e.g. numbers or reasons for missing data
imbalanced across groups; ‘as treated’ analysis done with
substantial departure of intervention received from that assigned
at randomisation);
• unclear risk of bias.
(5) Selective reporting (checking for reporting bias)
We described for each included study how we investigated the
possibility of selective outcome reporting bias and what we found.
We assessed the methods as:
• low risk of bias (where it was clear that all of the study’s pre-
specified outcomes and all expected outcomes of interest to the
review had been reported);
• high risk of bias (where not all the study’s pre-specified
outcomes had been reported; one or more reported primary
outcomes were not pre-specified; outcomes of interest were
reported incompletely and so could be used; study failed to
include results of a key outcome that would have been expected
to have been reported);
• unclear risk of bias.
(6) Other bias (checking for bias due to problems not
covered by (1) to (5) above)
We described for each included study any important concerns we
have about other possible sources of bias.
We assessed whether each study was free of other problems that
could put it at risk of bias:
• low risk of other bias;
• high risk of other bias;
• unclear whether there is risk of other bias.
(7) Overall risk of bias
We made explicit judgements about whether studies were at high
risk of bias, according to the criteria given in the Handbook (
Higgins 2011). With reference to (1) to (6) above, we assessed
the likely magnitude and direction of the bias and whether we
considered it was likely to impact on the findings. We explored the
impact of the level of bias through undertaking sensitivity analyses
- see Sensitivity analysis.
Assessment of the quality of the evidence using the
GRADE approach
We assessed the quality of the evidence using the GRADE ap-
proach as outlined in the GRADE handbook in order to assess
13Lifestyle interventions for the treatment of women with gestational diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
the quality of the body of evidence relating to the following out-
comes. We selected up to a maximum of seven outcomes for the
mother and seven for the infant covering both short- and long-
term outcomes for the main comparisons.
Maternal outcomes
• Hypertensive disorders of pregnancy (including pre-
eclampsia, pregnancy-induced hypertension, eclampsia)
• Perineal trauma/tear
• Induction of labour
• Caesarean section
• Postnatal depression
• Return to pre-pregnancy weight
• Development of type 2 diabetes
Neonatal/child/adult outcomes
• LGA (neonatal)
• Perinatal mortality (neonatal)
• Death or serious morbidity composite (variously defined by
trials, e.g. perinatal or infant death, shoulder dystocia, bone
fracture or nerve palsy) (neonatal)
• Neonatal hypoglycaemia (neonatal)
• Adiposity (neonatal, child, adult)
• Diabetes (type 2) (child or adult)
• Neurosensory disability (child, adult)
We used the GRADEpro Guideline Development Tool to import
data from Review Manager 5.3 (RevMan 2014) in order to create
’Summary of findings’ tables. A summary of the intervention effect
and a measure of quality for each of the above outcomes was
produced using the GRADE approach. The GRADE approach
uses five considerations (study limitations, consistency of effect,
imprecision, indirectness and publication bias) to assess the quality
of the body of evidence for each outcome. The evidence can be
downgraded from ’high quality’ by one level for serious (or by
two levels for very serious) limitations, depending on assessments
for risk of bias, indirectness of evidence, serious inconsistency,
imprecision of effect estimates or potential publication bias.
Measures of treatment effect
Dichotomous data
For dichotomous data, we presented results as summary risk ratio
with 95% confidence intervals.
Continuous data
For continuous data, we used the mean difference if outcomes are
measured in the same way between trials. We planned to use the
standardised mean difference to combine trials that measured the
same outcome, but used different methods.
Unit of analysis issues
Cluster-randomised trials
No cluster-randomised trials were identified in this version of the
review. In future updates, if identified, we will include cluster-ran-
domised trials in the analyses along with individually-randomised
trials. We will make adjustments using the methods described in
the Handbook [Section 16.3.4 or 16.3.6] using an estimate of the
intra-cluster correlation co-efficient (ICC) derived from the trial
(if possible), from a similar trial or from a study of a similar popu-
lation. If we use ICCs from other sources, we will report this and
conduct sensitivity analyses to investigate the effect of variation
in the ICC. We will consider it reasonable to combine the results
from both cluster-randomised trials and individually-randomised
trials if there is little heterogeneity between the study designs and
the interaction between the effect of intervention and the choice
of randomisation unit is considered to be unlikely. If cluster-ran-
domised trials are included, we will seek statistical advice on ap-
propriate analysis to enable inclusion of data in the meta-analyses.
Other unit of analysis issues
Multiple pregnancy
Wepresentedmaternal data as per woman randomised and neona-
tal data per infant.
Multiple-arm studies
If in future versions of the review a trial has multiple intervention
arms we will avoid ’double counting’ of participants by combining
groups to create a single pair-wise comparison if possible. Where
this is not possible, we will split the ’shared’ group into two or
more groups with smaller sample size and include two or more
(reasonably independent) comparisons.
Dealing with missing data
For included studies, we noted levels of attrition. We planned to
explore the impact of including studies with high levels of missing
data (> 20%) in the overall assessment of treatment effect by using
sensitivity analysis.
For all outcomes, we carried out analyses, as far as possible, on
an intention-to-treat basis, i.e. we attempted to include all partic-
ipants randomised to each group in the analyses, and all partici-
pants were analysed in the group to which they were allocated, re-
gardless of whether or not they received the allocated intervention.
The denominator for each outcome in each trial was the number
randomised minus any participants whose outcomes are known
to be missing.
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Assessment of heterogeneity
We assessed statistical heterogeneity in each meta-analysis using
the Tau², I² and Chi² statistics. We regarded heterogeneity as sub-
stantial if an I² was greater than 30% and either a Tau² was greater
than zero, or there was a low P value (less than 0.10) in the Chi²
test for heterogeneity.
Assessment of reporting biases
Where there were 10 or more studies in the meta-analysis, we in-
vestigated reporting biases (such as publication bias) using funnel
plots. We assessed funnel plot asymmetry visually. If asymmetry
was suggested by a visual assessment, we performed exploratory
analyses to investigate it.
Data synthesis
We carried out statistical analysis using the Review Manager soft-
ware (RevMan 2014).We used fixed-effect meta-analysis for com-
bining data where it was reasonable to assume that studies were
estimating the same underlying treatment effect: i.e. where trials
examined the same intervention, and the trials’ populations and
methods were judged sufficiently similar. If clinical heterogene-
ity was sufficient to expect that the underlying treatment effects
differed between trials, or if substantial statistical heterogeneity
was detected, we used random-effects meta-analysis to produce an
overall summary, if an average treatment effect across trials was
considered clinically meaningful. The random-effects summary
was treated as the average of the range of possible treatment effects
and we discussed the clinical implications of treatment effects dif-
fering between trials. If the average treatment effect was not clin-
ically meaningful, we did not combine trials.
Where we used random-effects analyses, the results were presented
as the average treatment effect with 95% confidence intervals, and
the estimates of Tau² and I².
Subgroup analysis and investigation of heterogeneity
If we identified substantial heterogeneity, we investigated it using
subgroup analyses and sensitivity analyses.We considered whether
an overall summary was meaningful, and if it was, used random-
effects analysis to produce it.
• Diagnostic test used: ADA 2013, IADPSG 2010, Nankervis
2014 versus ACOG 2013 versus NICE 2015 versus NICE 2008;
WHO 1999; WHO 2013 or Hoffman 1998 versus New Zealand
Ministry of Health 2014 versus other not previously specified
• Timing of diagnosis: early (< 28 weeks’ gestation) versus
late (≥ 28 weeks’ gestation)
The following outcomes were used in subgroup analysis.
Maternal outcomes
• Pre-eclampsia
• Caesarean section
• Development of type 2 diabetes
Neonatal outcomes
• LGA
• Perinatal mortality
• Death or morbidity composite (variously defined by trials,
e.g. infant death, shoulder dystocia, bone fracture or nerve palsy)
• Neurosensory disability in later childhood (as defined by
trialists)
We assessed subgroup differences by interaction tests available
within RevMan (RevMan 2014). We reported the results of sub-
group analyses quoting the Chi2 statistic and P value, and the in-
teraction test I² value.
Sensitivity analysis
If there was evidence of significant heterogeneity, we explored this
by using the quality of the included trials for the primary out-
comes. We compared trials that have low risk of bias for allocation
concealment with those judged to be of unclear or high risk of bias,
and conference abstracts were excluded from the meta-analysis.
We planned to investigate the effect of the randomisation unit (i.e.
if we had included cluster-randomised trials along with individu-
ally-randomised trials).
R E S U L T S
Description of studies
Results of the search
We assessed 253 abstracts from the electronic search and an addi-
tional 21 potential studies from other sources. Two hundred and
one of these abstracts were excluded due to lack of relevance and 73
publications were viewed in full-text format. Of these, 23 studies
(28 reports) were excluded. Twenty-five studies (45 reports) were
included in the qualitative synthesis (Figure 1).
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Figure 1. Study flow diagram.
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Three studies are awaiting classification as methodological queries
need to be answered or translations into English are required.
Where necessary authors have been contacted (Cao 2012; Kaveh
2012; Zhang 2012), See Characteristics of studies awaiting
classification.
There are seven studies that are currently ongoing and would
appear to meet the inclusion criteria for the review (See
Characteristics of ongoing studies). For the next update of this
review we will see if any data from these trials have been published.
Included studies
Forty-five publications associatedwith 15 trials are included in this
review (Bancroft 2000; Bo 2014; Crowther 2005; Elnour 2008;
Ferrara 2011; Garner 1997; Gillen 2004; Jovanovic-Peterson
1989; Kaviani 2014; Landon 2009;Mendelson 2008; Rahimikian
2014; Yang 2003; Yang 2014; Youngwanichsetha 2014). The 15
trials included a total of 4501 women and 3768 infants. Four tri-
als did not report any neonatal data (Kaviani 2014; Rahimikian
2014; Yang 2003; Youngwanichsetha 2014).
Design
All of the included studies used a parallel design in a randomised
controlled trial.
Sample sizes
Sample sizes ranged from 19 (Jovanovic-Peterson 1989) to 1000
(Crowther 2005) women. Twelve studies had a sample size of
300 women or fewer (Bancroft 2000; Bo 2014; Elnour 2008;
Ferrara 2011; Garner 1997; Gillen 2004; Jovanovic-Peterson
1989; Kaviani 2014; Mendelson 2008; Rahimikian 2014; Yang
2003; Youngwanichsetha 2014).
Settings
Four studies were conducted in the USA (Ferrara 2011; Landon
2009; Mendelson 2008; Jovanovic-Peterson 1989), two in China
(Yang 2003; Yang 2014), two in Iran (Kaviani 2014; Rahimikian
2014), two in Canada (Garner 1997; Gillen 2004), one each in
the UK (Bancroft 2000), Italy (Bo 2014), United Arab Emirates
(Elnour 2008), Thailand (Youngwanichsetha 2014), and one in
Australia and the UK (Crowther 2005).
Population
Eleven trials reported data for maternal age (see Table 2 In the in-
tervention groups the mean age ranged from a minimum of 29.2
± 5.7 years (Landon 2009) to maximum of 35.9 ± 4.8 years (Bo
2014). In the control groups, the mean age ranged from a mini-
mum of 28.9 ± 5.6 (Landon 2009) to 33.9 ± 5.3 years (Bo 2014).
Details on maternal BMI (kg/m2) at trial entry, reported in seven
trials and ethnicity reported in nine of 15 trials are summarised in
Table 3 and Table 4, respectively. Gestational age at trial entry and
treatment targets are described in Table 5 and Table 6, respectively.
Details of diagnostic criteria used
Criteria used to diagnose the women with gestational diabetes
were variable. Six different diagnostic criteria were used in the nine
trials that provided details (Table 7).
• World Health Organization (1999) Bancroft 2000;
Crowther 2005; Yang 2003
• Carpenter and Coustan criteria Elnour 2008; Landon 2009
• American Diabetes Association (2000) Ferrara 2011
• ADIPS (Hofman 1998) Gillen 2004
• IADPSG criteria Yang 2014
• Hatem (1988) 75 g OGTT > 7.5 mmol (second trimester)
and > 9.6 mmol/L (third trimester) (no other details) (Garner
1997)
Six trials did not provide details on the criteria used to diag-
nose the women with gestational diabetes (Bo 2014; Jovanovic-
Peterson 1989; Kaviani 2014; Mendelson 2008; Rahimikian
2014; Youngwanichsetha 2014).
Interventions
The types of interventions used varied, as can be seen below.
Bancroft 2000: Intensive intervention (standard dietary advice,
glucose monitoring five days a week, HbA1c monthly, serial ul-
trasound, Doppler studies, cardiotocography (CTG monitoring)
compared with usual care (dietary advice, HbA1c monthly).
Bo 2014: Reported on a multiple-arm trial that included a) Indi-
vidualised-dietary advice alone, b) Exercise alone, c) Behavioural
intervention and d) Behavioural intervention and exercise. We
used the combined behavioural and exercise group as the inter-
vention arm for this review and the Individualised-dietary advice
alone as the control group.
Crowther 2005: Intensive intervention (individualised-dietary ad-
vice, advice on self-monitoring of blood glucose) compared with
usual care (women and caregivers unaware of diagnosis).
Elnour 2008: Intensive intervention (structured pharmaceutical
care, structured education, self-monitoring of blood glucose) com-
paredwith usual care (no additional educationor pharmacist coun-
selling).
Ferrara 2011: Intensive intervention (individualised advice on
diet, exercise and breastfeeding) comparedwith usual care (printed
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material only in prenatal and postnatal period).
Garner 1997: Intensive intervention (dietary counselling, self-glu-
cose monitoring, biweekly review, monitoring of fetal growth, am-
niotic volume and cardiac size) versus usual care (no dietary coun-
selling).
Gillen 2004: Group session on education and diet followed by
specific dietary advice compared with group session on education
and diet followed by standard clinical care and advice.
Jovanovic-Peterson 1989: Diet alone compared with diet plus su-
pervised exercise.
Kaviani 2014: Relaxation training (education, breathing, muscle
relaxation, mental imagery, and contacted by telephone by the
researcher three times per week) compared with usual care (no
details).
Landon 2009: Nutritional counselling and diet therapy +/- insulin
plus self-monitoring of blood glucose compared with usual care
+/- insulin plus self-monitoring of blood glucose.
Mendelson 2008: Intensive education and spiritual intervention
compared with standard education.
Rahimikian 2014: Face-to-face education (risks of GDM, training
on glycaemic control, exercise, diet, medication and follow-up)
compared with usual care (no details).
Yang 2003: Intensive intervention (including diet and exercise ad-
vice, self-monitoring of blood glucose, insulin if required, fort-
nightly specialist review) versus usual care (no details).
Yang 2014: Shared care protocol adapted from Crowther 2005.
Individualised and group dietary and physical activity counselling,
self-monitoring blood glucose compared with usual care (group
education on exercise and physical activity, not specifically taught
blood glucose self-monitoring).
Youngwanichsetha 2014: Mindfulness eating and yoga compared
with standard diabetes care (no details).
Outcomes
For the maternal primary outcomes: pregnancy-induced hyper-
tension was reported in four trials (Crowther 2005; Elnour 2008;
Landon 2009; Yang 2014), and caesarean section in 10 trials
(Bancroft 2000; Bo 2014; Crowther 2005; Elnour 2008; Garner
1997; Gillen 2004; Landon 2009; Mendelson 2008; Yang 2003;
Yang 2014). Development of type 2 diabetes was reported in two
trials (Bancroft 2000; Landon 2009).
For the neonatal primary outcomes: Perinatal death was reported
in two trials (Crowther 2005; Landon 2009); large-for-gestational
age (LGA) in six trials (Bancroft 2000; Bo 2014; Crowther 2005;
Elnour 2008; Landon 2009; Yang 2014), and a composite of se-
rious neonatal outcomes in two trials (Crowther 2005; Landon
2009). Neurosensory disability in later childhood was not a pre-
specified outcome, nor reported for any of the included trials.
Data were available for the following maternal secondary out-
comes: need for supplementary medication, maternal hypogly-
caemia, fasting plasma glucose concentration, postprandial glu-
cose concentration, HbA1c, weight gain in pregnancy, induction
of labour, postpartum haemorrhage, postnatal infection/pyrexia,
perineal trauma/tear, breastfeeding, postnatal depression, quality
of life, impaired glucose tolerance, metabolic syndrome and return
to prepregnancy weight.
Data were available for the following neonatal secondary out-
comes: stillbirth, neonatal death, macrosomia, small-for-gesta-
tional age (SGA), birth trauma (shoulder dystocia, bone fracture,
nerve palsy), gestational age at birth, preterm birth, congenital
anomaly, five-minute Apgar less than seven, birthweight, length,
neonatal fat mass, neonatal hypoglycaemia, respiratory distress
syndrome, hyperbilirubinaemia, hypocalcaemia, polycythaemia,
childhood growth, childhood cholesterol and childhood impaired
glucose tolerance.
Data were available for the following health service outcomes:
visits to health professionals, antenatal hospital admissions and
admission to neonatal intensive care unit.
Funding sources
Funding sources were reported in seven trials (Bo 2014;
Crowther 2005; Ferrara 2011; Kaviani 2014; Landon 2009;
Mendelson 2008; Yang 2014). None of the sources were condi-
tional grants from pharmaceutical companies. The remaining tri-
als did not detail the sources of funding (if any) in the published
manuscript (Bancroft 2000; Elnour 2008; Garner 1997; Gillen
2004; Jovanovic-Peterson 1989; Rahimikian 2014; Yang 2003;
Youngwanichsetha 2014).
Declarations of interest
Declarations of conflicts of interest were made in four trials (Bo
2014; Ferrara 2011; Landon 2009; Yang 2014). Three reported
that there were no conflicts of interest for any of the authors (Bo
2014; Ferrara 2011; Landon 2009). One trial (Yang 2014) re-
ported that there was a conflict of interest for one of the 12 au-
thors. The conflict states that the authors institution had received
research funding fromEli Lilly and the author is amember of advi-
sory committee and speaker forum sponsored by Eli Lilly. The re-
maining trials did not provide any statements about conflicts of in-
terest (Bancroft 2000;Crowther 2005; Elnour 2008;Garner 1997;
Gillen 2004; Jovanovic-Peterson 1989; Kaviani 2014; Mendelson
2008; Rahimikian 2014; Yang 2003; Youngwanichsetha 2014).
Excluded studies
Twenty-three trials (28 reports) were excluded. Six studies were
not randomised (Abirami 2014;O’Sullivan1980; Reader 2006) or
were quasi-randomised trials (O’Sullivan 1971; O’Sullivan 1974;
Perichart-Perera 2009).
Twelve trials did not use an intervention/comparison included in
this review (Adam 2014; Bastani 2015; Berry 2013; Fadl 2015;
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Ford 1997; Grant 2011; Homko 2002; Holmes 2012; Langer
1989; Li 1987; Mirzamoradi 2015; Rey 1997).
Three trials included women not meeting the diagnosis of ges-
tational diabetes and representing the wrong population for this
review (Bevier 1999; Bonomo 2005; Osmundson 2015).
One trial, although registered, never started recruitment due to
insufficient funding (Branch 2010), and a second trial did not
start recruitment, although no reason could be found (Kitzmiller
1990).
Risk of bias in included studies
Refer to Figure 2; Figure 3.
Figure 2. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 3. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Allocation
Randomisation - 10 of the trials were considered to be of low
risk of bias for randomisation (Bancroft 2000; Crowther 2005;
Elnour 2008; Ferrara 2011; Gillen 2004; Jovanovic-Peterson
1989; Kaviani 2014; Landon 2009;Mendelson 2008; Yang 2014).
Seven of these trials (Bancroft 2000; Crowther 2005; Ferrara 2011;
Gillen 2004; Kaviani 2014; Mendelson 2008; Yang 2014) used
computer-generated randomisation. Elnour 2008 used a restricted
randomisation method; Jovanovic-Peterson 1989 randomised by
drawing a number; and Landon 2009 used a simple urn method.
Method of randomisation was judged as unclear in five trials due
to lack of sufficient details (Bo 2014; Garner 1997; Rahimikian
2014; Yang 2003; Youngwanichsetha 2014).
Allocation concealment - five trials were considered to be of low
risk of bias for allocation concealment (Bancroft 2000; Bo 2014;
Crowther 2005; Gillen 2004; Landon 2009). Bancroft 2000 used
a telephone randomisation service that was controlled by a trial
centre and Bo 2014 used a website (third person); Crowther 2005;
Gillen 2004; Landon 2009 performed randomisation centrally.
Allocation concealment was judged as unclear in 10 trials due
to lack of sufficient details (Elnour 2008; Ferrara 2011; Garner
1997; Jovanovic-Peterson 1989; Kaviani 2014; Mendelson 2008;
Rahimikian 2014; Yang 2003; Yang 2014; Youngwanichsetha
2014).
Blinding
Performance bias
Four trials were judged to be of low risk of bias. Bancroft 2000
reported that the obstetrician was blinded to randomisation. Yang
2014 reported that the women with GDM were masked to the
allocation although the research staff were not. Crowther 2005
reported women and caregivers were unaware of diagnosis in the
control group and Garner 1997 reported that healthcare workers
in the control group were blinded to allocation.
In two trials the risk of bias was judged to be unclear: in Gillen
2004 participants were unaware of differences in advice between
the intervention and control groups but the researchers were aware
and inMendelson 2008 the women were not blinded to allocation
but the diabetes educators were blinded to allocation (personal
communication). Nine trials were judged to be of high risk of bias,
including six trials (Bo 2014; Jovanovic-Peterson 1989; Kaviani
2014; Rahimikian 2014; Yang 2003; Youngwanichsetha 2014)
that provided no details of blinding for participants or researchers.
Due to the types of interventions blinding is unlikely. Three trials
clearly stated that the researchers and participants were not blinded
(Elnour 2008; Ferrara 2011; Landon 2009).
Detection bias
Six trials were considered to be of low risk of detection bias.
Bo 2014 reported that dieticians and obstetricians who reported
maternal/neonatal complications and laboratory personnel were
blinded to allocation. Elnour 2008 reported that nursing andphar-
macy staff who assisted with questionnaire administration were
blinded to allocation. Ferrara 2011 provided details in the trials
registration document that outcome assessors were blinded. Yang
2014 reported that outcome assessors for pregnancy-induced hy-
pertensionwere blinded to allocation andYoungwanichsetha 2014
reported that HbA1c testing was conducted in a laboratory and
the personnel there are likely to have been blinded (no further de-
tails). Landon 2009 reported that outcome assessors were blinded
for some relevant outcomes (no details).
Nine trials (Bancroft 2000; Crowther 2005; Garner 1997; Gillen
2004; Jovanovic-Peterson 1989; Kaviani 2014; Mendelson 2008;
Rahimikian 2014; Yang 2003) provided no details of blinding of
outcome assessors and were judged as having an unclear risk of
bias.
Incomplete outcome data
Ten trials were judged to be of low risk for attrition bias. Bo 2014;
Crowther 2005; Jovanovic-Peterson 1989; Kaviani 2014 reported
that all women who were randomised were analysed or that there
were no losses to follow-up. Attrition of less than10%was reported
by Elnour 2008 (9%); Ferrara 2011 (4%); Garner 1997 (< 1%);
Gillen 2004 (6%); Landon 2009 (6%) and Youngwanichsetha
2014 (6%). The Crowther 2005 trial, although reporting low at-
trition levels for clinical data, reported that only 68% of women
provided data for maternal health status.
Two trials were judged to be of unclear risk of bias. In the
Rahimikian 2014 trial, data appear to be missing for one of the
intervention groups but no reasons are provided. Bancroft 2000
reported that 18% of women failed to return for postnatal mea-
surements.
Three trials were judged to be at high risk for attrition bias.
Mendelson 2008 reported that only 27% (27/100) of women had
an HbA1c value recorded at birth; there is no explanation as to
why the remaining women did not have results. Yang 2003 re-
ported that only 51% (48/95) of women in the intervention group
completed the management plan. Yang 2014 reported that due
to construction work in the building where the intervention took
place during the trial, 242 women did not receive the intended
intervention and they excluded these women from the analysis.
Selective reporting
21Lifestyle interventions for the treatment of women with gestational diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Three trials were judged to be of low risk for reporting bias (
Crowther 2005; Elnour 2008; Landon 2009).
One trial was judged to be of unclear risk for reporting bias.
Mendelson 2008 reported one additional outcome of caesarean
section that was not prespecified in the methods section; all of the
other outcomes listed a priori were reported.
Eleven trials were judged to be of high risk for reporting bias.
Bancroft 2000; Bo 2014; Jovanovic-Peterson 1989 and Yang 2014
reported additional outcomes in the results section that were not
prespecified in the methods. Ferrara 2011 reported data for a pi-
lot study and the full trial is yet to be reported on; the primary
trial outcome was postpartum weight gain and there were very
limited neonatal outcomes. Garner 1997 did not pre-specify any
outcomes; Gillen 2004 did not clearly pre-specify trial outcomes,
the trial authors report no differences in pregnancy outcomes or
mode of birth but these data are not reported in the paper. Kaviani
2014 reported very limited maternal outcome and no neonatal
outcomes were reported. Rahimikian 2014 did not provide any
numeric data for any of the specified trial outcomes. Yang 2003
reported the trial as a letter and only data for caesarean section and
rupture of membranes were reported. Youngwanichsetha 2014 re-
ported on the effects of glycaemic control but no other neonatal
or maternal outcomes were reported.
Other potential sources of bias
Two trials were judged to be at high risk of other bias. Yang 2003
published findings in a letter and we were unable to find a full
publication. The sample size was estimated at 200 but only 100
women were randomised. Jovanovic-Peterson 1989 reported that
the women in the exercise plus diet group had a significantly higher
one-hour plasma glucose in the diagnostic test at baseline, the
treatment and control groups are therefore not balanced for an
important baseline prognostic variable.
There was no evidence of other risk of bias reported by
Bancroft 2000; Bo 2014; Crowther 2005; Elnour 2008;
Ferrara 2011; Garner 1997; Gillen 2004; Kaviani 2014;
Landon 2009; Mendelson 2008; Rahimikian 2014; Yang 2014;
Youngwanichsetha 2014. These studies were judged to be of low
risk of other potential sources of bias.
Effects of interventions
See: Summary of findings for the main comparison Lifestyle
interventions versus control - Maternal outcomes; Summary of
findings 2 Lifestyle versus control - Neonatal and later outcomes
1.0 Lifestyle intervention versus usual care or control
Maternal primary outcomes
1.1 Hypertensive disorders of pregnancy (including pre-
eclampsia, pregnancy-induced hypertension, eclampsia)
There was no evidence of a difference between lifestyle interven-
tion and control groups forrisk of pre-eclampsia (average risk ratio
(RR) 0.70; 95% confidence interval (CI) 0.40 to 1.22; four tri-
als, 2796 women; I2 = 79%, Tau2 = 0.23; low-quality of evidence)
(Analysis 1.1). The evidence was downgraded (-2) for inconsis-
tency.
We explored the heterogeneity by looking at the diagnostic cri-
teria used and the definitions used in the individual trials. Three
different diagnostic criteria were used by studies reporting data
for pregnancy-induced hypertension: (i) World Health Organi-
zation - WHO (1999) Crowther 2005; (ii) American Diabetes
Association - ADA (2013) Elnour 2008; Landon 2009 and (iii)
International Association for the Study of Diabetes in Pregnancy
- IADPSG (2010) Yang 2014. Subgroup analysis identified a sig-
nificant differential effect on the risk for pre-eclampsia based on
diagnostic criteria (Chi2 = 9.94, df = 2, P = 0.007, I2 = 79.9%).
Interpretation of these data remains unclear due to the limited
number of trials reporting data for each diagnostic criteria.
1.2 Caesarean section
Caesarean section was reported in 10 trials (Bancroft 2000; Bo
2014; Crowther 2005; Elnour 2008; Garner 1997; Gillen 2004;
Landon 2009; Mendelson 2008; Yang 2003; Yang 2014). There
was no evidence of a difference between lifestyle intervention and
control groups forrisk of birth by caesarean section (average RR
0.90; 95% CI 0.78 to 1.05; 10 trials, 3545 women; I2 = 48%,
Tau2 = 0.02; low-quality evidence) (Analysis 1.2). The evidence
was downgraded for selective reporting and inconsistency. There is
some suggestion of asymmetry observed in the funnel plot (Figure
4).
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Figure 4. Funnel plot of comparison: 1 Lifestyle intervention versus usual care/control, outcome: 1.2
Caesarean section.
1.3 Development of type 2 diabetes
Two trials (Bancroft 2000; Landon 2009) reported no evidence of
a difference between lifestyle interventions and control groups for
development of type 2 diabetes (RR 0.98, 95% CI 0.54 to 1.76; two
trials, 486 women; I2 = 16%; Analysis 1.3; low-quality evidence).
The evidence was downgraded for risk of bias and attrition bias.
Bancroft 2000 only states that diagnosis was postnatally. Bancroft
2000 reports data for postnatal glucose metabolism, but there are
no details at what time point the test was conducted. Landon 2009
reported follow-up at 4.5 to 10 years.
Neonatal primary outcomes
1.4 Perinatal (fetal and neonatal death) and later infant
mortality
There is substantial uncertainty about the size and he direction
of the effect for the outcome of perinatal death between lifestyle
intervention and control groups reported in two trials (Crowther
2005; Landon 2009) (RR 0.09, 95% CI 0.01 to 1.70; two trials,
1988 infants; Analysis 1.4; low-quality evidence). The evidence was
downgraded for risk of bias and imprecision. The evidence should
be interpreted with caution as no perinatal deaths were reported
in either intervention or control group in the Landon 2009 trial.
No data were reported for later infant mortality.
1.5 Large-for-gestational age (LGA) (as defined by the
trialists)
Lifestyle interventions were associated with a reduction in the
risk of being born large-for-gestational age reported in six trials
(Bancroft 2000; Bo 2014; Crowther 2005; Elnour 2008; Landon
2009; Yang 2014) (RR 0.60, 95% CI 0.50 to 0.71; six trials, 2994
infants; I2 = 4%; Analysis 1.5; moderate-quality evidence). The
evidence was downgraded due to unclear and high risk of bias for
allocation concealment, lack of blinding and selective reporting.
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1.6 Death of serious morbidity composite (variously defined
by trials, e.g. perinatal or infant death, should dystocia, bone
fracture or nerve palsy)
A composite of serious infant outcome was reported in two trials
(Crowther 2005; Landon 2009). There was no evidence of a
difference between lifestyle intervention and control groups for
risk of a composite of serious infant outcome (average RR 0.57,
95% CI 0.21 to 1.55; two trials, 1930 infants; I2 = 82%, Tau2
= 0.44; Analysis 1.6; very low-quality of evidence). The evidence
was downgraded for inconsistency, risk of bias and imprecision.
In the Crowther 2005 trial, the composite included one or more
of: death, shoulder dystocia, bone fracture and nerve palsy. In
the Landon 2009 trial the composite included: stillbirth, neonatal
death, hypoglycaemia, hyperbilirubinaemia, elevated cord-blood
C-peptide level and birth trauma.We decided to include themeta-
analysis as the direction of the treatment effect is the same in both
trials.
Primary outcomes not reported in the included studies
None of the included trials prespecified or reported neurosensory
disability in later childhood as a trial outcome.
Maternal secondary outcomes
1.7 Use of additional pharmacotherapy
Use of additional pharmacotherapywas reported in eight trials. One
trial (Ferrara 2011) found no evidence of a difference between
women who had received lifestyle interventions and those in the
control groups for the use of additional oral anti-diabetic agents
which were required by 28% (27/96) women in the intervention
group and 36% (36/101) in the control group (RR 0.79, 95% CI
0.52 to 1.19; one trial, n = 197 women; Analysis 1.7). Eight trials
reported on the need for additional insulin (Bancroft 2000; Bo
2014; Crowther 2005; Elnour 2008; Ferrara 2011; Gillen 2004;
Landon 2009; Yang 2014). Lifestyle interventions were associated
with an increase in the use of supplementary insulin (214/1626;
13%) compared with control interventions (62/1628; 4%) (aver-
age RR 2.54; 95% CI 1.19 to 5.42; nine trials, n = 3254 women;
I2 = 80%, Tau2 = 0.77; Analysis 1.7). We advise caution when
interpreting these results due to the observed heterogeneity (in-
consistency). The data suggest a wide spread of treatment effects
and incidence of the outcome (Analysis 1.7).
1.8 Maternal hypoglycaemia
One small trial of 19 women (Jovanovic-Peterson 1989) reported
no events of maternal hypoglycaemia in either the lifestyle inter-
vention or the control groups (Analysis 1.8).
1.9 Glycaemic control during/after treatment
Glycaemic control during/after treatment was reported in seven tri-
als that provided data suitable for meta-analysis. Data from the
Kaviani 2014 trial were not suitable for inclusion in themeta-anal-
ysis for fasting blood glucose concentration or postprandial blood
glucose concentration. Further information has been requested
from the authors.
1.9.1 Six trials reported on fasting blood glucose concentrations
(Bancroft 2000; Bo 2014; Elnour 2008; Garner 1997; Mendelson
2008; Youngwanichsetha 2014). There was no clear evidence of
a difference between lifestyle interventions and control groups in
fasting blood glucose concentrations during/at the end of treat-
ment (average standardised mean difference (SMD) -0.32; 95%
CI -0.72 to 0.07; six trials; 853 women; I2 = 85%, Tau2 = 0.18;
data not shown). Bancroft 2000 reported on median and range for
postnatal fasting blood glucose concentrations (Table 6). There
was no evidence of a difference between the intervention and con-
trol group.
1.9.2 Postprandial blood glucose concentration was reported at
one hour in two trials (Garner 1997; Jovanovic-Peterson 1989)
and at two hours in two trials (Bancroft 2000; Youngwanichsetha
2014); one trial did not provide details of the timing of the post-
prandial test (Bo 2014). The data from the Bancroft 2000 trial are
median and range which could not be included in a meta-analysis
and are summarised in Table 6. Lifestyle interventions were asso-
ciated with a decrease in postprandial blood glucose concentration
at the end of treatment (average mean difference (MD) -27.11
mg/dL; 95% CI -44.62 to -9.61; four trials, n = 588 women; I2 =
97%, Tau2 = 300.13). Visual inspection of the forest plot suggests
that the Jovanovic-Peterson 1989 trial is an outlier. This is a very
small trial of just 19 women in which the treatment effect suggests
very large benefit. The removal of this trial from the meta-analy-
sis does not substantially alter the estimate of treatment effect or
benefit (MD -10.95 mg/dL, 95% CI -13.50 to -8.40 - analysis
not shown), but observed heterogeneity is reduced to I2 = 0%
(Analysis 1.9).
1.9.3 HbA1c was reported at the end of treatment in six trials
(Bancroft 2000; Bo 2014; Elnour 2008; Jovanovic-Peterson 1989;
Mendelson 2008; Youngwanichsetha 2014). Lifestyle interven-
tions were associated with a reduction in HbA1c values at the end
of treatment (average MD -0.33 mmol/mol; 95% CI -0.47 to -
0.19; six trials, n = 532 women; I2 = 66%, Tau2 = 0.02; Analysis
1.9).
1.10 Weight gain in pregnancy
Weight gain in pregnancy was reported in four trials (Crowther
2005;Garner 1997; Landon 2009; Yang 2014). Lifestyle interven-
tions were associated with a decrease in weight gain in pregnancy
(average MD -1.30 kg, 95% CI -2.26 to -0.35; four trials, n =
2930 women; I2 = 80%, Tau2 = 0.75; Analysis 1.10). The largest
difference between groups was observed in the Landon 2009 trial
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(2 kg in the lifestyle intervention group versus 5 kg in the control
group), whereas the Yang 2014 trial found no evidence of a differ-
ence between groups but also reported a mean increase in weight
during pregnancy of approximately 15 kg.
1.11 Induction of labour
Induction of labour was reported in four trials (Bancroft 2000;
Crowther 2005; Landon 2009; Yang 2014). Therewas no evidence
of a difference between the lifestyle intervention groups and the
control groups (average RR 1.20, 95%CI 0.99 to 1.46; four trials,
n = 2699 women; I2 = 37%, T2 = 0.01; high-quality evidence;
Analysis 1.11).
1.12 Postpartum haemorrhage (as defined by trialists)
Two trials reported on postpartum haemorrhage (Crowther 2005;
Elnour 2008). There was no evidence of a difference for postpar-
tum haemorrhage between women in the lifestyle intervention or
the control groups (average RR 0.61, 95% CI 0.20 to 1.89; two
trials, n = 1165 women; I2 = 64%, Tau2 = 0.46; Analysis 1.12).
1.13 Postpartum infection
Postpartum infection was reported in the Crowther 2005 trial only.
There was no evidence of a difference for postpartum infection
between women in the lifestyle intervention or the control groups
(RR 0.61, 95% CI 0.34 to 1.10; one trial, n = 1000 women;
Analysis 1.13).
1.14 Perineal trauma/tearing
Perineal trauma/tearing was reported in the Crowther 2005 trial
only. There was no evidence of a difference for perineal trauma/
tearing between women in the lifestyle intervention or the con-
trol groups (RR 1.04, 95% CI 0.93 to 1.18; one trial, n = 1000
women; moderate-quality evidence; Analysis 1.14). Evidence was
downgraded due to imprecision as it is based on a single trial.
1.15 Breastfeeding at discharge, six weeks postpartum, six
months or longer
Breastfeeding was reported in two trials (Crowther 2005; Ferrara
2011). Crowther 2005 reported no clear difference for rates of
breastfeeding at discharge between the lifestyle intervention or
the control groups (RR 1.04, 95% CI 0.99 to 1.10; one trial, n
= 1000 women). Ferrara 2011 reported on breastfeeding at six
weeks’ postpartum (RR 0.97, 95% CI 0.87 to 1.07; one trial,
n = 188 women) and six months or longer (RR 1.31, 95% CI
0.99 to 1.74; one trial, n = 161 women). At neither six weeks’
postpartum nor six months postpartum was there evidence of a
difference in breastfeeding rates between lifestyle intervention and
control groups. See Analysis 1.15.
1.16 and 1.17 Sense of well-being and quality of life
Quality of life was reported in two trials (Crowther 2005; Elnour
2008) both during the treatment and at three months postpar-
tum using the SF36 questionnaire. Maternal quality of life was
improved during treatment for physical functioning, role physi-
cal, bodily pain, general health, vitality, social functioning, role
emotional, health state utility and overall physical component for
women receiving a lifestyle intervention compared with the con-
trol group (Analysis 1.16). There were no clear differences be-
tween intervention and control groups for mental health, overall
mental component or anxiety. At three months follow-up, only
social functioning remained different between intervention and
control groups. No other differences between groups were found
for quality of life (Analysis 1.17).
No data were reported for adherence to the intervention, pla-
cental abruption, maternal mortality, behavioural changes associ-
ated with the intervention, views of the intervention or relevant
biomarker changes associated with the intervention (including
adiponectin, free fatty acids, triglycerides, high-density lipopro-
teins, (HDL) low-density lipoproteins (LDL), insulin).
Long-term outcomes for mother
1.18 Postnatal depression
Postnatal depression was reported in the Crowther 2005 trial only
and defined as a Edinburgh Postnatal Depression Score > 12.
Lifestyle interventions were associated with a decrease in the risk of
postnatal depression compared with the control group (RR 0.49,
95% CI 0.31 to 0.78; one trial, n = 573 women; low-quality evi-
dence; Analysis 1.18). The evidence was downgraded for impreci-
sion as it is based on a single trial and risk of attrition bias as only
68% of randomised women responded to the questionnaire.
1.19 Postnatal weight retention or return to pre-pregnancy
weight
Ability to meet postpartum weight goals was reported in one study
(Ferrara 2011). At six weeks and seven months postpartum there
was no evidence of a difference between the lifestyle and control
groups for this outcome (RR 1.20, 95% CI 0.67 to 2.17; n = 189
women; RR 1.59, 95% CI 0.99 to 2.57, n = 159 women, respec-
tively; Analysis 1.19). At 12 months postpartum more women
in the lifestyle group had met postpartum weight goals than in
the control group (RR 1.75, 95% CI 1.05 to 2.90; participants =
156; low-quality evidence;Analysis 1.19). The evidence was down-
graded due to imprecision and risk of bias.
1.20 and 1.21 Impaired glucose intolerance
Fasting plasma glucose concentration at three months postpartum
was reported by Elnour 2008. There was a non-significant trend
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towards lower fasting glucose concentrations in the women who
had received a lifestyle intervention compared with the control
group (MD -0.08 mmol/L, 95% CI -0.16 to 0.00; one trial, n =
165 women; Analysis 1.20). At six months postpartum, there was
a reduction in fasting blood glucose concentrations in the lifestyle
intervention group compared with the control group (MD -0.14
mmol/L, 95%CI -0.22 to -0.06; one trial n = 165women;Analysis
1.20). Data from Kaviani 2014 were not suitable for inclusion in
the meta-analysis for postnatal glycaemic blood glucose concen-
trations. The authors have been contacted for further informa-
tion. Bancroft 2000 found no evidence of a difference between
lifestyle intervention and control groups for diagnosis of postnatal
impaired glucose tolerance (RR 0.67, 95% CI 0.12 to 3.69; one
trial, n = 56 women; Analysis 1.21).
1.22 Cardiovascular health (as defined by the trialists
including blood pressure, hypertension, cardiovascular
disease, metabolic syndrome)
Landon 2009 reportedno evidence of a difference between lifestyle
and interventions groups for the risk of maternal metabolic syn-
drome at follow-up at between 4.5 to 10 years after diagnosis of
gestational diabetes mellitus (GDM) (RR 0.93, 95% CI 0.71 to
1.22; n = 430 women; Analysis 1.22).
There was no evidence of a difference between lifestyle and control
groups for body mass index (BMI) at the follow-up. Landon 2009
reported data formaternal BMI at long-term follow-up, 4.5 and 10
years after diagnosis of GDM. The trial by Garner 1997 followed
up mothers and infants at nine to 11 years. The data in both trials
were not in a format suitable for inclusion in a meta-analysis and
are summarised in Table 8.
No data were reported for type 1 diabetes, subsequent gestational
diabetes, cardiovascular health (blood pressure, hypertension or
cardiovascular disease).
Neonatal secondary outcomes
1.23 Stillbirth
Stillbirth was reported in four trials (Bancroft 2000; Crowther
2005; Garner 1997; Landon 2009). There was no evidence of a
difference in the risk of stillbirth between the lifestyle and the
control groups (RR 0.15, 9%CI 0.01 to 2.86; four trials, n = 2355
infants). There were no events of stillbirth reported in the lifestyle
intervention group (0/1172) and three events in the control group
(3/1183). All three stillbirths were reported from a single trial
(Crowther 2005) (Analysis 1.23).
1.24 Neonatal death
Neonatal deathwas reported infive trials (Bancroft 2000;Crowther
2005; Garner 1997; Landon 2009; Yang 2014). There was no
evidence of a difference in the risk for neonatal death between the
lifestyle and the control groups (RR 0.73, 95% CI 0.22 to 2.42;
five trials, n = 3055 infants; I2 = 0%). Event rates were low with
4/1511 (0.3%) neonatal deaths in the lifestyle intervention group
and 6/1544 (0.4%) in the control group (Analysis 1.24).
1.25 Macrosomia (greater than 4000 g; or as defined by
individual study)
Macrosomia was reported in seven trials (Crowther 2005; Elnour
2008; Ferrara 2011; Garner 1997; Landon 2009; Mendelson
2008; Yang 2014). The Crowther 2005 and Yang 2014 trials de-
fined macrosomia as≥ 4 kg, the remaining trials used a definition
of > 4 kg. Lifestyle interventions were associated with a significant
reduction in the risk of macrosomia compared with the control
group (average RR 0.64, 95% CI 0.48 to 0.87; seven trials, n =
3422 infants; I2 = 65%, Tau2 = 0.10; Analysis 1.25). Sensitivity
analyses were used to explore the heterogeneity by looking at those
trials that were judged to be low risk of bias for allocation con-
cealment (Crowther 2005; Landon 2009). The direction of the
treatment effect was unchanged and heterogeneity was reduced to
I2 = 0% (RR 0.44, 95% CI 0.34 to 0.57; participants = 1961;
studies = two).
1.26 Small-for-gestational (SGA) age (as defined by trialists)
There was no evidence of a difference in the risk of the infant
being born SGA between the lifestyle or the control group (RR
0.98, 95% CI 0.73 to 1.31; n = 2324 infants; four trials; I2 = 0%;
Analysis 1.26).
1.27 Birth trauma (shoulder dystocia, bone fracture, nerve
palsy)
Birth trauma (not specified but including shoulder dystocia, bone
fracture and/or nerve palsy) was reported in three trials (Garner
1997; Landon 2009; Yang 2014). Event rates were low with
only the Landon 2009 trial reporting 3/964 (0.3%) events in the
lifestyle intervention group and 6/966 (0.6%) in the control group
(RR 0.48, 95% CI 0.12 to 1.90; three trials, n = 1930 infants)
(Analysis 1.27). Event rates for bone fracture were very low with
only one event being reported in the Crowther 2005 trial in the
control group (1/885) compared with no events in the lifestyle
intervention group (0/845). No events were reported by Yang
2014 (RR 0.35, 95% CI 0.01 to 8.45, two trials, n = 1730 in-
fants) (Analysis 1.27). Nerve palsy was only reported in one trial
(Crowther 2005) where there were no events in the lifestyle in-
tervention group (0/506) and 3/524 events in the control group.
The difference was not statistically significant. Shoulder dystocia
was reported in five trials (Bancroft 2000; Crowther 2005; Elnour
2008; Landon 2009; Yang 2014). Lifestyle interventions were as-
sociated with a significant decrease in the risk of shoulder dystocia
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(RR 0.38, 95% CI 0.21 to 0.66; five trials, 2894 infants; Analysis
1.27).
1.28 Gestational age at birth
There was no evidence of a difference for gestational age at birth be-
tween the lifestyle intervention and control groups reported in five
trials (Bancroft 2000; Garner 1997; Gillen 2004; Landon 2009;
Yang 2014) (MD 0.04 weeks, 95% CI -0.13 to 0.20; n = 2057
infants; five trials; I2 = 31%; Analysis 1.28). Two trials (Crowther
2005; Jovanovic-Peterson 1989) reported data in a format that
could not be included in a meta-analysis (Table 9); their results
concur with the meta-analysis indicating no evidence of a differ-
ence in gestational age at birth between infants exposed to the
lifestyle intervention and control groups.
1.29 Preterm birth (< 37 weeks’ gestation; and < 32 weeks’
gestation)
Lifestyle interventions were associated with a reduction in the risk
of preterm birth (< 37 weeks’ gestation) compared with the control
group as reported in four trials (Elnour 2008; Landon 2009; Yang
2014) (RR 0.71, 95% CI 0.53 to 0.96; n = 1797 infants; three
trials; I2 = 27%; Analysis 1.29).
1.30 Five-minute Apgar less than seven
There was no evidence of a difference between the lifestyle inter-
vention and control groups for a five-minute Apgar score less than
seven reported by Crowther 2005 (RR 0.56; 95% CI 0.21 to 1.52;
one trial, n = 1030 infants; Analysis 1.30).
1.31 Birthweight and z score
Birthweight was reported in six trials (Bancroft 2000; Crowther
2005;Garner 1997; Jovanovic-Peterson 1989; Landon 2009; Yang
2014). Lifestyle interventions were associated with a significant
reduction in birthweight (MD -109.64 g, 95% CI -149.77 to -
69.51; six trials, n = 3074 infants; Analysis 1.31) without a conse-
quent increase in the risk of SGA as previously reported (Analysis
1.26). No data were reported for z scores.
1.32 Length and z score
Length at birth - one trial (Yang 2014) reported no evidence of a
difference in infant length at birth between infants exposed to a
lifestyle intervention or the control group (MD -0.10 cm, 95%
CI -0.37 to 0.17; one trial, n = 700 infants; Analysis 1.32). No
data were reported for z scores.
1.33 Adiposity (including skinfold thickness measurements
(mm); fat mass)
Neonatal fat mass - one trial (Landon 2009) reported that the in-
fants exposed to the lifestyle intervention had a decreased whole-
body fat mass (estimated from skinfold thickness) compared with
the control group (MD -37.30 g, 95% CI -63.97 to -10.63; one
trial, 958 infants; low-quality evidence; Analysis 1.33). The evi-
dence was downgraded for risk of bias and imprecision as it was
based on a single study. No data were reported for skinfold thick-
ness.
1.34 Neonatal hypoglycaemia
Neonatal hypoglycaemia - six trials (Bancroft 2000; Crowther 2005;
Elnour 2008; Garner 1997; Landon 2009; Yang 2014) found no
evidence of a difference in the risk of neonatal hypoglycaemia
between the infants exposed to a lifestyle intervention and those
exposed to the control group (average RR 0.99, 95% CI 0.65 to
1.52; six trials, n = 3000 infants; I2 = 48%, Tau2 = 0.12;moderate-
quality evidence;Analysis 1.34). The evidence was downgraded for
risk of bias.
1.35 Respiratory distress syndrome
Respiratory distress syndrome - four trials (Bancroft 2000; Crowther
2005; Elnour 2008; Landon 2009) found no evidence of a differ-
ence in the risk of respiratory distress syndrome between exposure
to lifestyle intervention or control groups (average RR 0.79, 95%
CI 0.34 to 1.85, four trials, n = 2195 infants; I2 = 64%, Tau2 =
0.44; Analysis 1.35).
1.36 Neonatal jaundice (hyperbilirubinaemia)
Neonatal jaundice (hyperbilirubinaemia) - four trials (Crowther
2005; Elnour 2008; Garner 1997; Landon 2009) found no evi-
dence of a difference in the risk for hyperbilirubinaemia between
infants exposed to the lifestyle intervention or the control group
(average RR 0.76, 95% CI 0.50 to 1.16; four trials, n = 2362; I2
= 47%, Tau2 = 0.08; Analysis 1.36).
1.37 Hypocalcaemia
Hypocalcaemia was reported in two trials (Elnour 2008; Garner
1997). Lifestyle interventions were associated with an increased
risk for hypocalcaemia compared with the control groups (RR
1.38, 95% CI 1.01 to 1.88; two trials, n = 464 infants; Analysis
1.37).
1. 38 Polycythaemia
Polycythaemia was reported in one trial (Elnour 2008). There was
no evidence of a difference between lifestyle intervention and con-
trol group for the risk for infant polycythaemia (RR 0.22, 95% CI
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0.01 to 5.40; one trial, n = 165 infants; Analysis 1.38). Caution
is recommended in interpreting the results due to the low event
rates (0/99 in the lifestyle group; 1/66 in the control group).
No data were reported for head circumference, z scores for anthro-
pometric measures, ponderal index, skinfold thickness or relevant
biochemical markers.
Childhood follow-up
Three trials reported follow-up data into childhood (Crowther
2005; Garner 1997; Landon 2009).
The Landon 2009 trial has reported on follow-up of children at
ages five to 10 years. Seventy-four per cent (666/905) of the origi-
nal trial cohort were contacted and 500 (55%) consented to enrol
in the follow-up. Continuous data for BMI z score, cholesterol
concentration, triglycerides and impaired glucose tolerance were
reported as adjusted means with 95% CIs and we have therefore
not included these data in the meta-analysis.
Gillman 2010 reported on the follow-up at four to five years from
199 (20%) children in Australia who were born to 1000 mothers
who participated in the ACHOIS trial (Crowther 2005). This
cohort of data is likely to be biased as it does not represent the
entire trial population. The mean age at follow-up in this cohort
was 4.7 ± 0.2 years in the intervention group and 4.7 ± 0.4 years
in the control group.
The offspring of the Garner 1997 trial were followed up at seven
to 11 years by Keely (2008) (for metabolic markers of insulin
resistance).
1.39 Childhood weight and z score
Childhood weight was reported in one trial (Crowther 2005) who
foundno evidence of a difference between the lifestyle intervention
and control group exposed infants (MD -0.30 kg, 95% CI -1.29
to 0.69; one trial, n = 199 children; Analysis 1.39). No data were
reported for z scores.
1.40 Childhood height and z score
Childhood height was reported in one trial (Crowther 2005) who
foundno evidence of a difference between the lifestyle intervention
and control group exposed infants (MD -0.60 cm, 95% CI -2.05
to 0.85; one trial, n = 199 children; Analysis 1.39). No data were
reported for z scores.
1.41 and 1.42 Adiposity (including BMI, skinfold thickness,
fat mass)
Childhood BMI was reported in three trials (Crowther 2005;
Garner 1997; Landon 2009).
There was no evidence of a difference between groups for BMI
≥ 85th percentile reported in the three trials (Crowther 2005;
Garner 1997; Landon 2009) (RR 0.91, 95% CI 0.75 to 1.11; par-
ticipants = 767; I2 = 4%; Analysis 1.41;moderate-quality evidence).
The evidence was downgraded for risk of bias. Childhood BMI z
score was reported in one trial (Crowther 2005) which found no
evidence of a difference between groups at four to five years of age
(MD0.08, 95%CI -0.28 to 0.44; one trial, n = 199 children). The
Landon 2009 follow-up of children at five to 10 years reported
an adjusted mean BMI z score of 0.33 (95% CI 0.15 to 0.51; n
= 264) in the treated group and an adjusted mean BMI z score
of 0.36 (95% CI 0.17 to 0.55, n = 236) in the untreated group.
These data could not be combined in a meta-analysis (Analysis
1.42).
1.43 Impaired glucose tolerance
One study (Garner 1997) reported no evidence of a difference
between the treated and untreated groups for fasting blood glucose
concentration at seven to 11 years of age (MD 0.10 mg/dL, 95%
CI -0.10 to 0.30; one trial, n = 68 children). The follow-up of
the Landon 2009 trial reported that 12/264 (5.4%) of children
from the treated group and 13/236 (7.2%) of children from the
untreated group had impaired fasting glucose concentration≥ 5.6
mmol/L (100 mg/dL). An adjusted mean fasting blood glucose
concentration of 88.41 mg/dL (95% CI 87.33 to 89.50; n = 264)
was reported for the treated group and an adjusted mean blood
glucose concentration of 88.67 mg/dL (95% CI 87.56 to 89.78,
n = 236) was reported for the untreated group. These data could
not be combined in a meta-analysis. There was no evidence of a
difference between the lifestyle intervention and control groups
for child two-hour postprandial glucose concentration (MD 0.00
mg/dL, 95% CI -0.48 to 0.48; one trial, n = 68 children). See
Analysis 1.43.
1.44 Dyslipidaemia or metabolic syndrome
Dyslipidaemia or metabolic syndrome - in Garner 1997 there was
no evidence of a difference between groups in total cholesterol
concentration (MD -0.20 mg/dL, 95%CI -0.55 to 0.15; one trial,
n = 68 children); HDL (MD 0.10 mg/dL, 95% CI -0.05 to 0.25;
one trial, n = 68 children) or LDL (MD -0.12 mg/dL, 95% CI
-0.50 to 0.26; one trial, n = 68 children). The follow-up of the
Landon 2009 trial reported lowHDL cholesterol (< 40 mg/dL) in
27/264 (13%) of children in the treated group and 22/236 (12%)
in the untreated group. The adjusted mean for HDL cholesterol
concentration for the treated group was 54.35 mg/dL (95% CI
52.42 to 56.28; n = 264) and for the untreated group the adjusted
mean HDL cholesterol concentration was 55.10 mg/dL (95% CI
53.16 to 57.05; n = 236). These data could not be combined in a
meta-analysis (Analysis 1.44).
The Landon 2009 follow-up also reported elevated triglyceride
concentrations (≥ 100 mg/dL four to nine years,≥ 130 mg/dL 10
years) in 38/264 (18%) of the treated group and 29/236 (16%) in
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the untreated group.The adjustedmean triglyceride concentration
was 58.91 mg/dL (95% CI 54.82 to 63.30; n = 264) for the
treated group and adjusted mean triglyceride concentration for
the untreated group was 57.38 mg/dL (95% CI 53.33 to 61.73;
n = 236). These data could not be combined in a meta-analysis.
Childhood data for triglyceride concentrations were reported by
Garner 1997 who found a median value of 0.8 mmol/L (range 0.4
to 2.7) in 43 children followed up whose mothers had been in the
lifestyle intervention group and a median (range) of 0.83 mmol/L
(0.5 to 5.4) in 25 children whose mothers had been in the control
group.
Blood pressure - the follow-up of the Landon 2009 trial reported
data for the number of children with hypertension (≥ 95th per-
centile for age, sex and height) which occurred in 30/264 (11.5%)
children from the treated group and 23/236 (10%) in the un-
treated group. The adjusted mean systolic blood pressure in the
treated group was 100 mm/Hg (95% CI 98 to 101, n = 264) and
for the untreated group the adjusted mean systolic blood pressure
was 100 mm/Hg (95% CI 98 to 101, n = 236). The adjusted
mean diastolic blood pressure in the treated group was 60 mm/
Hg (95% CI 59 to 61, n = 264) and for the untreated group the
adjusted mean systolic blood pressure was 59 mm/Hg (95% CI
58 to 60, n = 236).
No data were reported for the following childhood outcomes:
weight or height z scores, head circumference and z scores, educa-
tional attainment, type 1 diabetes or type 2 diabetes.
Adult outcomes
No data were reported for any of the pre-specified adult outcomes
for this review (weight, height, adiposity, employment, education
and social status/achievement, dyslipidaemia or metabolic syn-
drome, type 1diabetes, type 2diabetes, impaired glucose tolerance,
cardiovascular health (as defined by trialists including blood pres-
sure, hypertension, cardiovascular disease, metabolic syndrome)).
Health service use
1.45 Number of antenatal visits or admissions
There was no evidence of a difference between the lifestyle inter-
vention and control groups for the number of antenatal visits or
admissions - (RR 1.06, 95% CI 0.87 to 1.29; one trial, n = 1000
women; Analysis 1.45) reported in one trial (Crowther 2005).
1.46 and 1.47 Number of hospital or health professional
visits (including midwife, obstetrician, physician, dietician,
diabetic nurse)
Number of hospital or health professional visits (during pregnancy) -
the women randomised to the lifestyle intervention groups were
more likely to have a visit with a dietitian compared with the
control groups (RR 9.24, 95% CI 7.12 to 12.01; one trial, n =
1000women; Analysis 1.46) or a visit with a diabetes care educator
(RR 8.55, 95% CI 6.67 to 10.96; one trial, n = 1000 women;
Analysis 1.46) than the control group. This is most likely due
to the trial protocol requiring a visit with a dietician (Crowther
2005). One trial (Yang 2014) reported no evidence of a difference
in the number of visits to an obstetrician between the lifestyle
intervention and control groups (MD 0.20 visits, 95% CI -0.21
to 0.61; one trial, n = 700 women; Analysis 1.47) and Ferrara
2011 reported no evidence of a difference between groups for the
number of visits to an antenatal care provider (not specified) -
(MD 0.10 visits, 95% CI -1.58 to 1.78; one trial, 197 women;
Analysis 1.47). Other data reported as median or mean without
standard deviation are summarised in Table 10.
1.48 Admission to neonatal intensive care unit/nursery
There was no evidence of a difference in the admission to neonatal
intensive care unit or special care baby unit between infants who had
been exposed to the lifestyle intervention or the control groups
(average RR 0.91, 95% CI 0.59 to 1.40; three trials, n = 2030
infants; I2 = 70%, Tau2 = 0.09; Analysis 1.48) reported in three
trials (Bancroft 2000; Crowther 2005; Landon 2009).
Costs - only one trial (Crowther 2005) provided data for the eco-
nomic impact of a lifestyle intervention compared with usual care.
Table 11 illustrates the costs of gestational diabetes to the families
and the health service for the lifestyle and control groups. Not
surprisingly the costs were higher in the intervention group than
the control group which is mainly due to increased surveillance
and increased contact with health professionals.
No data were reported for duration of stay in neonatal intensive
care or special care baby unit, or the duration of the mothers’ stay
in hospital (antenatal, neonatal, postnatal), extra use of healthcare
services or women’s view of treatment advice.
29Lifestyle interventions for the treatment of women with gestational diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
Lifestyle intervent ions versus usual care or diet alone for the treatment of women with gestat ional diabetes
Patient or population: Women with gestat ional diabetes
Settings: UK, Italy, Australia, United Arab Emirates, Canada, China, USA
Intervention: Lifestyle intervent ion
Comparison: Usual care or diet alone
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with usual care/
control
Risk with lifestyle in-
tervention
Large-for-gestat ional
age
189 per 1000 113 per 1000
(95 to 134)
RR 0.60
(0.50 to 0.71)
2994
(6 RCTs)
⊕⊕⊕©
MODERATE9
Perinatal (fetal and
neonatal death) and
later infant mortality
5 per 1000 0 per 1000
(0 to 9)
RR 0.09
(0.01 to 1.70)
1988
(2 RCTs)
⊕⊕©©
LOW 24
Analysis refers to peri-
natal death only. No
data were reported for
later infant mortality
Composite outcome in
infant (death, shoulder
dystocia, nerve palsy,
bone f racture)
193 per 1000 110 per 1000
(41 to 299)
RR 0.57
(0.21 to 1.55)
1930
(2 RCTs)
⊕©©©
VERY LOW 125
Neonatal
hypoglycaemia
75 per 1000 74 per 1000
(49 to 114)
RR 0.99
(0.65 to 1.52)
3000
(6 RCTs)
⊕⊕⊕©
MODERATE 6
Adiposity (neonatal) -
Neonatal fat mass (g)
The mean neonatal fat
mass was 427 g
The mean neonatal fat
mass in the interven-
t ion group was 37.30 g
fewer (63.97 fewer to
10.63 fewer)
- 958
(1 RCT)
⊕⊕©©
LOW 37
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Adiposity (child) - Child-
hood BMI > 85th per-
cent ile
350 per 1000 318 per 1000
(262 to 388)
RR 0.91
(0.75 to 1.11)
767
(3 RCTs)
⊕⊕⊕©
MODERATE 8
Adiposity (adult) not
measured
see comment see comment not est imable None of the included tri-
als pre-specif ied adult
adiposity as an out-
come
Diabetes (type 2)
(child) - not measured
see comment see comment not est imable None of the included tri-
als pre-specif ied child-
hood diabetes (type 2)
as an outcome
Diabetes (type 2)
(adult) - not measured
see comment see comment not est imable None of the included tri-
als pre-specif ied adult-
hood diabetes (type 2)
as an outcome
Neurosensory disability
(child) - not measured
see comment see comment not est imable None of the included tri-
als pre-specif ied child-
hood neurosensory dis-
ability as an outcome
Neurosensory disability
(adult) - not measured
see comment see comment not est imable None of the included tri-
als pre-specif ied adult-
hood neurosensory dis-
ability as an outcome
* The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95% CI).
CI: Conf idence interval; RR: Risk rat io
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GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1 Evidence of inconsistency with I2 > 70%, downgraded 2 levels
2 1 of the 2 studies did not blind part icipants/ researchers, downgraded 1 level
3 Imprecision. Evidence is based on a single trial, downgraded 1 level
4 There is evidence of imprecision with wide conf idence intervals and low event rates, downgraded 1 level
5 Evidence of imprecision with wide conf idence intervals crossing the line of no ef fect, downgraded 1 level
6 Allocat ion concealment was unclear in 2/ 6 trials and blinding was not undertaken in 2/ 6 trials, downgraded 1 level
7 There was no blinding of researchers/ part icipants in this single trial, downgraded 1 level
8 Allocat ion concealment and randomisat ion was unclear in 1/ 3 trials and 1/ 3 trials did not blind part icipants/ researchers,
downgraded 1 level
9 Several of the included studies had high risk of bias for lack of blinding, incomplete outcome data and select ive report ing,
allocat ion concealment was unclear in 2 of the 6 studies. Downgraded 1 level.
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D I S C U S S I O N
Summary of main results
Fifteen trials (in 45 reports) are included in this review (4501
women, 3768 infants).
The evidence suggests that for women diagnosed with gestational
diabetes mellitus (GDM), a lifestyle intervention (two or more
interventions including dietary advice, physical activity, educa-
tion, self-monitoring of blood glucose), there is no clear difference
in risk of developing hypertension in pregnancy or of having a
caesarean birth (Summary of findings for the main comparison).
There was no evidence of a difference between lifestyle interven-
tion and control groups for the mother developing type 2 diabetes
at follow-up ranging from 4.5 to 10 years. A lifestyle intervention
was associated with a decrease in weight gain in pregnancy com-
pared with a control group. The lifestyle intervention group did
have more visits to health professionals and an increased use of
additional pharmacological therapies. One small study (n = 159
women; Ferrara 2011) found that women in the lifestyle interven-
tion group were more likely to meet postpartum weight goals at
one year compared with the control group. Few trials reported on
long-term maternal outcomes.
There was no evidence of a difference between infants exposed to
lifestyle interventions or control for the risk of perinatal death or a
composite of serious infant adverse events. Those infants exposed
to the lifestyle interventionhad a decreased risk of beingborn large-
for-gestational age (LGA) (Summary of findings 2) compared with
the infants whose mothers had been in the control group. None of
the included trials reported on childhood neurodisability. Infants
who had been exposed to a lifestyle intervention had a decreased
risk of or having macrosomia, being born preterm (< 37 weeks’)
and had a lower birthweight compared with the infants whose
mothers had been in the control group. There was also a reduced
risk of shoulder dystocia associated with lifestyle interventions.
No infant adverse effects or increased likelihood of admission to
neonatal intensive care were associated with the interventions re-
viewed. Follow-up into childhood was poorly reported with only
three of the 15 included trials contributing data (Crowther 2005;
Garner 1997; Landon 2009). There was no evidence of a differ-
ence between groups for body mass index (BMI) greater or equal
to the 85th percentile and no evidence of a difference in dyslipi-
daemia or blood pressure. None of the trials have yet reported data
for the infant as an adult (Summary of findings 2).
Overall completeness and applicability of
evidence
This review has focused on lifestyle interventions for the treatment
of women with GDM that included a combination of interven-
tions such as nutritional advice, physical activity, education, and
self-monitoring of blood glucose concentrations. Lifestyle inter-
ventions are used as the primary therapeutic strategy for women
diagnosed with GDM. Some women who commence lifestyle in-
terventions will require supplementary pharmacological interven-
tions (insulin or oral anti-diabetic pharmacological therapies), and
this is evident from this review with 10 of the included studies
reporting an increase in the use of supplementary pharmacological
therapy.
The evidence for treatment needs to be taken in context for the
needs of the individual woman, and other Cochrane systematic
reviews have examined or plan to examine different dietary advice
for women with GDM (Han 2013), exercise (Ceysens 2016), in-
sulin (Brown 2016) and oral anti-diabetic pharmacological ther-
apies (Brown 2015b). This review does not include women with
impaired glucose tolerance, not meeting criteria for diagnosis of
GDM, which is covered by the Han 2012 Cochrane systematic
review.
Due to insufficient data we are unable to make any judgements
on lifestyle interventions as a sole intervention without any sup-
plementary pharmacological therapy. Nor are we able to make any
judgements on the effectiveness of treatment based on duration
of treatment as gestational age at trial entry was poorly reported
for the included trials. In the description of included studies we
have listed all of the interventions described by the included trials.
There is a wide variety and diversity of interventions that include
exercise, diet, self-monitoring of blood glucose and education for
example.We are unable to determine which if any of the interven-
tions are more effective than another but most of the interventions
include some dietary component.
Quality of the evidence
Fifteen trials (45 publications) are included in this review (4501
women and their infants). The main reasons for downgrading ev-
idence was inconsistency, imprecision and risk of bias. Overall,
the evidence was judged to be of unclear risk of bias due to inad-
equate reporting of allocation concealment and blinding of out-
come assessors and selective outcome reporting. There is variation
between the trials with regards to the content of the lifestyle in-
terventions (see Characteristics of included studies). The evidence
is dominated by two large trials (Crowther 2005; Landon 2009)
that included 1000 women and 958 women, respectively. Both of
these trials were judged to be at low risk of bias.
Potential biases in the review process
We believe that we have made every effort to minimise biases in
the review process. We have conducted a systematic search of the
literature for randomised controlled trial evidence, not restricted
by language or date of publication. Where necessary we have at-
tempted tomake contact with authors of primary studies to obtain
additional methodological and/or outcome data.We have adhered
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to Cochrane methodology for searching, data extraction and anal-
ysis.
Agreements and disagreements with other
studies or reviews
A systematic review assessing the effect of treatment of GDM by
Poolsup 2014 included 10 studies and reported a decreased risk
of macrosomia, LGA, shoulder dystocia and gestational hyperten-
sion. Seven of the 10 studies included in the Poolsup 2014 were
excluded from our review based on study design and the remain-
ing three trials that they included were also included in our review
(Crowther 2005; Garner 1997; Landon 2009). Another system-
atic review by Hartling 2013 reported on the benefits and harms
of treating GDM. The review found increased antenatal visits,
reduced pre-eclampsia, shoulder dystocia and macrosomia in the
treated group. No clear differences between intervention and con-
trol groups were found for neonatal hypoglycaemia, caesarean sec-
tion, induction of labour or admission to neonatal intensive care.
The evidence was based on five randomised trials (including quasi-
randomised trials) and six cohort studies. Three of the studies were
included in our review (Crowther 2005; Garner 1997; Landon
2009).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Lifestyle interventions are resource-intensive and require trained
personnel to provide optimal education andmanagement support.
Low-quality evidence suggests that women receiving lifestyle in-
terventions are less likely to have postnatal depression and aremore
likely to achieve postpartum weight goals than women in usual
care or diet-only groups.
For the infant, there is moderate-quality evidence of a reduced
risk of being born large-for-gestational age (LGA) and low-quality
evidence for reduced adiposity (neonatal fat mass) for infants ex-
posed to lifestyle interventions compared with usual care or diet-
alone groups. The limited available moderate-quality evidence for
longer-term follow-up suggests there is no clear difference between
groups for adiposity in childhood (childhood BMI > 85th centile)
and no trials reported data into adulthood for adiposity.
The value of lifestyle interventions in low- and middle-income
countries or for different ethnicities remains unclear. The longer-
term benefits or harms of lifestyle interventions remains unclear
due to limited reporting. Lifestyle interventions are useful as the
primary therapeutic strategy and most commonly includes com-
ponents of healthy eating, physical activity and self-monitoring of
blood glucose levels.
Implications for research
Future research should focus on which specific interventions are
most useful, which health professionals should give them and the
optimal format for providing the information. Evaluation of long-
term outcomes for the mother and her child should be a priority
when planning future trials. There has been no in-depth explo-
ration of the costs ‘saved’ from reduction in risk of LGA/macro-
somia and potential longer-term risks for the infants.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bancroft 2000
Methods Randomised controlled pilot study recruiting from 2 centres.
Participants 68 women.
Inclusion criteria: impaired glucose tolerance (Table 7).
Exclusion criteria: none stated.
Setting: specialist diabetic/antenatal clinics, Leeds, UK.
Timeframe: not specified.
Interventions 1) Intervention (Monitored) group women were given standard dietary advice about
restricting carbohydrate intake to 185 g/day and a diet sheet listing calorific values of
common foods. Glucose metabolism was monitored by capillary glucose series 5 days a
week (1 to 2 hours postprandial), HbA1c was measuredmonthly (insulin was introduced
if 5 or more capillary measurements > 7.0 mmol/L in 1 week), serial ultrasound for
growth and amniotic fluid, Doppler studies, CTG monitoring (n = 32)
versus
2) Control (Unmonitored) group women received dietary advice, HbA1c monthly (but
data not made available) but no capillary glucose measurements (n = 36)
Women cared for in a combined diabetic clinic run jointly by a diabetologist and an
obstetrician. Birth was no later than 41 weeks’ gestation
Outcomes Primary outcome measure was admission to special care baby unit.
Secondary outcomes: perinatal morbidity (including birth trauma, metabolic distur-
bance, gestation at birth, birthweight, stillbirth, neonatal hypoglycaemia, RDS), LGA,
measures of maternal inconvenience, number of capillary samples, number of antenatal
clinic visits, mode of delivery, IOL, frequency of insulin use, HbA1c
Notes 2 women in the unmonitored group developed diabetes mellitus, both were diagnosed
postnatally and both delivered prematurely
ITT analysis: not stated (but all women remained in their allocated groups)
Funding: not stated.
Sample size calculation: not stated.
Conflicts of interest: no declarations made in manuscript.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Computer-generated codes, telephone ran-
domisation service used
Allocation concealment (selection bias) Low risk Randomisation was controlled from a trial
centre and administered by telephone
44Lifestyle interventions for the treatment of women with gestational diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bancroft 2000 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “the diabetologist was aware of the group
to which each woman was randomised but
the obstetrician was blinded.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No dropouts but 12 failed to attend follow-
up postnatal measurements
Selective reporting (reporting bias) High risk The original protocol was not seen. Addi-
tional outcomes listed in the methods sec-
tion were reported in the results
Other bias Low risk No evidence of other bias; groups balanced
at baseline.
Bo 2014
Methods Randomised controlled trial.
Participants 200 women randomised.
Inclusion criteria: age 18-50 years; 24-26 weeks’ gestational age; GDM diagnosis based
on a 75 g OGTT (Table 7); singleton pregnancy.
Exclusion criteria: BMI > 40 kg/m2; any known diseases, medications or obstetrical
contraindications to exercise
Setting: Sant’Anna Hospital, Turin, Italy.
Timing: July 2009 to February 2012.
Interventions Intervention - Behavioural and exercise (n = 50) - advised to walk briskly at least 20 min/
day every day (140 min/week; Borg’s scale target rating 12-14) plus individually oral/
written recommendations for helping with healthy dietary choices (i.e. lowering carbo-
hydrate intake, strategies for out-of-home eating, healthy cooking and food shopping
and related behavioural suggestions) and debunking false myths about diet in pregnancy
Control - Diet (n = 50) - an individually-prescribed diet was given to each woman
(carbohydrates 48% to 50%, proteins 18% to 20%, fats 30% to 35%, fibre 20-25 g/
day, no alcohol)
Exercise (n = 51) - advised to walk briskly at least 20 min/day every day (140 min/week;
Borg’s scale target rating 12-14)
Behavioural (n = 49) - individually oral/written recommendations for helping with
healthy dietary choices (i.e. lowering carbohydrate intake, strategies for out-of-home
eating, healthy cooking and food shopping and related behavioural suggestions) and
debunking false myths about diet in pregnancy
All women self-monitored blood glucose 4 to 6 times daily (preprandial and 2-hours
postprandial)
For this review we used the diet only group as the control group and the combined
behavioural and exercise intervention as the intervention group
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Bo 2014 (Continued)
Outcomes Maternal outcomes - pregnancy-induced hypertension, infectious diseases, caesarean
section, cholestasis duringpregnancy andperi- andpostpartumcomplications.Metabolic
equivalents, triglycerides, insulin, insulin resistance, CRP. Fasting and postprandial blood
glucose, and HbA1c
Neonatal outcomes - LGA; birthweight > 90th percentile), pre-term birth (gestational
age at delivery < 37 weeks), and any neonatal conditions requiring a specific treatment
or a prolonged in-hospital stay
Notes Treatment glycaemic targets were not detailed but insulin was started in the presence
of fetal abdominal ultrasound > 70th percentile and or maternal hyperglycaemia (no
details)
Power calculation: yes, based on an expected 10% reduction in fasting glucose by exercise
ITT analysis: yes.
Funding: Regione Piemonte 2009.
Conflict of interest: the paper specifies that there authors report no conflicts of interest
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Randomisation was conducted through a website and
is likely to be low risk of bias but there are insufficient
details to be sure
Allocation concealment (selection bias) Low risk ’implemented through a website’ - third person.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No details, but due to the different interventions the
research staff and participants are unlikely to have been
blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The dieticians, the obstetricians who reported mater-
nal/neonatal complications and the laboratory person-
nel were blinded to the group assignment.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk All women randomised were analysed.
Selective reporting (reporting bias) High risk Additional outcomes are reported that are not listed in
the methods section. Outcomes listed are very gener-
alised. Primary outcomes are not pre-specified. Birth-
weight is listed in the trial registration document but is
not reported or listed in the manuscript
Other bias Low risk Groups appeared balanced at baseline.
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Crowther 2005
Methods Multi-centre randomised controlled trial (n = 18 centres; 14 in Australia and 4 in UK)
Participants 1000 women.
Inclusion criteria: singleton or twin pregnancy between 16 and 30 weeks’ gestation, 1
or more risk factors on selective screening or impaired glucose tolerance (Table 7), and
had an abnormal 75 g OGTT at 24 to 34 weeks’ gestation (Table 7).
Exclusion criteria: women with previously treated GDM or active chronic systemic
disease (except essential hypertension), more severe glucose impairment or less than 16
or more than 30 weeks’ pregnant.
Setting: 18 centres in antenatal clinics in Australia and UK.
Timing: September 1993 to June 2003.
Interventions 1) Intervention group (n = 490): care replicated clinical care in which universal screening
and treatment for GDM was available, individualised dietary advice from a qualified
dietician, instructions on how to self-monitor glucose levels 4 times a day until fasting
glucose levels of at least 3.5 mmol/L [63 mg/dL] and no more than 5.5 mmol/L [99 mg/
dL], preprandial levels of no more than 5.5 mmol/L, and levels 2 hours postprandially
that were no more than 7.0 mmol/L [126 mg/dL], followed by daily monitoring at
rotating times during the day; and insulin therapy, with the dose adjusted based on
glucose levels, if there were 2 capillary-blood glucose results during the 2-week period in
which the fasting level was at least 5.5 mmol/L or the postprandial level was at least 7.
0 mmol/L at 35 weeks’ gestation or less, if the postprandial level was at least 8.0 mmol/
L (144 mg/dL) at more than 35 weeks’ gestation, or if 1 capillary-blood glucose results
during the 2-week period was at least 9.0 mmol per L (162 mg per dL).
2) Control group (n = 510): care replicated clinical care in which screening for GDM
was not available, women and caregivers were not aware of the diagnosis of glucose
intolerance, at the discretion of the attending clinician, if indications arose that were
suggestive of diabetes, further assessment for GDM was permitted, with treatment as
considered appropriate
Outcomes Primary outcomes - infant: composite measures of serious perinatal complications (de-
fined as 1 or more of death, shoulder dystocia, bone fracture, and nerve palsy), admission
to neonatal nursery, and jaundice requiring phototherapy.
Primary outcomes - women: need for IOL and caesarean section, health status, and
psychological outcomes.
Secondary outcomes - infant: gestational age at birth, birthweight, Apgar score of less
than 7 at 5 mins, hypoglycaemia requiring IV therapy, convulsions, RDS, perinatal
death, stillbirth, LGA, macrosomia, SGA. Childhood weight, BMI and height
Secondary outcomes - women: number of prenatal visits to a health professional, mode of
birth, weight during pregnancy, number of antenatal admissions, presence or absence of
pregnancy-induced hypertension (BP≥ 140/90 mmHg on 2 occasions 4 or more hours
apart, perineal trauma, postpartum haemorrhage, postnatal infection, breastfeeding at
hospital discharge, use of medication, postnatal depression
Notes 93% of the women had been found to be at risk of GDM on the basis of OGTT, and
the remainder on the basis of risk factors.
5 perinatal deaths (3 stillbirths and 2 neonatal deaths) occurred in the control group: 2
stillbirths were unexplained intrauterine deaths at term of appropriately grown infants,
and 1 at 35 weeks’ gestation, was associated with pre-eclampsia and intrauterine growth
restriction. 1 infant had a lethal congenital anomaly, and 1 infant died after an asphyxial
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Crowther 2005 (Continued)
condition during labour with antepartum haemorrhage.
After consent had been obtained, a proportion of the women (not fewer than 1 in 5)
who had normal OGTT results were assigned to the routine-care group to helpmaintain
blinding
Funding:National Health and Medical Research Council, Australia, Queen Victoria
Hospital Research Foundation, Department of Obstetrics and Gynaecology- University
of Adelaide
ITT: yes.
Sample size calculation: yes based on the risk of serious perinatal outcome
Conflicts of interest: conflicts of interested were not documented in the manuscript
Gillman 2010 reports on 4-5 year follow-up from the ACHOIS trial (subgroup of 199
children from Australia)
Pirc 2007 reports on a subgroup of women and infants from the ACHOIS trial from a
single centre in Australia (n = 95 women)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisationmethodusednumbers gen-
erated by computer with variable block
sizes of 6, 8, and 10
Allocation concealment (selection bias) Low risk Randomisation method was performed
centrally.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Women and their health providers did not
know the blood glucose results until after
the birth
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts: no losses to follow-up for pri-
mary and secondary clinical outcomes for
women at end of treatment. No losses to
follow-up for primary and secondary clin-
ical outcomes for infants at end of treat-
ment. For maternal health status outcomes
of postnatal depression and quality of life
68% of women provided data for maternal
health status. Overall data for clinical out-
comes are complete
Selective reporting (reporting bias) Low risk Includes maternal and infant outcomes.
Other bias Low risk No evidence of other bias, no differences in
baseline.
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Elnour 2008
Methods Randomised controlled trial, stratified by age.
Participants 165 women randomised.
Inclusion criteria: UAE national, within 20 weeks’ gestation, confirmed diagnosis of
GDM (Table 7), age 20 to 39 years.
Exclusion criteria: abnormal renal or hepatic function, haemoglobinopathy.
Setting: out-patient and primary care clinics, United Arab Emirates.
Timeframe: not specified.
Interventions 1) Intervention group (structured pharmaceutical care) (n = 108) 10 to 30 mins with
a clinical pharmacist. Options of treatment explained and encouraged to participate in
self management. Structured education on GDM and management provided (diet and
exercise, glycaemic control, self-monitoring, review of treatment if glycaemic control
inadequate). Received printed education booklet which contained general information
on diabetes, aims of treatment, diet and exercise and action to take if hypo- or hypergly-
caemic. Asked to record plasma glucose at least 5 times per day for 3-4 days per week.
Intervention took place at baseline and at monthly clinic visits. encourage to telephone
pharmacist if any queries/concerns
versus
2) Control group (usual care) (n = 72) - monthly clinic visits and self monitoring but
no additional education or counselling or liaison between pharmacist and prescribing
doctor
Followed up to 6 months postpartum.
Outcomes Knowledge, quality of life, maternal (hydramnios, severe hyperglycaemia, pre-eclamp-
sia, gestational hypertension, lactation, postpartum haemorrhage, preterm labour, ob-
structed delivery, caesarean section, use of insulin, fasting blood glucose, HbA1c) and
neonatal (macrosomia > 4 kg, hypoglycaemia, hyperbilirubinaemia, shoulder dystocia,
congenital malformation, respiratory difficulties, SGA, LGA, polycythaemia, hypocal-
caemia, preterm birth, admission to NICU) complications
Notes Nodetails onmethod of screening or diagnosing GDM. Authors contacted in September
2012. Authors responded immediately with additional information
Power calculation: yes.
ITT analysis: yes.
Funding: not stated.
Conflicts of interest: no evidence of a declaration made in the manuscript
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Restricted randomisation method ’to en-
sure that the number of patients allocated
to control and intervention were in the
same proportion in relation to their sub-
group classification’ This additional infor-
mation was obtained through correspon-
dence with the authors
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Elnour 2008 (Continued)
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Participants and researchers were not
blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk In additional information received from
the authors it was stated that “nursing and
pharmacy staff who assisted with the ques-
tionnaire administration were blinded re-
garding group to which individual patients
had been assigned”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 165 patients completed the trial (99 inter-
vention and 66 control). 9 were lost to fol-
low-up in the intervention group due to
abortion (n = 4) and withdrawal (n = 5)
. 6 were lost in the control group (n = 3
abortion, n = 3 withdrawal). Per-protocol
analysis
Selective reporting (reporting bias) Low risk Reported onmaternal and infant outcomes
of relevance.
Other bias Low risk No evidence of other risk of bias.
Ferrara 2011
Methods Randomised controlled trial - pilot study.
Participants 235 eligible women; 197 randomised. Mean age not provided although 77% were over
30 years
Inclusion criteria: women with GDM according to ADA (2000) criteria (Table 7), age
20 to 45 years.
Exclusion criteria: < 18 years, multiple gestation, diagnosis of diabetic retinopathy,
high risk pregnancy, thyroid disease diagnosed within 30 days, non-English speaker, pre-
gestational diabetes, known cardiovascular or lung disease, haemoglobin < 9.5 mg/dL,
haematocrit < 30%, hypertension within the last month
Setting: Northern California, USA.
Timing: October 2005 to May 2008.
Interventions Intervention (n = 96) Diet and exercise and breastfeeding intervention (DEBI). Deliv-
ered by a dietician using Social Cognitive Theory and Transtheoretical Model. Deliv-
ered prenatal, postpartum and maintenance based on 1-to-1 sessions and 2 individual
telephone counselling sessions with a lifestyle coach. Advised not to exceed 11.4 kg for
obese women and to follow ADA diet and moderate physical activity (150 min/week).
Also had lactation consultant and contact maintained for 6 weeks postpartum
versus
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Ferrara 2011 (Continued)
Control group (usual care) (n = 101) Printed material only in prenatal and postnatal
period
The maintenance phase continued for 6 months.
Outcomes Primary outcome - meeting postpartum weight goal.
Secondary outcome - medication use, perinatal clinic visits, birthweight, macrosomia,
physical activity, diet, breastfeeding, SGA
Trials registration document also lists plasma glucose levels, plasma insulin levels, markers
of insulin resistance and adiponectin as additional outcomes not reported in the published
papers
Notes Power calculation: not stated.
ITT analysis: yes.
Funding: National Institute of Diabetes and Digestive Kidney Diseases, Kaiser Garfield
Foundation
Conflicts of interest: the authors report no potential conflicts of interest of relevance to
the article in the Acknowledgements section of the manuscript
Follow-up of 72 women postpartum is reported by Erlich 2014 for those women in the
intervention group who lost weight or did maintained/gained weight postpartum
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomly assigned. Computer-randomi-
sation programme stratified for age, pre-
gravid BMI
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No blinding, open-label.
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Trials registration document indicates that
outcome assessors were blinded
Incomplete outcome data (attrition bias)
All outcomes
Low risk 97% follow-up to postpartum in the usual
care group and 95% in the intervention
group
Selective reporting (reporting bias) High risk The main outcome was meeting postpar-
tum weight gain. This is a pilot study and
the full trial is yet to be reported on. There
are very limited neonatal outcomes and ad-
ditional outcomes are listed in the trial reg-
istration document that are not reported in
the published papers
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Ferrara 2011 (Continued)
Other bias Low risk There was no evidence of other bias.
Garner 1997
Methods Randomised controlled pilot trial.
Participants 300 women from Canada.
Inclusion criteria: diagnosis of gestational diabetes between 24 to 32 weeks’ using 75 g
glucose screen with 1-hour cut-off level of 8 mmol/L (Table 7).
Exclusion criteria: multiple gestation, maternal foetal blood group incompatibility,
known congenital anomaly, prior evidence of planta praevia/abruptio, significant mater-
nal disease (chronic hypertension, connective tissue disease, endocrine disorders, chronic
hepatic disease), long-termmedical therapy affecting glucose metabolism such as steroids
and beta-mimetic tocolytic agents, and imminent delivery
Setting: 2 teaching hospitals in Ottawa, Canada.
Timing: September 1991 to May 1994.
Interventions Tight versus minimal control.
1) Intervention group - Dietary counselling, calories restricted diet (35 kcal/kg/day),
home glucose monitoring, if not controlled by diet alone then insulin supplementation,
seen bi-weekly, ultrasound assessment of fetal growth, amniotic fluid volume and cardiac
size. Aim to maintain blood glucose within the target range of < 4.4 mmol/L fasting and
< 7.8 mmol/L 1-hour post-prandial (n = 149)
versus
2) Control group (n = 150) - no dietary counselling but asked to continue unrestricted
healthy diet for pregnancy as perCanadaFoodGuide. Theyweremanagedby the primary
obstetric provider and were not seen again in the teaching unit. Treatment failures were
transferred to the treatment arm of the trial and treated with diet/insulin/monitoring
Outcomes Nonewere prespecified but reported on hyperbilirubinaemia, hypoglycaemia, fasting and
postprandial blood glucose, hypocalcaemia, macrosomia, mortality, congenital anomaly,
birth trauma, birthweight, weight gain in pregnancy and mode of delivery, gestational
age at birth. Childhood BMI, cholesterol, blood glucose concentration
Notes Sample size calculation: yes.
ITT analysis: yes, treatment failures in the control group who were moved to the inter-
vention group were analysed in the control arm
Funding: no details.
Conflicts of interest: there were no details on conflicts of interest published in the
manuscript
The trial was followed up at 7 to 11 years by Keely (2008) for metabolic markers of
insulin resistance in the offspring
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
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Garner 1997 (Continued)
Random sequence generation (selection
bias)
Unclear risk “randomly allocated” no other details.
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Health care workers in the control group were
blinded to the blood glucose group.”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 1 woman in the treatment arm of the trial was lost
to follow-up
Selective reporting (reporting bias) High risk Outcomes were not prespecified. An original pro-
tocol was not seen
Other bias Low risk There is no evidence of other bias.
Gillen 2004
Methods Single-centre randomised controlled trial.
Participants 32 women. No data provided on mean maternal age or ethnicity.
Inclusion criteria: GDM diagnosed at approximately 28 weeks’ gestation (Table 7).
Exclusion criteria: significant other health concerns, poor English language skills.
Setting: Diabetic clinic. Wollongong, Australia.
Timing: May to December 2002.
Interventions 1) Intervention group: following a group session on management of GDM from a
registered nurse diabetes educator and dietician the group received standard clinical
practice plus advice for targeted intakes of foods rich in unsaturated fats based onmeeting
energy requirements
2) Control group: following a group session on management of GDM from a registered
nurse diabetes educator and dietician the group received standard clinical practice (indi-
vidualised carbohydrate portion-controlled meal plan, with low-fat and low-glycaemic
index dietary strategies and general advice about meeting nutritional requirements of
pregnancy)
Outcomes Outcomes: gestation at birth, mode of birth, changes in dietary intakes, use of insulin
Notes ITT analysis was used. not stated.
Funding: not stated.
Sample size calculation: not stated.
Conflicts of interest: no details.
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Gillen 2004 (Continued)
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Open table of random numbers con-
structed by an independent person and
kept confidential from members of the
study team. Women were matched consec-
utively to the next available number in the
table and the study team informed of the
result
Allocation concealment (selection bias) Low risk Randomisation done centrally.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants unaware of differences in ad-
vice between intervention and control
groups, research staff were aware
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Dropouts: data not available for 1 woman
from each group.
Selective reporting (reporting bias) High risk An original protocol was not seen. The out-
comes were not clearly prespecified. The
authors report that there were no differ-
ences in pregnancy outcomes or nature of
birth but they do not report any of this data
in the paper
Other bias Low risk No evidence of other bias, no differences at
baseline.
Jovanovic-Peterson 1989
Methods Randomised controlled trial.
Participants 19 women
Inclusion criteria: women diagnosed with GDM (Table 7).
Exclusion criteria: none detailed.
Setting: USA.
Timing: not specified.
Interventions Intervention group - 6 week diet (24 to 30 kcal/kg/24 hours; 20% protein, 40% carbo-
hydrates, 40% fat divided into 3 meals and 3 snacks) plus 20 mins of supervised aerobic
exercise 3 times per week for the 6 weeks. An arm ergometer was used to maintain heart
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Jovanovic-Peterson 1989 (Continued)
rate (220-age in years) x 70% unless this heart rate exceeded 140 bpm and then 140
bpm was the target heart rate. The exercise session never exceeded 50% maximal oxygen
consumption. 6 women exercised between 4 pm and 5 pm and 4 women between 10
am and 11 am
Control group - 6 week diet alone (24 to 30 kcal/kg/24 hours; 20% protein, 40%
carbohydrates, 40% fat divided into 3 meals and 3 snacks)
All women performed glucose self monitoring 4 times per day (before breakfast and 1
hour postprandial). Seen weekly by a physician. Insulin was started if FPG > 5.8 mmol/
L or 105 mg/dL) and/or 1 hour postprandial plasma glucose was > 7.8 mmol/L or 140
mg/dL)
Outcomes HbA1c, fasting and 1-hour postprandial blood glucose, 50 g glucose challenge test,
maternal hypoglycaemia, C-peptide, use of insulin, birthweight. No primary outcomes
were pre-specified
Notes Power calculation - not reported.
ITT analysis - not reported.
Funding - not reported.
Conflicts of interest - not reported in the manuscript.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’Randomized’, by drawing a number.
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No details but unlikely to have been blinded.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Data reported for all 19 women randomised.
Selective reporting (reporting bias) High risk Additional outcomes are reported that were not listed a
priori in the methods section including gestational age
at delivery and birthweight
Other bias High risk The women randomised to the exercise and diet inter-
vention had a significantly higher 1 hour plasma glucose
in the diagnostic test at baseline
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Kaviani 2014
Methods Randomised controlled trial.
Participants 58 pregnant women with gestational diabetes (69 eligible).
Inclusion criteria: having gestational diabetes (Table 7), being in the pre-diabetic stage,
not using insulin and psychiatric medications, no previous history of relaxation therapy,
age 18 to 40 years, gestational age 24 to 30 weeks’
Exclusion criteria: overt diabetes, unwillingness to co-operate at any stage of the study,
being absent for more than 1 session of the training classes, not doing the relaxation
exercises at home for more than 5 days, changing diet or physical activity during study,
having pregnancy complications during study
Setting: Shiraz, Iran.
Timing: February to April 2013.
Interventions Intervention group (Relaxation training) (n = 29) over 10 weeks, five 45 min sessions
- Session 1 Training on the nature and mechanism of diabetes, nature of stress and
effect on body; Session 2 Different breathing techniques and body positions during
relaxation; Session 3 How to relax muscles in various parts of the body after stress;
Session 4 Relaxation through conditioning; Session 5 Training of differential relaxation
and relaxation along with positive mental imagery (Based on the principles of Herbert
Benson). Encouraged to practice relaxation at home for a month. Provided with a chart
for recording relaxation exercises to evaluate their performance, CD with soft music
explaining how do perform the relaxation. Contacted by telephone by the researcher 3
times per week
Control group (n = 29) routine prenatal care (no details).
Outcomes BP, fasting blood sugar, 2-hour postprandial blood sugar, use of insulin
Notes Sample size calculation: yes but unclear on what outcome the calculation was based
ITT analysis: yes.
Funding: University funding.
Conflicts of interest: not reported in the manuscript.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’random numbers’ and ’permutation blocks.’
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No details but unlikely to be blinded due to nature of
intervention
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details.
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Kaviani 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 58 women randomised and analysed.
Selective reporting (reporting bias) High risk Very limited outcomes reported for mother, no neonatal
outcomes reported
Other bias Low risk No differences at baseline.
Landon 2009
Methods Randomised controlled trial.
Participants 958 women.
Inclusion criteria: abnormal result on glucose loading test (Table 7).
Between 24 and 30 weeks’ gestation.
Exclusion criteria: pregestational diabetes, abnormal glucose screen before 24 weeks’,
previous GDM, history of stillbirth, multiple gestation, asthma, chronic hypertension,
taking corticosteroids, known fetal anomaly or imminent preterm delivery. Fasting glu-
cose > 5.3 mmol/L (95 mg/dL)
Setting: Obstetric research centre, Washington, USA.
Timing: October 2002 to November 2007.
Interventions 1) Intervention group - Formal nutrition counselling and diet therapy +/- insulin and
daily self monitoring (fasting and 2 hour post-prandial) (n = 485)
versus
2) Control group - usual prenatal care +/- insulin and self monitoring (n = 473)
Insulin was commenced if fasting glucose levels were predominantly at 5.3 mmol/L or
greater or postprandial glucose was 6.7 mmol/L or greater
Outcomes Primary outcome was a composite score (perinatal mortality, hyperglycaemia, hypogly-
caemia, hyperbilirubinaemia, neonatal hyperinsulinaemia, birth trauma)
Secondary outcomes included individual components of the composite score, C-peptide,
birthweight, preterm birth, macrosomia, LGA, SGA, neonatal glucose levels, neonatal
hypoglycaemia, hyperbilirubinaemia, birth trauma, gestational age at birth, NICU ad-
mission, RDS, neonatal fat mass, adiposity, gestational weight gain, hypertension, pre-
eclampsia, caesarean section, IOL, shoulder dystocia, maternal diabetes, use of insulin,
metabolic syndrome. Childhood BMI
Notes Sample size calculation: yes based on composite score.
ITT analysis: yes.
Funding: Eunice Kennedy Shriver National Institute of Child Health and Human De-
velopment
Conflicts of interest: the authors reported that there were no potential conflicts of interest
relevant to this manuscript
Casey 2015 reported on long-term maternal outcomes from this trial on 457 (50%) of
the eligible 905 women. 243 women were treated in the original trial and 214 untreated.
430 women had blood drawn for analysis
Bahado-Singh 2012 reported on gender differences in fetal outcomes
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Landon 2009 (Continued)
Durnwald 2011 reported on glycaemic characteristics and neonatal outcomes but do not
report on differences between treatment and intervention groups
Sutton 2014 reported on timing of delivery and caesarean section
Landon 2015 reported on long-term follow-up of children at 5 to 10 years of age
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’simple urn method.’
Allocation concealment (selection bias) Low risk ’by the coordinating centre.’
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not possible to blind participants; staff were not blinded
to allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors were blinded for some outcomes.
Incomplete outcome data (attrition bias)
All outcomes
Low risk 25 women in the intervention group were lost to follow-
up (8 had no delivery data and 17 hadmissing laboratory
data)
33 women in the control group were lost to follow-up
(18 had no delivery data and 15 had missing laboratory
data)
ITT analysis was conducted.
Selective reporting (reporting bias) Low risk The original protocol was not seen. All outcomes ap-
pear to be reported and include maternal and neonatal
outcomes. Long-term maternal outcomes are reported
in abstract form by Casey 2015
Other bias Low risk No evidence of other bias, no differences in baseline
measurements between groups
Mendelson 2008
Methods Randomised trial.
Participants 100 Mexican-American women. Mean age in Parish nurse group was 30.6 ± 5.6 years
and in the usual care group was 31.5 ± 5.2 years
Inclusion criteria: diagnosed and referred for treatment for gestational diabetes (Table
7), self-reported Mexican descent, able to speak, read and write in English or Spanish,
18 to 40 years of age, between 12 and 32 weeks’ gestation, singleton pregnancy
Exclusion criteria: not specified.
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Mendelson 2008 (Continued)
Setting: outpatient clinic for women with gestational diabetes in a hospital in California,
USA
Timing: no details.
Interventions Intervention group (Parish nurse intervention program) (n = 49) Enhanced education
and support provided by parish nurses fluent in Spanish. A supplemental 1-hour Parish
nurse led discussion regarding medical recommendations for control of gestational dia-
betes to clarify areas of concern or misunderstanding. Also included spiritual principles
such as encouragement of prayer and spiritual connection within the belief system of
the women. Education included what is diabetes, types and risk factors; diabetes control
with nutrition, activity, and medical treatment; and nutrition therapy (food groups and
measurements)
Control group (Usual care) (n = 51) Education on diet, exercise, blood glucose testing
and insulin administration if required in individual 1-hour sessions provided through
handouts, demonstration and discussion
Outcomes Health promotions behaviour questionnaire,macrosomia, fasting blood glucose, random
blood glucose, HbA1c, duration of maternal and neonatal hospitalisation, caesarean
section, use of insulin. Primary outcomes were not specified
Notes Power calculation: no data provided.
ITT analysis: not stated
Funding: Eugene Cota Robles Fellowship.
Conflicts of interest: not provided in the manuscript.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’random number tables.’
Allocation concealment (selection bias) Unclear risk No clear details provided despite contacting author.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Women were not blinded (information obtained from email),
diabetes educators were blinded to allocation
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details provided.
Incomplete outcome data (attrition bias)
All outcomes
High risk Not all women had an HbA1c at birth (27 out of 100).
Selective reporting (reporting bias) Unclear risk The outcomes listed in the methods section were all reported
in the results. Caesarean section which was not prespecified was
reported as an outcome in the results
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Mendelson 2008 (Continued)
Other bias Low risk No differences between groups at baseline. No evidence of other
bias
Rahimikian 2014
Methods Randomised controlled trial.
Participants 126 women with gestational diabetes (diagnostic criteria unclear)
Inclusion criteria: gestational age 28 to 36 weeks’, hospitalised due to high blood sugar
or gestational diabetes (Table 7), not attending education sessions before, literate.
Exclusion criteria: absent for 1 of the training sessions, not wanting to continue with
the study
Setting: Iran.
Timing: 2013.
Interventions Intervention group (Face-to-face education) (n = 42) 2 sessions of 40 mins as individuals
or in groups. Session 1 definition of GDM, causes, symptoms, those at risk, management
of GDM including training on glycaemic control; session 2 nutrition, physical activity
and exercise, insulin, pregnancy follow-up
or (Instructional booklet education) (n = 42) a booklet provided that includes all the
information given in the face-to-face sessions (not used in this review)
Control (n = 42) routine hospital services (no details).
Outcomes Maternal hospitalisation due to gestational diabetes and duration, type of delivery, use
of insulin, birthweight, gestational age at birth, Apgar 1 and 5 mins, stillbirth
Notes Sample size calculation - no.
ITT analysis - no.
Funding - no details.
Conflicts of interest - no details.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’randomly assigned.’
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No details but unlikely that participants or researchers
were blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No details.
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Rahimikian 2014 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Data appear to be missing for 1 of the intervention
groups but no details provided
Selective reporting (reporting bias) High risk Raw data not reported for all outcomes.
Other bias Low risk No differences at baseline.
Yang 2003
Methods Randomised controlled trial.
Participants 150 women randomised.
No details of inclusion or exclusion. Women were diagnosed with GDM after a 50 g,
1-hour screen at 26 to 30 weeks (Table 7).
Setting: Tianjin, China.
Timing: no details of time that trial was conducted.
Interventions 1) Intervention group (Intensive care) (n = 95) Intensive Diabetes Management Plan
- diet and exercise advice, self home blood glucose monitoring ± insulin if required.
Fortnightly specialist review. Low calorie intake prescribed according to pre-gravid BMI.
Goal: to achieve fasting capillary blood glucose < 5.5 mmol/L and 1 hour post prandial
< 7.0 mmol/L
versus
2) Control group (usual obstetric care) no details (n = 55).
Outcomes Not prespecified but reported premature rupture of membranes, preterm birth, perinatal
morbidity, caesarean section, birthweight, perinatal mortality, congenital anomaly, birth
trauma, dystocia, use of insulin
Notes Power calculation: power analysis was performed but the variable was not reported. The
sample size was estimated at 200 whereas only 100 were randomised
ITT analysis: state that used ITT for pregnancy outcomes.
Funding: not stated.
Conflicts of interest - no details.
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ’randomized’ no other details.
Allocation concealment (selection bias) Unclear risk No details.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No details but unlikely that participants or researchers
were blinded
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Yang 2003 (Continued)
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Not reported.
Incomplete outcome data (attrition bias)
All outcomes
High risk Of 95 women in the intervention group, only 48 com-
pleted the management plan compared with 55/55 in
the usual care group
Selective reporting (reporting bias) High risk The study is reported as a letter only. There was no ev-
idence of a full paper and only the data on caesarean
section and PROM is reported
Other bias High risk Unable to establish if there are other biases due to lack
of information. Power analysis was performed but the
variable was not reported. The sample size was estimated
at 200 whereas only 100 were randomised
Yang 2014
Methods Randomised trial.
Participants 948 women randomised. Mean age of usual care group was 29.7 ± 3.2 years and 29.9 ±
3.5 years in the shared care group. 97% were Han Chinese
GDM diagnosed by 50 g 1-hour glucose challenge test between 24 and 28 weeks’ gesta-
tion (Table 7).
Exclusion criteria: OGTT meeting criteria for diabetes (FPG ≥ 7.0 mmol/L, 2 hour
≥ 11.1 mmol/L or HbA1c ≥ 6.5%/48 mmol/mol); < 18 years of age, multiple preg-
nancy, maternal fetal ABO blood type incompatibility, maternal diseases such as chronic
hypertension, thyrotoxicosis, pre-pregnancy diabetes and long-term use of medications
that might affect glucose metabolism
Setting: Tianjin, China.
Timing: December 2010 to October 2012.
Interventions Intervention group (Shared care) (n = 344) - adapted from ACHOIS protocol. Inter-
vention delivered by trained nurses and doctors. All women were offered individualised
dietary advice and physical activity counselling. Different energy intakes were recom-
mended based on prepregnancy BMI. All women were asked to engage in at least 30
mins of light to moderate physical activity daily. All women were offered a free glucose
meter with memory function and free test strips. Asked to perform self-monitoring 4
times daily for first 2 weeks and then daily at different times in rotation. Glycaemic
target was ≥ 3.5 to ≤ 5.1 mmol/L for fasting capillary glucose and ≤ 7.0 mmol/L for
2-hour post-prandial capillary glucose up to 36 weeks’ gestation and ≤ 8.0 mmol/L
from 36 weeks’ onwards. If target levels were exceeded 2 or more times during a 2-week
interval or the 2-hour postprandial level exceed 9.0 mmol/L once during a 1 week period
then insulin was recommended. At 30 and 34 weeks’ gestation the group was offered 2
additional individualised counselling sessions to reinforce diet, physical activity and self
monitoring. They were also offered group education sessions lasting 2 hours at 27, 29
and 33 weeks’ gestation
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Yang 2014 (Continued)
Control group (Usual care) (n = 362) - offered group education class lasting 30-40 mins
delivered by a diabetes educator. Received advice on diet and physical activity but not
specifically taught to self monitor blood glucose. Insulin treatment recommended if
HbA1c ≥ 6.5% (48 mol/mol)
Outcomes Primary - macrosomia (≥ 4000 g), LGA.
Secondary - pregnancy-induced hypertension.
Other outcomes included depression, caesarean section, use of insulin, weight gain in
pregnancy, IOL, neonatal death, birth trauma, gestational age at birth, preterm birth,
birthweight, birth length, neonatal hypoglycaemia, visits to health professional. Physical
activity, food recall. Other outcomes were not reported a priori
Notes During Nov 2010 to July 2011 separate areas for intervention and follow-up in the 2
groups were unavailable due to building renovation and data collection for the usual care
women was performed by the intervention staff members. The 242 women entering the
trials during this period also received unintentional intervention. The authors excluded
these women from the analysis
Power calculation: yes based on a reduction in risk for pregnancy-induced hypertension
ITT analysis: no, women wrongly allocated during a specific period were excluded from
the analysis
Funding: funding from BRIDGES an educational grant from Lilly Diabetes
Conflicts of interest: a conflict was reported by 1 of the 12 authors: the author’s institution
had received research funding from Eli Lilly and the author is a member of advisory
committee and speaker forum sponsored by Eli Lilly
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk ’simple randomization procedure without replacement’ ’com-
puter generated random assignment’
Allocation concealment (selection bias) Unclear risk No details provided.
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk ’The women with GDM in the trial but not the research team
members were masked to the random assignment.’
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessors for pregnancy-induced hypertension were
blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
High risk During Nov 2010 to July 2011 separate areas for intervention
and follow-up in the 2 groups were unavailable due to building
renovation and data collection for the usual care women was
performed by the intervention staff members. The 242 women
entering the trials during this period also received unintentional
intervention. The authors excluded these women from the anal-
ysis
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Yang 2014 (Continued)
In addition to this 1woman in the usual care group and 5women
in the shared care group gave birth outside Tianjin. 339 women
in the usual care and 361 women in the shared care group were
analysed
Selective reporting (reporting bias) High risk Additional outcomes are reported that were not pre-specified in
the methods section
Other bias Low risk Groups were similar at baseline. No other risk of bias was iden-
tified
Youngwanichsetha 2014
Methods Randomised controlled trial.
Participants 180 women randomised. Mean maternal age in the intervention group was 32.58 ± 5.
01 years and for the control group was 31.24 ± 4.54 years. No ethnicity is reported but
women were Thai
Inclusion criteria: diagnosed with GDM A1 at 24 to 30 weeks’ gestation (Table 7); not
receiving insulin therapy for glycaemic control; having no serious complications such as
gestational hypertension, pre-eclampsia, preterm labour or other serious health problems
Exclusion criteria: none detailed.
Setting: tertiary hospital in Thailand.
Timing: not specified.
Interventions Intervention (n = 90) Trained to perform mindfulness eating and yoga exercise in 2 50-
min sessions. Videos were used in classes and practicing manuals were offered for all
the women to follow. Afterwards they were encouraged to continue with mindfulness
eating and yoga at home 5 times a week for 8 weeks. Mindfulness eating involved
setting a goal for blood glucose control, integrating medical nutrition therapy including
carbohydrate choices and low glycaemic index food, considering portion size, being
aware while consuming diabetic food, and eating slowly for 30 to 40 mins. The yoga
that was used was yoga pranayama (deep breathing techniques) and asanas (posture and
movements). it was designed for 15 to 20 mins daily practice for 5 days a week. The
group were encouraged weekly by research staff
Control group (n = 90) Standard diabetes care (no details).
Outcomes Primary: capillary fasting glucose and postprandial blood glucose and HbA1c, use of
insulin
Notes Power calculation: yes based on an expected difference in glycaemic control
ITT analysis: no, they did not analyse the women who did not complete the study or
who had been lost to follow-up
Funding: no details provided in manuscript.
Conflicts of interest: no details provided in manuscript.
Risk of bias Risk of bias
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Youngwanichsetha 2014 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No details on method of randomisation.
Allocation concealment (selection bias) Unclear risk ’randomization was performed by a research assistant
using opaque envelopes technique’. Not clear if this was
sequential or not
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No details provided but staff and participants are un-
likely to have been blinded
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk HbA1c testing was conducted by a laboratory and the
personnel are likely to have been blinded to allocation
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3 women in the intervention group moved to another
town for work and did not complete the study and an-
other 2 were lost to follow-up for the same reason, there-
fore 85 women were analysed
5 women in the control group were lost to follow-up as
they had moved to another town for work, therefore 85
were analysed
Selective reporting (reporting bias) High risk The trial only reports on the effects on glycaemic control
andnoneonatal or othermaternal outcomes are reported
Other bias Low risk Groups appear balanced at baseline, no evidence of other
bias
BMI: body mass index
BP: blood pressure
BPM: beats per minute
CRP: C-reactive protein
CTG: cardiotocography
dL: decilitre
FPG: fasting plasma glucose
GDM: gestational diabetes mellitus
IOL: induction of labour
ITT: intention-to-treat
IV: intravenous
L: litre
LGA: large-for-gestational age
min: minute
NICU: neonatal intensive care unit
OGTT: oral glucose tolerance test
RDS: respiratory distress syndrome
65Lifestyle interventions for the treatment of women with gestational diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
SGA: small-for-gestational age
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abirami 2014 After contacting the authors it was clarified that this was not a randomised controlled trial
Adam 2014 This is a randomised controlled trial of exercise interventions and belongs in the exercise for pregnant diabetic
women review
Bastani 2015 This is a randomised trial using acupressure to treat anxiety in women with GDM and not being used for
glycaemic control
Berry 2013 Although women are recruited in pregnancy with GDM, the main intervention starts at 6 weeks postpartum
Bevier 1999 Women did not meet the criteria for GDM as they only had an elevated glucose challenge test and a normal
glucose tolerance test
Bonomo 2005 Women did not meet the criteria for GDM as they only had an elevated glucose challenge test and a normal
glucose tolerance test
Branch 2010 This trial was registered but never started due to insufficient funding for enrolling participants
Fadl 2015 Wrong comparison for this review - insulin versus no additional treatment
Ford 1997 Trial compared diet alone versus usual care. Does not meet the review criteria for a lifestyle intervention
Grant 2011 Wrong comparison for this review. This trial is included in the Cochrane systematic review on different types
of dietary advice for women with GDM
Holmes 2012 This is not a treatment trial for women with GDM.
Homko 2002 Trial compared different types of monitoring of blood glucose - Wrong comparison
Kitzmiller 1990 Informed by author that trial never started (March 2006).
Langer 1989 Trial compared diet alone versus usual care. Not meeting the review criteria for a lifestyle intervention
Li 1987 This trial randomised women to 2 different screening/diagnosis strategies. Wrong comparison
Mirzamoradi 2015 This trial randomised women to 2 different screening/diagnosis strategies. Wrong comparison
O’Sullivan 1971 Quasi-randomised, alternate allocation.
O’Sullivan 1974 Primary outcome death. Allocation used an alternate method, no intention-to-treat analysis. Endpoints
unclear
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(Continued)
O’Sullivan 1980 Not randomised.
Osmundson 2015 Randomised trial of treatingwomenwith prediabetes, screened at < 14weeks’ gestation. GDMwas confirmed
by screening at 26 to 28 weeks’ if not on insulin. Therefore not a trial treating women with GDM
Perichart-Perera 2009 Quasi-experimental design with an historical control group.
Reader 2006 This was an implementation trial for clinical practice guidelines rather than an intervention trial
Rey 1997 Study compared home monitoring of blood glucose with clinic follow-up. Wrong comparison
GDM: gestational diabetes mellitus
Characteristics of studies awaiting assessment [ordered by study ID]
Cao 2012
Methods States that groups were randomly allocated and also that the control group was age-matched to the intensive treatment
group. Unclear if true randomisation took place
Participants Pregnant women with GDM.
Interventions A comprehensive intensive individualised therapy including education, dietary and exercise advice and instructions
on self monitoring. Monitored by physician every 2 weeks
Standard group received group education on diet and exercise, self-monitoring information given but not required
at the same frequency as intensive group
Outcomes Caesarean section, pre-eclampsia, postpartum complications, birthweight, stillbirth, jaundice, neonatal death, ad-
mission to NICU, preterm delivery, congenital malformation, neonatal hypoglycaemia. Later follow-up maternal
diabetes and metabolic syndrome
Notes Contact author emailed 20/01/2015.
Kaveh 2012
Methods Randomised controlled trial.
Participants Women with GDM.
Interventions Educational intervention with nutrition and exercise
versus
control.
Outcomes Fasting and postprandial glucose levels; knowledge.
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Kaveh 2012 (Continued)
Notes The article is in Persian and we are awaiting a translation to confirm inclusion/exclusion in this review
Zhang 2012
Methods ’randomly divided.’
Participants Women with gestational diabetes.
Interventions Health education intervention with nutrition, exercise and foot care
versus
standard care.
Outcomes Self-efficacy, blood glucose levels.
Notes Translation required to determine if true randomisation and if intervention and control groups meet inclusion criteria
for this review
GDM: gestational diabetes mellitus
NICU: neonatal intensive care unit
Characteristics of ongoing studies [ordered by study ID]
Durnwald NCT01858233
Trial name or title The IBEP Study: an intervention for lifestyle modification in women with gestational diabetes
Methods Randomised open-label trial.
Participants 120 women with GDM between 20 and 34 weeks’ gestation.
Interventions Intensive behavioural modification, dietary counselling, lactation counselling
versus
routine care and standard dietary counselling.
Outcomes Primary outcomes: OGTT at 6 weeks postpartum.
Secondary outcomes: weight loss and lipid profiles.
Starting date November 2012.
Contact information Valerie.armendariz@uphs.upenn.edu
Notes
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Ferrara NCT01489163
Trial name or title Lifestyle intervention program for women with gestational diabetes or gestational impaired glucose tolerance
(APPLES)
Methods Randomised double-blind trial.
Participants 350 women with pregnancy complicated by high glucose levels.
Interventions Lifestyle counselling
versus
no intervention.
Outcomes Primary - postpartum body weight.
Secondary - proportion of women reaching body weight goals, percent of calories from fat, time spent in
physical activity, postpartum glycaemia
Starting date December 2011.
Contact information Assiamira Ferrara - Kaiser Permanente. USA.
Notes
Hoseinzadeh IRCT2014080418682N1
Trial name or title The effects of an educational intervention based on the theory of planned behavior on self-care behavior and
blood glucose levels in pregnant women with gestational diabetes treated with insulin
Methods Randomised open-label trial ongoing in Iran.
Participants 60 pregnant women with gestational diabetes treated with insulin gestational age 20 to 24 weeks’
Interventions Education based on the theory of planned behaviour performed with 4 sessions of 60 minutes duration
versus
routine prenatal care.
Outcomes Primary outcome - self-care behaviour.
Secondary outcomes - fasting and 2-hour post-prandial blood glucose level
Starting date 2014.
Contact information HoseinzadehM911@mums.ac.ir
Notes
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Mirfeizi IRCT201406022892N3
Trial name or title The effect of self-care education on quality of life in women with gestational diabetes
Methods Randomised controlled trial.
Participants 240 women with gestational diabetes from Iran. Singleton pregnancy, 20 to 24 weeks’ gestation
Interventions 4, 45-minute group education sessions for a month in self-care
versus
routine prenatal care.
Outcomes Primary outcome - quality of life.
Starting date 2014.
Contact information latibari@kiau.ac.ir; mani@kiau.ac.ir
Notes
Roeder NCT01926457
Trial name or title Treating prediabetes in the first trimester.
Methods Randomised controlled trial, single-blind.
Participants 240 women from USA diagnosed with pre-diabetes < 15 weeks’ gestational age
Interventions First trimester diabetes education, blood glucose monitoring, medication if required, growth ultrasounds,
antenatal testing
versus
third trimester diabetes education, blood glucose monitoring, medication if required, growth ultrasounds,
antenatal testing
Outcomes Primary outcomes - cord C-peptide.
Secondary outcomes - neonatal fat mass, gestational weight gain, return to pre-pregnancy weight, maternal
adiponectin, birthweight, LGA, ponderal index, admission to NICU, infant weight-for-length, need for
maternal pharmacotherapy, birth trauma,mode of birth, gestational weight gain, postpartumweight retention,
pre-eclampsia
Starting date 2013.
Contact information haroeder@ucsd.edu
Notes
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Sahnaz IRCT2014042017346N1
Trial name or title Effectiveness of stress management with cognitive behavioural method on blood sugar levels and stress among
patient with gestational diabetes
Methods Randomised controlled trial.
Participants Iranian trial in progress. Pregnant women with gestational diabetes, age 18 to 45 years, gestational age 24 to
32 weeks’
Interventions Stress management training with 6, 2-hour sessions of cognitive-behavioural group-based treatment
versus
routine prenatal care.
Outcomes Primary outcomes - fasting blood sugar, stress.
Secondary outcomes - anxiety, depression.
Starting date 2014.
Contact information najarshanaz@yahoo.com
Notes
Ziegler DRKS00000465
Trial name or title MuKiS - Mother-child sports - a study to evaluate the impact of exercise on maternal metabolism and fetal
development in women with gestational diabetes
Methods Randomised controlled trial, open-label.
Participants 60 women with gestational diabetes in Munich, Germany. Age > 18 years, 24 to 30 weeks’ gestation
Interventions Supervised physical activity twice a week for 45 minutes including walking and bicycle ergometry plus diet
as recommended by the German Diabetes Society
versus
diet therapy alone.
Outcomes Participation rates, mood, cardiovascular measurements, maternal biomarkers, fetal abdominal circumference,
polyhydramnios, caesarean section rate, birthweight, macrosomia, cardiac hypertrophy
Starting date 2009.
Contact information anziegler@lrz.uni-muenchen.de; Lydia.Henneberger@lrz.uni-muenchen.de
Notes
LGA: large-for-gestational age
OGTT: oral glucose tolerance test
GDM: gestational diabetes mellitus
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NICU: neonatal intensive care unit
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D A T A A N D A N A L Y S E S
Comparison 1. Lifestyle intervention versus usual care/control
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Hypertensive disorders
of pregnancy (including
pre-eclampsia,
pregnancy-induced
hypertension, eclampsia)
4 2796 Risk Ratio (M-H, Random, 95% CI) 0.70 [0.40, 1.22]
1.1 World Health
Organization 1999
1 1000 Risk Ratio (M-H, Random, 95% CI) 0.65 [0.48, 0.88]
1.2 ADA 2013 2 1096 Risk Ratio (M-H, Random, 95% CI) 0.44 [0.18, 1.06]
1.3 IADPSG 2010 1 700 Risk Ratio (M-H, Random, 95% CI) 2.40 [1.06, 5.44]
2 Caesarean section 10 3545 Risk Ratio (M-H, Random, 95% CI) 0.90 [0.78, 1.05]
2.1 WHO 1999/ADIPS 1998 4 1250 Risk Ratio (M-H, Random, 95% CI) 0.89 [0.78, 1.02]
2.2 ADA 2013 2 1096 Risk Ratio (M-H, Random, 95% CI) 0.63 [0.33, 1.22]
2.3 IADPSG 2010 1 700 Risk Ratio (M-H, Random, 95% CI) 1.09 [0.99, 1.21]
2.4 Other/not specified 3 499 Risk Ratio (M-H, Random, 95% CI) 0.94 [0.65, 1.38]
3 Development of type 2 diabetes 2 486 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.54, 1.76]
4 Perinatal (fetal and neonatal
death) and later infant
mortality
2 1988 Risk Ratio (M-H, Fixed, 95% CI) 0.09 [0.01, 1.70]
5 Large-for-gestational age 6 2994 Risk Ratio (M-H, Fixed, 95% CI) 0.60 [0.50, 0.71]
6 Death or serious morbidity
composite (variously defined
by trials, e.g. perinatal or infant
death, shoulder dystocia, bone
fracture or nerve palsy)
2 1930 Risk Ratio (M-H, Random, 95% CI) 0.57 [0.21, 1.55]
7 Use of additional
pharmacotherapy
9 Risk Ratio (M-H, Random, 95% CI) Subtotals only
7.1 Use of anti-diabetic oral
medication
1 197 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.52, 1.19]
7.2 Use of insulin treatment 9 3254 Risk Ratio (M-H, Random, 95% CI) 2.54 [1.19, 5.42]
8 Maternal hypoglycaemia 1 19 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
9 Glycaemic control during/end
treatment
7 Mean Difference (IV, Random, 95% CI) Subtotals only
9.1 Fasting blood glucose
concentration mg/dL
6 853 Mean Difference (IV, Random, 95% CI) -3.10 [-7.01, 0.81]
9.2 Postprandial blood glucose
concentration mg/dL
4 588 Mean Difference (IV, Random, 95% CI) -27.11 [-44.62, -9.
61]
9.3 HbA1c mmol/mol 6 532 Mean Difference (IV, Random, 95% CI) -0.33 [-0.47, -0.19]
10 Weight gain in pregnancy (kg) 4 2930 Mean Difference (IV, Random, 95% CI) -1.30 [-2.26, -0.35]
11 Induction of labour 4 2699 Risk Ratio (M-H, Random, 95% CI) 1.20 [0.99, 1.46]
12 Postpartum haemorrhage 2 1165 Risk Ratio (M-H, Random, 95% CI) 0.61 [0.20, 1.89]
13 Postnatal infection/pyrexia 1 1000 Risk Ratio (M-H, Fixed, 95% CI) 0.61 [0.34, 1.10]
14 Perineal trauma/tear 1 1000 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.93, 1.18]
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15 Breastfeeding at discharge, six
weeks postpartum, six months
or longer
2 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
15.1 At discharge 1 1000 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.99, 1.10]
15.2 At six months
postpartum
1 188 Risk Ratio (M-H, Fixed, 95% CI) 0.97 [0.87, 1.07]
15.3 Six months postpartum
or longer
1 161 Risk Ratio (M-H, Fixed, 95% CI) 1.31 [0.99, 1.74]
16 Sense of well-being and quality
of lifeduring treatment
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
16.1 Physical functioning 2 847 Mean Difference (IV, Fixed, 95% CI) 3.09 [0.63, 5.54]
16.2 Role physical 2 847 Mean Difference (IV, Fixed, 95% CI) 7.94 [3.29, 12.59]
16.3 Bodily pain 2 847 Mean Difference (IV, Fixed, 95% CI) 3.69 [1.33, 6.05]
16.4 General health 2 847 Mean Difference (IV, Fixed, 95% CI) 1.76 [0.30, 3.21]
16.5 Vitality 2 847 Mean Difference (IV, Fixed, 95% CI) 2.71 [0.88, 4.54]
16.6 Social functioning 2 847 Mean Difference (IV, Fixed, 95% CI) 3.27 [0.81, 5.74]
16.7 Role emotional 2 847 Mean Difference (IV, Fixed, 95% CI) 9.08 [4.49, 13.67]
16.8 Mental health 2 847 Mean Difference (IV, Fixed, 95% CI) 0.90 [-0.96, 2.77]
16.9 Health state utility 1 682 Mean Difference (IV, Fixed, 95% CI) 0.02 [0.00, 0.04]
16.10 Overall physical
component
1 682 Mean Difference (IV, Fixed, 95% CI) 1.5 [0.12, 2.88]
16.11 Overall mental
component
1 682 Mean Difference (IV, Fixed, 95% CI) 1.30 [-0.17, 2.77]
16.12 Anxiety 1 682 Mean Difference (IV, Fixed, 95% CI) -0.30 [-0.88, 0.28]
17 Sense of well-being and quality
of life three months postpartum
2 Mean Difference (IV, Random, 95% CI) Subtotals only
17.1 Physical functioning 3
months postpartum
2 738 Mean Difference (IV, Random, 95% CI) 5.05 [-0.91, 11.02]
17.2 Physical role 3 months
postpartum
2 738 Mean Difference (IV, Random, 95% CI) 8.45 [-3.21, 20.12]
17.3 Bodily pain 3 months
postpartum
2 738 Mean Difference (IV, Random, 95% CI) 2.37 [-1.03, 5.77]
17.4 General health 3 months
postpartum
2 738 Mean Difference (IV, Random, 95% CI) 3.98 [-0.46, 8.43]
17.5 Vitality 3 months
postpartum
2 738 Mean Difference (IV, Random, 95% CI) 4.47 [-1.67, 10.62]
17.6 Social functioning 3
months
2 738 Mean Difference (IV, Random, 95% CI) 9.73 [5.17, 14.28]
17.7 Role emotional 3 months
postpartum
2 738 Mean Difference (IV, Random, 95% CI) 6.92 [-8.24, 22.08]
17.8 Mental health 3 months
postpartum
2 738 Mean Difference (IV, Random, 95% CI) -0.09 [-2.58, 2.40]
17.9 Health state utility 3
months postpartum
1 573 Mean Difference (IV, Random, 95% CI) 0.01 [-0.01, 0.03]
17.10 Overall physical
component 3 months
postpartum
1 573 Mean Difference (IV, Random, 95% CI) 1.20 [-0.19, 2.59]
17.11 Overall mental
component 3 months
postpartum
1 573 Mean Difference (IV, Random, 95% CI) 0.20 [-1.51, 1.91]
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17.12 Anxiety scores 3
months postpartum
1 573 Mean Difference (IV, Random, 95% CI) -0.20 [-0.83, 0.43]
18 Postnatal depression 1 573 Risk Ratio (M-H, Fixed, 95% CI) 0.49 [0.31, 0.78]
19 Postnatal weight retention or
return to pre-pregnancy weight
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
19.1 Six weeks postpartum 1 189 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.67, 2.17]
19.2 Seven months
postpartum
1 159 Risk Ratio (M-H, Fixed, 95% CI) 1.59 [0.99, 2.57]
19.3 12 months postpartum 1 156 Risk Ratio (M-H, Fixed, 95% CI) 1.75 [1.05, 2.90]
20 Fasting plasma glucose 3
months postpartum mmol/L
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
20.1 Three months
postpartum
1 165 Mean Difference (IV, Fixed, 95% CI) -0.08 [-0.16, 0.00]
20.2 Six months postpartum 1 165 Mean Difference (IV, Fixed, 95% CI) -0.14 [-0.22, -0.06]
21 Maternal postnatal impaired
glucose tolerance
1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.67 [0.12, 3.69]
22 Maternal metabolic syndrome
(follow-up)
1 430 Risk Ratio (M-H, Fixed, 95% CI) 0.93 [0.71, 1.22]
23 Stillbirth 4 2355 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 2.86]
24 Neonatal death 5 3055 Risk Ratio (M-H, Fixed, 95% CI) 0.73 [0.22, 2.42]
25 Macrosomia 7 3422 Risk Ratio (M-H, Random, 95% CI) 0.64 [0.48, 0.87]
26 Small-for-gestational age 4 2324 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.73, 1.31]
27 Birth trauma (shoulder
dystocia, bone fracture, nerve
palsy)
6 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
27.1 Birth trauma not
specified
3 1930 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.12, 1.90]
27.2 Bone fracture 2 1730 Risk Ratio (M-H, Fixed, 95% CI) 0.35 [0.01, 8.45]
27.3 Nerve palsy 1 1030 Risk Ratio (M-H, Fixed, 95% CI) 0.15 [0.01, 2.86]
27.4 Shoulder dystocia 5 2894 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.21, 0.66]
28 Gestational age at birth (weeks) 5 2057 Mean Difference (IV, Fixed, 95% CI) 0.04 [-0.13, 0.20]
29 Preterm birth (< 37 weeks’
gestation; and < 32 weeks’
gestation)
3 1797 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.53, 0.96]
30 Five-minute Apgar less than
seven
1 1030 Risk Ratio (M-H, Fixed, 95% CI) 0.56 [0.21, 1.52]
31 Birthweight (grams) 6 3074 Mean Difference (IV, Fixed, 95% CI) -109.64 [-149.77, -
69.51]
32 Length (cm) 1 700 Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.37, 0.17]
33 Adiposity (Neonatal fat mass
(g))
1 958 Mean Difference (IV, Fixed, 95% CI) -37.30 [-63.97, -10.
63]
34 Neonatal hypoglycaemia 6 3000 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.65, 1.52]
35 Respiratory distress syndrome 4 2195 Risk Ratio (M-H, Random, 95% CI) 0.79 [0.34, 1.85]
36 Neonatal jaundice
(hyperbilirubinaemia)
4 2362 Risk Ratio (M-H, Random, 95% CI) 0.76 [0.50, 1.16]
37 Hypocalcaemia 2 464 Risk Ratio (M-H, Fixed, 95% CI) 1.38 [1.01, 1.88]
38 Polycythemia 1 165 Risk Ratio (M-H, Fixed, 95% CI) 0.22 [0.01, 5.40]
39 Childhood weight (kg) 1 199 Mean Difference (IV, Fixed, 95% CI) -0.30 [-1.29, 0.69]
40 Childhood height (cm) 1 199 Mean Difference (IV, Fixed, 95% CI) -0.60 [-2.05, 0.85]
41 Adiposity (Childhood BMI >
85th percentile)
3 767 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.75, 1.11]
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42 Adiposity (BMI Z score
childhood)
1 199 Mean Difference (IV, Fixed, 95% CI) 0.08 [-0.28, 0.44]
43 Childhood glycaemic control
(mmol/L)
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
43.1 Fasting blood glucose 1 68 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.10, 0.30]
43.2 Two-hour postprandial
blood glucose
1 68 Mean Difference (IV, Fixed, 95% CI) 0.0 [-0.48, 0.48]
44 Dyslipidaemia or metabolic
syndrome (Childhood
cholesterol (mg/dL))
1 Mean Difference (IV, Fixed, 95% CI) Subtotals only
44.1 Total cholesterol 1 68 Mean Difference (IV, Fixed, 95% CI) -0.20 [-0.55, 0.15]
44.2 LDL cholesterol 1 68 Mean Difference (IV, Fixed, 95% CI) -0.12 [-0.50, 0.26]
44.3 HDL cholesterol 1 68 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.05, 0.25]
45 Number of antenatal visits or
admissions
1 1000 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.87, 1.29]
46 Number of hospital or health
professional visits (including
midwife, obstetrician,
physician, dietician, diabetic
nurse)
1 Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
46.1 Dietitian 1 1000 Risk Ratio (M-H, Fixed, 95% CI) 9.24 [7.12, 12.01]
46.2 Diabetes educator 1 1000 Risk Ratio (M-H, Fixed, 95% CI) 8.55 [6.67, 10.96]
47 Number of hospital or health
professional visits (including
midwife, obstetrician,
physician, dietician, diabetic
nurse)l
2 Mean Difference (IV, Fixed, 95% CI) Subtotals only
47.1 Obstetrician 1 700 Mean Difference (IV, Fixed, 95% CI) 0.20 [-0.21, 0.61]
47.2 Healthcare provider (not
specified)
1 197 Mean Difference (IV, Fixed, 95% CI) 0.10 [-1.58, 1.78]
48 Admission to neonatal intensive
care unit/nursery
3 2030 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.59, 1.40]
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Analysis 1.1. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 1 Hypertensive
disorders of pregnancy (including pre-eclampsia, pregnancy-induced hypertension, eclampsia).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 1 Hypertensive disorders of pregnancy (including pre-eclampsia, pregnancy-induced hypertension, eclampsia)
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 World Health Organization 1999
Crowther 2005 58/490 93/510 31.5 % 0.65 [ 0.48, 0.88 ]
Subtotal (95% CI) 490 510 31.5 % 0.65 [ 0.48, 0.88 ]
Total events: 58 (Lifestyle intervention), 93 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.79 (P = 0.0053)
2 ADA 2013
Elnour 2008 6/99 16/66 18.6 % 0.25 [ 0.10, 0.61 ]
Landon 2009 41/476 62/455 30.1 % 0.63 [ 0.44, 0.92 ]
Subtotal (95% CI) 575 521 48.6 % 0.44 [ 0.18, 1.06 ]
Total events: 47 (Lifestyle intervention), 78 (Usual care)
Heterogeneity: Tau2 = 0.31; Chi2 = 3.59, df = 1 (P = 0.06); I2 =72%
Test for overall effect: Z = 1.83 (P = 0.068)
3 IADPSG 2010
Yang 2014 18/339 8/361 19.9 % 2.40 [ 1.06, 5.44 ]
Subtotal (95% CI) 339 361 19.9 % 2.40 [ 1.06, 5.44 ]
Total events: 18 (Lifestyle intervention), 8 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.09 (P = 0.037)
Total (95% CI) 1404 1392 100.0 % 0.70 [ 0.40, 1.22 ]
Total events: 123 (Lifestyle intervention), 179 (Usual care)
Heterogeneity: Tau2 = 0.23; Chi2 = 14.20, df = 3 (P = 0.003); I2 =79%
Test for overall effect: Z = 1.26 (P = 0.21)
Test for subgroup differences: Chi2 = 9.94, df = 2 (P = 0.01), I2 =80%
0.01 0.1 1 10 100
Lifestyle intervention Usual care
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Analysis 1.2. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 2 Caesarean section.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 2 Caesarean section
Study or subgroup Lifestyle intervention
Usual care
or diet
alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 WHO 1999/ADIPS 1998
Bancroft 2000 (1) 10/32 11/36 3.7 % 1.02 [ 0.50, 2.08 ]
Crowther 2005 152/490 164/510 19.6 % 0.96 [ 0.80, 1.16 ]
Gillen 2004 1/16 1/16 0.3 % 1.00 [ 0.07, 14.64 ]
Yang 2003 61/95 44/55 18.5 % 0.80 [ 0.66, 0.98 ]
Subtotal (95% CI) 633 617 42.1 % 0.89 [ 0.78, 1.02 ]
Total events: 224 (Lifestyle intervention), 220 (Usual care or diet alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 2.27, df = 3 (P = 0.52); I2 =0.0%
Test for overall effect: Z = 1.69 (P = 0.090)
2 ADA 2013
Elnour 2008 7/99 12/66 2.6 % 0.39 [ 0.16, 0.94 ]
Landon 2009 128/476 154/455 18.7 % 0.79 [ 0.65, 0.97 ]
Subtotal (95% CI) 575 521 21.3 % 0.63 [ 0.33, 1.22 ]
Total events: 135 (Lifestyle intervention), 166 (Usual care or diet alone)
Heterogeneity: Tau2 = 0.15; Chi2 = 2.43, df = 1 (P = 0.12); I2 =59%
Test for overall effect: Z = 1.37 (P = 0.17)
3 IADPSG 2010
Yang 2014 239/339 233/361 24.6 % 1.09 [ 0.99, 1.21 ]
Subtotal (95% CI) 339 361 24.6 % 1.09 [ 0.99, 1.21 ]
Total events: 239 (Lifestyle intervention), 233 (Usual care or diet alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.093)
4 Other/not specified
Bo 2014 (2) 8/50 13/50 3.1 % 0.62 [ 0.28, 1.35 ]
Garner 1997 30/149 28/150 7.5 % 1.08 [ 0.68, 1.71 ]
Mendelson 2008 5/49 5/51 1.5 % 1.04 [ 0.32, 3.37 ]
Subtotal (95% CI) 248 251 12.1 % 0.94 [ 0.65, 1.38 ]
Total events: 43 (Lifestyle intervention), 46 (Usual care or diet alone)
Heterogeneity: Tau2 = 0.0; Chi2 = 1.48, df = 2 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 0.29 (P = 0.77)
0.2 0.5 1 2 5
Lifestyle intervention Usual care or diet alone
(Continued . . . )
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(. . . Continued)
Study or subgroup Lifestyle intervention
Usual care
or diet
alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Total (95% CI) 1795 1750 100.0 % 0.90 [ 0.78, 1.05 ]
Total events: 641 (Lifestyle intervention), 665 (Usual care or diet alone)
Heterogeneity: Tau2 = 0.02; Chi2 = 18.83, df = 9 (P = 0.03); I2 =52%
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Chi2 = 7.65, df = 3 (P = 0.05), I2 =61%
0.2 0.5 1 2 5
Lifestyle intervention Usual care or diet alone
(1) LSCS
(2) Control group was diet alone
Analysis 1.3. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 3 Development of
type 2 diabetes.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 3 Development of type 2 diabetes
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bancroft 2000 (1) 0/28 2/28 12.1 % 0.20 [ 0.01, 3.99 ]
Landon 2009 (2) 21/229 17/201 87.9 % 1.08 [ 0.59, 2.00 ]
Total (95% CI) 257 229 100.0 % 0.98 [ 0.54, 1.76 ]
Total events: 21 (Lifestyle intervention), 19 (Usual care)
Heterogeneity: Chi2 = 1.19, df = 1 (P = 0.28); I2 =16%
Test for overall effect: Z = 0.08 (P = 0.94)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Lifestyle intervention Usual care
(1) No details
(2) 4.5 to 10 years follow-up
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Analysis 1.4. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 4 Perinatal (fetal and
neonatal death) and later infant mortality.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 4 Perinatal (fetal and neonatal death) and later infant mortality
Study or subgroup Lifestyle Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Crowther 2005 (1) 0/506 5/524 100.0 % 0.09 [ 0.01, 1.70 ]
Landon 2009 (2) 0/485 0/473 Not estimable
Total (95% CI) 991 997 100.0 % 0.09 [ 0.01, 1.70 ]
Total events: 0 (Lifestyle), 5 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.60 (P = 0.11)
Test for subgroup differences: Not applicable
0.001 0.01 0.1 1 10 100 1000
Lifestyle intervention Usual care
(1) Perinatal death
(2) Perinatal death
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Analysis 1.5. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 5 Large-for-
gestational age.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 5 Large-for-gestational age
Study or subgroup Lifestyle intervention
Usual care
or diet
alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bancroft 2000 8/32 7/36 2.3 % 1.29 [ 0.53, 3.15 ]
Bo 2014 (1) 5/50 7/50 2.5 % 0.71 [ 0.24, 2.10 ]
Crowther 2005 68/506 115/524 40.1 % 0.61 [ 0.47, 0.81 ]
Elnour 2008 9/99 15/66 6.4 % 0.40 [ 0.19, 0.86 ]
Landon 2009 34/477 66/454 24.0 % 0.49 [ 0.33, 0.73 ]
Yang 2014 44/339 72/361 24.7 % 0.65 [ 0.46, 0.92 ]
Total (95% CI) 1503 1491 100.0 % 0.60 [ 0.50, 0.71 ]
Total events: 168 (Lifestyle intervention), 282 (Usual care or diet alone)
Heterogeneity: Chi2 = 5.21, df = 5 (P = 0.39); I2 =4%
Test for overall effect: Z = 5.74 (P < 0.00001)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Lifestyle intervention Usual care or diet alone
(1) Control group was diet alone
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Analysis 1.6. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 6 Death or serious
morbidity composite (variously defined by trials, e.g. perinatal or infant death, shoulder dystocia, bone
fracture or nerve palsy).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 6 Death or serious morbidity composite (variously defined by trials, e.g. perinatal or infant death, shoulder dystocia, bone fracture or nerve palsy)
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Crowther 2005 (1) 7/506 23/524 41.9 % 0.32 [ 0.14, 0.73 ]
Landon 2009 (2) 149/460 163/440 58.1 % 0.87 [ 0.73, 1.05 ]
Total (95% CI) 966 964 100.0 % 0.57 [ 0.21, 1.55 ]
Total events: 156 (Lifestyle intervention), 186 (Usual care)
Heterogeneity: Tau2 = 0.44; Chi2 = 5.60, df = 1 (P = 0.02); I2 =82%
Test for overall effect: Z = 1.10 (P = 0.27)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Lifestyle intervention Usual care
(1) Composite included one or more of: death, shoulder dystocia, bone fracture and nerve palsy
(2) Composite included: stillbirth, neonatal death, hypoglycaemia, hyperbilirubinaemia, elevated cord-blood C-peptide level and birth trauma
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Analysis 1.7. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 7 Use of additional
pharmacotherapy.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 7 Use of additional pharmacotherapy
Study or subgroup Lifestyle intervention
Usual care
and diet
alone Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
1 Use of anti-diabetic oral medication
Ferrara 2011 27/96 36/101 100.0 % 0.79 [ 0.52, 1.19 ]
Subtotal (95% CI) 96 101 100.0 % 0.79 [ 0.52, 1.19 ]
Total events: 27 (Lifestyle intervention), 36 (Usual care and diet alone)
Heterogeneity: not applicable
Test for overall effect: Z = 1.12 (P = 0.26)
2 Use of insulin treatment
Bancroft 2000 6/32 0/36 5.2 % 14.58 [ 0.85, 248.95 ]
Bo 2014 (1) 3/50 5/50 11.9 % 0.60 [ 0.15, 2.38 ]
Crowther 2005 100/490 17/510 17.9 % 6.12 [ 3.72, 10.08 ]
Elnour 2008 37/108 15/72 17.8 % 1.64 [ 0.98, 2.77 ]
Ferrara 2011 5/96 4/101 12.5 % 1.32 [ 0.36, 4.75 ]
Gillen 2004 1/16 1/16 5.7 % 1.00 [ 0.07, 14.64 ]
Jovanovic-Peterson 1989 (2) 0/10 0/9 Not estimable
Landon 2009 37/485 2/473 11.6 % 18.04 [ 4.37, 74.44 ]
Yang 2014 25/339 18/361 17.4 % 1.48 [ 0.82, 2.66 ]
Subtotal (95% CI) 1626 1628 100.0 % 2.54 [ 1.19, 5.42 ]
Total events: 214 (Lifestyle intervention), 62 (Usual care and diet alone)
Heterogeneity: Tau2 = 0.77; Chi2 = 34.82, df = 7 (P = 0.00001); I2 =80%
Test for overall effect: Z = 2.40 (P = 0.016)
Test for subgroup differences: Chi2 = 7.00, df = 1 (P = 0.01), I2 =86%
0.01 0.1 1 10 100
Usual care and diet alone Lifestyle intervention
(1) Control group was diet alone
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Analysis 1.8. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 8 Maternal
hypoglycaemia.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 8 Maternal hypoglycaemia
Study or subgroup Lifestyle Diet alone Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Jovanovic-Peterson 1989 0/10 0/9 Not estimable
Total (95% CI) 10 9 Not estimable
Total events: 0 (Lifestyle), 0 (Diet alone)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 1.9. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 9 Glycaemic control
during/end treatment.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 9 Glycaemic control during/end treatment
Study or subgroup Lifestyle intervention
Usual care
and diet
alone
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Fasting blood glucose concentration mg/dL
Bo 2014 (1) 50 72.3 (10.6) 50 74.1 (10.1) 16.4 % -1.80 [ -5.86, 2.26 ]
Elnour 2008 99 5.06 (0.18) 66 5.14 (0.26) 19.9 % -0.08 [ -0.15, -0.01 ]
Garner 1997 149 80.46 (14.76) 150 84.6 (18.8) 16.7 % -4.14 [ -7.97, -0.31 ]
Jovanovic-Peterson 1989 (2) 10 70.1 (6.6) 9 87.6 (6.2) 13.9 % -17.50 [ -23.26, -11.74 ]
Mendelson 2008 (3) 49 101 (9.26) 51 92.9 (17.3) 14.4 % 8.10 [ 2.69, 13.51 ]
Youngwanichsetha 2014 85 83.39 (7.69) 85 87.85 (7.94) 18.6 % -4.46 [ -6.81, -2.11 ]
Subtotal (95% CI) 442 411 100.0 % -3.10 [ -7.01, 0.81 ]
Heterogeneity: Tau2 = 19.94; Chi2 = 62.27, df = 5 (P<0.00001); I2 =92%
Test for overall effect: Z = 1.55 (P = 0.12)
2 Postprandial blood glucose concentration mg/dL
Bo 2014 (4) 50 107.8 (18.3) 50 121.8 (16.1) 25.6 % -14.00 [ -20.76, -7.24 ]
Garner 1997 (5) 149 126.18 (25.2) 150 135.36 (34.14) 25.6 % -9.18 [ -15.98, -2.38 ]
Jovanovic-Peterson 1989 (6) 10 105.9 (18.9) 9 187.5 (12.9) 22.5 % -81.60 [ -96.03, -67.17 ]
Youngwanichsetha 2014 (7) 85 103.67 (9.93) 85 114.36 (10.15) 26.4 % -10.69 [ -13.71, -7.67 ]
Subtotal (95% CI) 294 294 100.0 % -27.11 [ -44.62, -9.61 ]
Heterogeneity: Tau2 = 300.13; Chi2 = 90.35, df = 3 (P<0.00001); I2 =97%
Test for overall effect: Z = 3.04 (P = 0.0024)
3 HbA1c mmol/mol
Bancroft 2000 (8) 24 5.3 (0.9) 27 5.5 (0.9) 6.3 % -0.20 [ -0.69, 0.29 ]
Bo 2014 (9) 50 4.7 (0.4) 50 5 (0.4) 22.5 % -0.30 [ -0.46, -0.14 ]
Elnour 2008 99 6.38 (0.2) 66 6.55 (0.5) 25.0 % -0.17 [ -0.30, -0.04 ]
Jovanovic-Peterson 1989 (10) 10 4.16 (0.28) 9 4.67 (0.25) 16.4 % -0.51 [ -0.75, -0.27 ]
Mendelson 2008 15 5.62 (1.03) 12 5.73 (1.29) 2.2 % -0.11 [ -1.01, 0.79 ]
Youngwanichsetha 2014 85 5.23 (0.22) 85 5.68 (0.38) 27.6 % -0.45 [ -0.54, -0.36 ]
Subtotal (95% CI) 283 249 100.0 % -0.33 [ -0.47, -0.19 ]
Heterogeneity: Tau2 = 0.02; Chi2 = 14.89, df = 5 (P = 0.01); I2 =66%
Test for overall effect: Z = 4.69 (P < 0.00001)
Test for subgroup differences: Chi2 = 10.91, df = 2 (P = 0.00), I2 =82%
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(1) End of trial; control group was diet alone
(2) Control group was diet alone
(3) Mendelson 2008 data was end of treatment at birth
(4) Unknown timing; control group was diet alone
(5) one hour postprandial
(6) One hour postprandial; control group was diet alone
(7) two hour postprandial
(8) 38 weeks’ gestation
(9) Control group was diet alone
(10) Control group was diet alone
Analysis 1.10. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 10 Weight gain in
pregnancy (kg).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 10 Weight gain in pregnancy (kg)
Study or subgroup Lifestyle intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Crowther 2005 490 8.1 (6.6) 510 9.8 (9) 24.0 % -1.70 [ -2.68, -0.72 ]
Garner 1997 149 12.5 (4.8) 150 13.4 (4.8) 22.6 % -0.90 [ -1.99, 0.19 ]
Landon 2009 476 2.8 (4.5) 455 5 (3.3) 29.3 % -2.20 [ -2.71, -1.69 ]
Yang 2014 339 15.5 (6.5) 361 15.7 (6.4) 24.2 % -0.20 [ -1.16, 0.76 ]
Total (95% CI) 1454 1476 100.0 % -1.30 [ -2.26, -0.35 ]
Heterogeneity: Tau2 = 0.75; Chi2 = 15.22, df = 3 (P = 0.002); I2 =80%
Test for overall effect: Z = 2.67 (P = 0.0077)
Test for subgroup differences: Not applicable
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Analysis 1.11. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 11 Induction of
labour.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 11 Induction of labour
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bancroft 2000 20/32 15/36 14.0 % 1.50 [ 0.94, 2.40 ]
Crowther 2005 189/490 150/510 46.1 % 1.31 [ 1.10, 1.56 ]
Landon 2009 130/476 122/455 39.5 % 1.02 [ 0.82, 1.26 ]
Yang 2014 0/339 1/361 0.4 % 0.35 [ 0.01, 8.68 ]
Total (95% CI) 1337 1362 100.0 % 1.20 [ 0.99, 1.46 ]
Total events: 339 (Lifestyle intervention), 288 (Usual care)
Heterogeneity: Tau2 = 0.01; Chi2 = 4.76, df = 3 (P = 0.19); I2 =37%
Test for overall effect: Z = 1.85 (P = 0.064)
Test for subgroup differences: Not applicable
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Analysis 1.12. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 12 Postpartum
haemorrhage.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 12 Postpartum haemorrhage
Study or subgroup Specific treatment Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Crowther 2005 29/490 32/510 63.6 % 0.94 [ 0.58, 1.54 ]
Elnour 2008 3/99 7/66 36.4 % 0.29 [ 0.08, 1.07 ]
Total (95% CI) 589 576 100.0 % 0.61 [ 0.20, 1.89 ]
Total events: 32 (Specific treatment), 39 (Usual care)
Heterogeneity: Tau2 = 0.46; Chi2 = 2.79, df = 1 (P = 0.10); I2 =64%
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
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Analysis 1.13. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 13 Postnatal
infection/pyrexia.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 13 Postnatal infection/pyrexia
Study or subgroup Lifestyle Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Crowther 2005 17/490 29/510 100.0 % 0.61 [ 0.34, 1.10 ]
Total (95% CI) 490 510 100.0 % 0.61 [ 0.34, 1.10 ]
Total events: 17 (Lifestyle), 29 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.65 (P = 0.098)
Test for subgroup differences: Not applicable
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Analysis 1.14. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 14 Perineal
trauma/tear.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 14 Perineal trauma/tear
Study or subgroup Experimental Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Crowther 2005 255/490 254/510 100.0 % 1.04 [ 0.93, 1.18 ]
Total (95% CI) 490 510 100.0 % 1.04 [ 0.93, 1.18 ]
Total events: 255 (Experimental), 254 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.71 (P = 0.48)
Test for subgroup differences: Not applicable
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Analysis 1.15. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 15 Breastfeeding at
discharge, six weeks postpartum, six months or longer.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 15 Breastfeeding at discharge, six weeks postpartum, six months or longer
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 At discharge
Crowther 2005 413/490 412/510 100.0 % 1.04 [ 0.99, 1.10 ]
Subtotal (95% CI) 490 510 100.0 % 1.04 [ 0.99, 1.10 ]
Total events: 413 (Lifestyle intervention), 412 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.46 (P = 0.14)
2 At six months postpartum
Ferrara 2011 79/90 89/98 100.0 % 0.97 [ 0.87, 1.07 ]
Subtotal (95% CI) 90 98 100.0 % 0.97 [ 0.87, 1.07 ]
Total events: 79 (Lifestyle intervention), 89 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.67 (P = 0.50)
3 Six months postpartum or longer
Ferrara 2011 47/75 41/86 100.0 % 1.31 [ 0.99, 1.74 ]
Subtotal (95% CI) 75 86 100.0 % 1.31 [ 0.99, 1.74 ]
Total events: 47 (Lifestyle intervention), 41 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
Test for subgroup differences: Chi2 = 4.63, df = 2 (P = 0.10), I2 =57%
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Analysis 1.16. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 16 Sense of well-
being and quality of lifeduring treatment.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 16 Sense of well-being and quality of lifeduring treatment
Study or subgroup Lifestyle Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Physical functioning
Crowther 2005 332 56.4 (23.1) 350 54 (22.7) 51.0 % 2.40 [ -1.04, 5.84 ]
Elnour 2008 99 67.2 (8.9) 66 63.4 (12.6) 49.0 % 3.80 [ 0.29, 7.31 ]
Subtotal (95% CI) 431 416 100.0 % 3.09 [ 0.63, 5.54 ]
Heterogeneity: Chi2 = 0.31, df = 1 (P = 0.58); I2 =0.0%
Test for overall effect: Z = 2.46 (P = 0.014)
2 Role physical
Crowther 2005 332 40.7 (41.4) 350 32.4 (38.1) 60.4 % 8.30 [ 2.32, 14.28 ]
Elnour 2008 99 51 (20.8) 66 43.6 (25.5) 39.6 % 7.40 [ 0.01, 14.79 ]
Subtotal (95% CI) 431 416 100.0 % 7.94 [ 3.29, 12.59 ]
Heterogeneity: Chi2 = 0.03, df = 1 (P = 0.85); I2 =0.0%
Test for overall effect: Z = 3.35 (P = 0.00081)
3 Bodily pain
Crowther 2005 332 63.1 (24.6) 350 59 (24.1) 41.6 % 4.10 [ 0.44, 7.76 ]
Elnour 2008 99 72.8 (12.7) 66 69.4 (7.5) 58.4 % 3.40 [ 0.31, 6.49 ]
Subtotal (95% CI) 431 416 100.0 % 3.69 [ 1.33, 6.05 ]
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 3.07 (P = 0.0022)
4 General health
Crowther 2005 332 73.4 (17.4) 350 72.5 (18.9) 28.6 % 0.90 [ -1.82, 3.62 ]
Elnour 2008 99 68.4 (6.9) 66 66.3 (4.4) 71.4 % 2.10 [ 0.38, 3.82 ]
Subtotal (95% CI) 431 416 100.0 % 1.76 [ 0.30, 3.21 ]
Heterogeneity: Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 2.36 (P = 0.018)
5 Vitality
Crowther 2005 332 50 (21) 350 46.7 (20.3) 34.8 % 3.30 [ 0.20, 6.40 ]
Elnour 2008 99 58.8 (6.6) 66 56.4 (7.7) 65.2 % 2.40 [ 0.13, 4.67 ]
Subtotal (95% CI) 431 416 100.0 % 2.71 [ 0.88, 4.54 ]
Heterogeneity: Chi2 = 0.21, df = 1 (P = 0.65); I2 =0.0%
Test for overall effect: Z = 2.91 (P = 0.0037)
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Study or subgroup Lifestyle Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
6 Social functioning
Crowther 2005 332 73.5 (24) 350 70.9 (23.2) 48.3 % 2.60 [ -0.95, 6.15 ]
Elnour 2008 99 63.5 (9.3) 66 59.6 (12) 51.7 % 3.90 [ 0.47, 7.33 ]
Subtotal (95% CI) 431 416 100.0 % 3.27 [ 0.81, 5.74 ]
Heterogeneity: Chi2 = 0.27, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 2.60 (P = 0.0092)
7 Role emotional
Crowther 2005 332 77.5 (35.3) 350 69.1 (40.9) 64.2 % 8.40 [ 2.67, 14.13 ]
Elnour 2008 99 68.4 (20.7) 66 58.1 (26.9) 35.8 % 10.30 [ 2.64, 17.96 ]
Subtotal (95% CI) 431 416 100.0 % 9.08 [ 4.49, 13.67 ]
Heterogeneity: Chi2 = 0.15, df = 1 (P = 0.70); I2 =0.0%
Test for overall effect: Z = 3.88 (P = 0.00010)
8 Mental health
Crowther 2005 332 75.1 (15.4) 350 73.8 (16.6) 60.4 % 1.30 [ -1.10, 3.70 ]
Elnour 2008 99 60.7 (7.6) 66 60.4 (10.6) 39.6 % 0.30 [ -2.66, 3.26 ]
Subtotal (95% CI) 431 416 100.0 % 0.90 [ -0.96, 2.77 ]
Heterogeneity: Chi2 = 0.26, df = 1 (P = 0.61); I2 =0.0%
Test for overall effect: Z = 0.95 (P = 0.34)
9 Health state utility
Crowther 2005 332 0.72 (0.11) 350 0.7 (0.11) 100.0 % 0.02 [ 0.00, 0.04 ]
Subtotal (95% CI) 332 350 100.0 % 0.02 [ 0.00, 0.04 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
10 Overall physical component
Crowther 2005 332 38.8 (9.4) 350 37.3 (9) 100.0 % 1.50 [ 0.12, 2.88 ]
Subtotal (95% CI) 332 350 100.0 % 1.50 [ 0.12, 2.88 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.13 (P = 0.033)
11 Overall mental component
Crowther 2005 332 50.9 (9.2) 350 49.6 (10.4) 100.0 % 1.30 [ -0.17, 2.77 ]
Subtotal (95% CI) 332 350 100.0 % 1.30 [ -0.17, 2.77 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.73 (P = 0.083)
12 Anxiety
Crowther 2005 332 11.2 (3.7) 350 11.5 (4) 100.0 % -0.30 [ -0.88, 0.28 ]
Subtotal (95% CI) 332 350 100.0 % -0.30 [ -0.88, 0.28 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.02 (P = 0.31)
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Study or subgroup Lifestyle Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Test for subgroup differences: Chi2 = 71.22, df = 11 (P = 0.00), I2 =85%
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Analysis 1.17. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 17 Sense of well-
being and quality of life three months postpartum.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 17 Sense of well-being and quality of life three months postpartum
Study or subgroup LIfestyle Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
1 Physical functioning 3 months postpartum
Crowther 2005 278 85.8 (19.5) 295 83.6 (19.6) 53.3 % 2.20 [ -1.00, 5.40 ]
Elnour 2008 99 86.6 (18.5) 66 78.3 (10.4) 46.7 % 8.30 [ 3.88, 12.72 ]
Subtotal (95% CI) 377 361 100.0 % 5.05 [ -0.91, 11.02 ]
Heterogeneity: Tau2 = 14.72; Chi2 = 4.79, df = 1 (P = 0.03); I2 =79%
Test for overall effect: Z = 1.66 (P = 0.097)
2 Physical role 3 months postpartum
Crowther 2005 278 79.9 (33.7) 295 75.9 (36.3) 64.1 % 4.00 [ -1.73, 9.73 ]
Elnour 2008 99 81.6 (39.3) 66 65.2 (48.9) 35.9 % 16.40 [ 2.29, 30.51 ]
Subtotal (95% CI) 377 361 100.0 % 8.45 [ -3.21, 20.12 ]
Heterogeneity: Tau2 = 46.69; Chi2 = 2.55, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 1.42 (P = 0.16)
3 Bodily pain 3 months postpartum
Crowther 2005 278 77.7 (23) 295 77.3 (21.6) 43.7 % 0.40 [ -3.26, 4.06 ]
Elnour 2008 99 94.1 (10.9) 66 90.2 (7) 56.3 % 3.90 [ 1.17, 6.63 ]
Subtotal (95% CI) 377 361 100.0 % 2.37 [ -1.03, 5.77 ]
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Study or subgroup LIfestyle Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Heterogeneity: Tau2 = 3.41; Chi2 = 2.26, df = 1 (P = 0.13); I2 =56%
Test for overall effect: Z = 1.37 (P = 0.17)
4 General health 3 months postpartum
Crowther 2005 278 76.8 (17.5) 295 74.2 (18.2) 72.8 % 2.60 [ -0.32, 5.52 ]
Elnour 2008 99 78 (26.4) 66 70.3 (21.6) 27.2 % 7.70 [ 0.34, 15.06 ]
Subtotal (95% CI) 377 361 100.0 % 3.98 [ -0.46, 8.43 ]
Heterogeneity: Tau2 = 4.84; Chi2 = 1.59, df = 1 (P = 0.21); I2 =37%
Test for overall effect: Z = 1.76 (P = 0.079)
5 Vitality 3 months postpartum
Crowther 2005 278 60 (19.3) 295 57.7 (19.7) 67.6 % 2.30 [ -0.89, 5.49 ]
Elnour 2008 99 84.6 (22.6) 66 75.6 (29.6) 32.4 % 9.00 [ 0.58, 17.42 ]
Subtotal (95% CI) 377 361 100.0 % 4.47 [ -1.67, 10.62 ]
Heterogeneity: Tau2 = 11.90; Chi2 = 2.13, df = 1 (P = 0.14); I2 =53%
Test for overall effect: Z = 1.43 (P = 0.15)
6 Social functioning 3 months
Crowther 2005 278 81.4 (21.3) 295 70 (23.3) 65.8 % 11.40 [ 7.75, 15.05 ]
Elnour 2008 99 87.3 (17.8) 66 80.8 (22.8) 34.2 % 6.50 [ -0.02, 13.02 ]
Subtotal (95% CI) 377 361 100.0 % 9.73 [ 5.17, 14.28 ]
Heterogeneity: Tau2 = 4.73; Chi2 = 1.65, df = 1 (P = 0.20); I2 =39%
Test for overall effect: Z = 4.19 (P = 0.000028)
7 Role emotional 3 months postpartum
Crowther 2005 278 78.9 (35) 295 78.5 (35.7) 58.5 % 0.40 [ -5.39, 6.19 ]
Elnour 2008 99 82.8 (38.3) 66 66.7 (48.5) 41.5 % 16.10 [ 2.18, 30.02 ]
Subtotal (95% CI) 377 361 100.0 % 6.92 [ -8.24, 22.08 ]
Heterogeneity: Tau2 = 93.65; Chi2 = 4.16, df = 1 (P = 0.04); I2 =76%
Test for overall effect: Z = 0.89 (P = 0.37)
8 Mental health 3 months postpartum
Crowther 2005 278 77 (15.4) 295 77.4 (16.7) 90.0 % -0.40 [ -3.03, 2.23 ]
Elnour 2008 99 86.3 (22.6) 66 83.6 (27) 10.0 % 2.70 [ -5.19, 10.59 ]
Subtotal (95% CI) 377 361 100.0 % -0.09 [ -2.58, 2.40 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.53, df = 1 (P = 0.47); I2 =0.0%
Test for overall effect: Z = 0.07 (P = 0.94)
9 Health state utility 3 months postpartum
Crowther 2005 278 0.79 (0.1) 295 0.78 (0.11) 100.0 % 0.01 [ -0.01, 0.03 ]
Subtotal (95% CI) 278 295 100.0 % 0.01 [ -0.01, 0.03 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.14 (P = 0.25)
10 Overall physical component 3 months postpartum
Crowther 2005 278 51.2 (8.5) 295 50 (8.5) 100.0 % 1.20 [ -0.19, 2.59 ]
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Study or subgroup LIfestyle Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Subtotal (95% CI) 278 295 100.0 % 1.20 [ -0.19, 2.59 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.69 (P = 0.091)
11 Overall mental component 3 months postpartum
Crowther 2005 278 48.6 (10) 295 48.4 (10.9) 100.0 % 0.20 [ -1.51, 1.91 ]
Subtotal (95% CI) 278 295 100.0 % 0.20 [ -1.51, 1.91 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.23 (P = 0.82)
12 Anxiety scores 3 months postpartum
Crowther 2005 278 10.6 (3.9) 295 10.8 (3.8) 100.0 % -0.20 [ -0.83, 0.43 ]
Subtotal (95% CI) 278 295 100.0 % -0.20 [ -0.83, 0.43 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.53)
Test for subgroup differences: Chi2 = 33.26, df = 11 (P = 0.00), I2 =67%
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Analysis 1.18. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 18 Postnatal
depression.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 18 Postnatal depression
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Crowther 2005 23/278 50/295 100.0 % 0.49 [ 0.31, 0.78 ]
Total (95% CI) 278 295 100.0 % 0.49 [ 0.31, 0.78 ]
Total events: 23 (Lifestyle intervention), 50 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 3.02 (P = 0.0025)
Test for subgroup differences: Not applicable
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Analysis 1.19. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 19 Postnatal weight
retention or return to pre-pregnancy weight.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 19 Postnatal weight retention or return to pre-pregnancy weight
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Six weeks postpartum
Ferrara 2011 19/91 17/98 100.0 % 1.20 [ 0.67, 2.17 ]
Subtotal (95% CI) 91 98 100.0 % 1.20 [ 0.67, 2.17 ]
Total events: 19 (Lifestyle intervention), 17 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.62 (P = 0.54)
2 Seven months postpartum
Ferrara 2011 27/71 21/88 100.0 % 1.59 [ 0.99, 2.57 ]
Subtotal (95% CI) 71 88 100.0 % 1.59 [ 0.99, 2.57 ]
Total events: 27 (Lifestyle intervention), 21 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.92 (P = 0.055)
3 12 months postpartum
Ferrara 2011 27/72 18/84 100.0 % 1.75 [ 1.05, 2.90 ]
Subtotal (95% CI) 72 84 100.0 % 1.75 [ 1.05, 2.90 ]
Total events: 27 (Lifestyle intervention), 18 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 2.17 (P = 0.030)
Test for subgroup differences: Chi2 = 0.94, df = 2 (P = 0.63), I2 =0.0%
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Analysis 1.20. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 20 Fasting plasma
glucose 3 months postpartum mmol/L.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 20 Fasting plasma glucose 3 months postpartum mmol/L
Study or subgroup Lifestyle intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Three months postpartum
Elnour 2008 99 5.07 (0.2) 66 5.15 (0.3) 100.0 % -0.08 [ -0.16, 0.00 ]
Subtotal (95% CI) 99 66 100.0 % -0.08 [ -0.16, 0.00 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.90 (P = 0.057)
2 Six months postpartum
Elnour 2008 99 5.33 (0.2) 66 5.47 (0.3) 100.0 % -0.14 [ -0.22, -0.06 ]
Subtotal (95% CI) 99 66 100.0 % -0.14 [ -0.22, -0.06 ]
Heterogeneity: not applicable
Test for overall effect: Z = 3.33 (P = 0.00087)
Test for subgroup differences: Chi2 = 1.02, df = 1 (P = 0.31), I2 =2%
-0.2 -0.1 0 0.1 0.2
Lifestyle intervention Usual care
97Lifestyle interventions for the treatment of women with gestational diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.21. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 21 Maternal
postnatal impaired glucose tolerance.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 21 Maternal postnatal impaired glucose tolerance
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bancroft 2000 2/28 3/28 100.0 % 0.67 [ 0.12, 3.69 ]
Total (95% CI) 28 28 100.0 % 0.67 [ 0.12, 3.69 ]
Total events: 2 (Lifestyle intervention), 3 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.46 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 1.22. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 22 Maternal
metabolic syndrome (follow-up).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 22 Maternal metabolic syndrome (follow-up)
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Landon 2009 73/229 69/201 100.0 % 0.93 [ 0.71, 1.22 ]
Total (95% CI) 229 201 100.0 % 0.93 [ 0.71, 1.22 ]
Total events: 73 (Lifestyle intervention), 69 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 1.23. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 23 Stillbirth.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 23 Stillbirth
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bancroft 2000 0/32 0/36 Not estimable
Crowther 2005 0/506 3/524 100.0 % 0.15 [ 0.01, 2.86 ]
Garner 1997 0/149 0/150 Not estimable
Landon 2009 0/485 0/473 Not estimable
Total (95% CI) 1172 1183 100.0 % 0.15 [ 0.01, 2.86 ]
Total events: 0 (Lifestyle intervention), 3 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.21)
Test for subgroup differences: Not applicable
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Analysis 1.24. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 24 Neonatal death.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 24 Neonatal death
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bancroft 2000 0/32 0/36 Not estimable
Crowther 2005 0/506 2/524 38.8 % 0.21 [ 0.01, 4.30 ]
Garner 1997 0/149 0/150 Not estimable
Landon 2009 0/485 0/473 Not estimable
Yang 2014 4/339 4/361 61.2 % 1.06 [ 0.27, 4.22 ]
Total (95% CI) 1511 1544 100.0 % 0.73 [ 0.22, 2.42 ]
Total events: 4 (Lifestyle intervention), 6 (Usual care)
Heterogeneity: Chi2 = 0.95, df = 1 (P = 0.33); I2 =0.0%
Test for overall effect: Z = 0.51 (P = 0.61)
Test for subgroup differences: Not applicable
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Analysis 1.25. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 25 Macrosomia.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 25 Macrosomia
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Crowther 2005 (1) 49/506 110/524 18.5 % 0.46 [ 0.34, 0.63 ]
Elnour 2008 (2) 11/99 16/66 10.2 % 0.46 [ 0.23, 0.92 ]
Ferrara 2011 (3) 15/96 11/101 9.8 % 1.43 [ 0.69, 2.97 ]
Garner 1997 (4) 24/149 28/150 14.1 % 0.86 [ 0.53, 1.42 ]
Landon 2009 (5) 28/477 65/454 15.8 % 0.41 [ 0.27, 0.63 ]
Mendelson 2008 (6) 19/49 22/51 14.7 % 0.90 [ 0.56, 1.44 ]
Yang 2014 (7) 38/339 63/361 17.0 % 0.64 [ 0.44, 0.93 ]
Total (95% CI) 1715 1707 100.0 % 0.64 [ 0.48, 0.87 ]
Total events: 184 (Lifestyle intervention), 315 (Usual care)
Heterogeneity: Tau2 = 0.10; Chi2 = 17.02, df = 6 (P = 0.01); I2 =65%
Test for overall effect: Z = 2.89 (P = 0.0038)
Test for subgroup differences: Not applicable
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Analysis 1.26. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 26 Small-for-
gestational age.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 26 Small-for-gestational age
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Crowther 2005 33/506 38/524 44.4 % 0.90 [ 0.57, 1.41 ]
Elnour 2008 12/99 11/66 15.7 % 0.73 [ 0.34, 1.55 ]
Ferrara 2011 4/96 4/101 4.6 % 1.05 [ 0.27, 4.09 ]
Landon 2009 36/477 29/455 35.3 % 1.18 [ 0.74, 1.90 ]
Total (95% CI) 1178 1146 100.0 % 0.98 [ 0.73, 1.31 ]
Total events: 85 (Lifestyle intervention), 82 (Usual care)
Heterogeneity: Chi2 = 1.37, df = 3 (P = 0.71); I2 =0.0%
Test for overall effect: Z = 0.14 (P = 0.89)
Test for subgroup differences: Not applicable
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Analysis 1.27. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 27 Birth trauma
(shoulder dystocia, bone fracture, nerve palsy).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 27 Birth trauma (shoulder dystocia, bone fracture, nerve palsy)
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Birth trauma not specified
Garner 1997 0/149 0/150 Not estimable
Landon 2009 3/476 6/455 100.0 % 0.48 [ 0.12, 1.90 ]
Yang 2014 0/339 0/361 Not estimable
Subtotal (95% CI) 964 966 100.0 % 0.48 [ 0.12, 1.90 ]
Total events: 3 (Lifestyle intervention), 6 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
2 Bone fracture
Crowther 2005 0/506 1/524 100.0 % 0.35 [ 0.01, 8.45 ]
Yang 2014 0/339 0/361 Not estimable
Subtotal (95% CI) 845 885 100.0 % 0.35 [ 0.01, 8.45 ]
Total events: 0 (Lifestyle intervention), 1 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.65 (P = 0.51)
3 Nerve palsy
Crowther 2005 0/506 3/524 100.0 % 0.15 [ 0.01, 2.86 ]
Subtotal (95% CI) 506 524 100.0 % 0.15 [ 0.01, 2.86 ]
Total events: 0 (Lifestyle intervention), 3 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.27 (P = 0.21)
4 Shoulder dystocia
Bancroft 2000 0/32 1/36 3.3 % 0.37 [ 0.02, 8.86 ]
Crowther 2005 7/506 16/524 36.8 % 0.45 [ 0.19, 1.09 ]
Elnour 2008 2/99 6/66 16.8 % 0.22 [ 0.05, 1.07 ]
Landon 2009 7/476 18/455 43.1 % 0.37 [ 0.16, 0.88 ]
Yang 2014 0/339 0/361 Not estimable
Subtotal (95% CI) 1452 1442 100.0 % 0.38 [ 0.21, 0.66 ]
Total events: 16 (Lifestyle intervention), 41 (Usual care)
Heterogeneity: Chi2 = 0.60, df = 3 (P = 0.90); I2 =0.0%
Test for overall effect: Z = 3.41 (P = 0.00064)
Test for subgroup differences: Chi2 = 0.50, df = 3 (P = 0.92), I2 =0.0%
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Analysis 1.28. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 28 Gestational age
at birth (weeks).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 28 Gestational age at birth (weeks)
Study or subgroup Lifestyle intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bancroft 2000 32 39 (1.25) 36 39 (1.15) 8.3 % 0.0 [ -0.57, 0.57 ]
Garner 1997 149 38.79 (1.77) 150 39.14 (1.64) 18.2 % -0.35 [ -0.74, 0.04 ]
Gillen 2004 16 39.5 (2) 16 38.9 (1.2) 2.1 % 0.60 [ -0.54, 1.74 ]
Landon 2009 485 39 (1.8) 473 38.9 (1.8) 52.3 % 0.10 [ -0.13, 0.33 ]
Yang 2014 339 39.4 (2.9) 361 39.2 (2.1) 19.1 % 0.20 [ -0.18, 0.58 ]
Total (95% CI) 1021 1036 100.0 % 0.04 [ -0.13, 0.20 ]
Heterogeneity: Chi2 = 5.80, df = 4 (P = 0.21); I2 =31%
Test for overall effect: Z = 0.47 (P = 0.64)
Test for subgroup differences: Not applicable
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Analysis 1.29. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 29 Preterm birth (<
37 weeks’ gestation; and < 32 weeks’ gestation).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 29 Preterm birth (< 37 weeks gestation; and < 32 weeks’ gestation)
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elnour 2008 4/99 9/66 11.7 % 0.30 [ 0.10, 0.92 ]
Landon 2009 45/477 53/455 58.9 % 0.81 [ 0.56, 1.18 ]
Yang 2014 18/339 28/361 29.4 % 0.68 [ 0.39, 1.21 ]
Total (95% CI) 915 882 100.0 % 0.71 [ 0.53, 0.96 ]
Total events: 67 (Lifestyle intervention), 90 (Usual care)
Heterogeneity: Chi2 = 2.76, df = 2 (P = 0.25); I2 =27%
Test for overall effect: Z = 2.21 (P = 0.027)
Test for subgroup differences: Not applicable
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Analysis 1.30. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 30 Five-minute
Apgar less than seven.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 30 Five-minute Apgar less than seven
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Crowther 2005 6/506 11/524 100.0 % 0.56 [ 0.21, 1.52 ]
Total (95% CI) 506 524 100.0 % 0.56 [ 0.21, 1.52 ]
Total events: 6 (Lifestyle intervention), 11 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
Test for subgroup differences: Not applicable
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Analysis 1.31. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 31 Birthweight
(grams).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 31 Birthweight (grams)
Study or subgroup Lifestyle intervention
Usual care
and diet
only
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Bancroft 2000 32 3580 (550) 36 3620 (550) 2.3 % -40.00 [ -301.90, 221.90 ]
Crowther 2005 506 3335 (551) 524 3482 (660) 29.3 % -147.00 [ -221.15, -72.85 ]
Garner 1997 149 3437 (575) 150 3544 (601) 9.1 % -107.00 [ -240.32, 26.32 ]
Jovanovic-Peterson 1989 (1) 10 3634 (317) 9 3465 (343) 1.8 % 169.00 [ -129.02, 467.02 ]
Landon 2009 485 3302 (502.4) 473 3408 (589.4) 33.4 % -106.00 [ -175.43, -36.57 ]
Yang 2014 339 3371 (530) 361 3469 (574) 24.1 % -98.00 [ -179.79, -16.21 ]
Total (95% CI) 1521 1553 100.0 % -109.64 [ -149.77, -69.51 ]
Heterogeneity: Chi2 = 4.69, df = 5 (P = 0.45); I2 =0.0%
Test for overall effect: Z = 5.35 (P < 0.00001)
Test for subgroup differences: Not applicable
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Analysis 1.32. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 32 Length (cm).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 32 Length (cm)
Study or subgroup Lifestyle intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Yang 2014 339 50.1 (1.8) 361 50.2 (1.9) 100.0 % -0.10 [ -0.37, 0.17 ]
Total (95% CI) 339 361 100.0 % -0.10 [ -0.37, 0.17 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.72 (P = 0.47)
Test for subgroup differences: Not applicable
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Analysis 1.33. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 33 Adiposity
(Neonatal fat mass (g)).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 33 Adiposity (Neonatal fat mass (g))
Study or subgroup Lifestyle intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Landon 2009 485 427 (197.9) 473 464.3 (222.3) 100.0 % -37.30 [ -63.97, -10.63 ]
Total (95% CI) 485 473 100.0 % -37.30 [ -63.97, -10.63 ]
Heterogeneity: not applicable
Test for overall effect: Z = 2.74 (P = 0.0061)
Test for subgroup differences: Not applicable
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Analysis 1.34. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 34 Neonatal
hypoglycaemia.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 34 Neonatal hypoglycaemia
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bancroft 2000 2/32 6/36 6.6 % 0.38 [ 0.08, 1.73 ]
Crowther 2005 35/506 27/524 27.0 % 1.34 [ 0.82, 2.18 ]
Elnour 2008 2/99 7/66 6.5 % 0.19 [ 0.04, 0.89 ]
Garner 1997 21/149 13/150 21.1 % 1.63 [ 0.85, 3.13 ]
Landon 2009 62/381 55/357 33.1 % 1.06 [ 0.76, 1.47 ]
Yang 2014 2/339 4/361 5.6 % 0.53 [ 0.10, 2.89 ]
Total (95% CI) 1506 1494 100.0 % 0.99 [ 0.65, 1.52 ]
Total events: 124 (Lifestyle intervention), 112 (Usual care)
Heterogeneity: Tau2 = 0.12; Chi2 = 9.70, df = 5 (P = 0.08); I2 =48%
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 1.35. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 35 Respiratory
distress syndrome.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 35 Respiratory distress syndrome
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bancroft 2000 2/32 1/36 9.9 % 2.25 [ 0.21, 23.66 ]
Crowther 2005 27/506 19/524 35.6 % 1.47 [ 0.83, 2.61 ]
Elnour 2008 4/99 10/66 24.4 % 0.27 [ 0.09, 0.81 ]
Landon 2009 9/477 13/455 30.0 % 0.66 [ 0.29, 1.53 ]
Total (95% CI) 1114 1081 100.0 % 0.79 [ 0.34, 1.85 ]
Total events: 42 (Lifestyle intervention), 43 (Usual care)
Heterogeneity: Tau2 = 0.44; Chi2 = 8.44, df = 3 (P = 0.04); I2 =64%
Test for overall effect: Z = 0.53 (P = 0.59)
Test for subgroup differences: Not applicable
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Analysis 1.36. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 36 Neonatal
jaundice (hyperbilirubinaemia).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 36 Neonatal jaundice (hyperbilirubinaemia)
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Crowther 2005 (1) 44/506 48/524 39.6 % 0.95 [ 0.64, 1.40 ]
Elnour 2008 1/99 8/66 3.9 % 0.08 [ 0.01, 0.65 ]
Garner 1997 8/149 10/150 16.1 % 0.81 [ 0.33, 1.98 ]
Landon 2009 43/450 54/418 40.4 % 0.74 [ 0.51, 1.08 ]
Total (95% CI) 1204 1158 100.0 % 0.76 [ 0.50, 1.16 ]
Total events: 96 (Lifestyle intervention), 120 (Usual care)
Heterogeneity: Tau2 = 0.08; Chi2 = 5.63, df = 3 (P = 0.13); I2 =47%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
Lifestyle intervention Usual care
(1) Requiring phototherapy
110Lifestyle interventions for the treatment of women with gestational diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Analysis 1.37. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 37 Hypocalcaemia.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 37 Hypocalcaemia
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elnour 2008 3/99 1/66 2.6 % 2.00 [ 0.21, 18.82 ]
Garner 1997 61/149 45/150 97.4 % 1.36 [ 1.00, 1.86 ]
Total (95% CI) 248 216 100.0 % 1.38 [ 1.01, 1.88 ]
Total events: 64 (Lifestyle intervention), 46 (Usual care)
Heterogeneity: Chi2 = 0.11, df = 1 (P = 0.74); I2 =0.0%
Test for overall effect: Z = 2.05 (P = 0.041)
Test for subgroup differences: Not applicable
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Analysis 1.38. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 38 Polycythemia.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 38 Polycythemia
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Elnour 2008 0/99 1/66 100.0 % 0.22 [ 0.01, 5.40 ]
Total (95% CI) 99 66 100.0 % 0.22 [ 0.01, 5.40 ]
Total events: 0 (Lifestyle intervention), 1 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 0.92 (P = 0.36)
Test for subgroup differences: Not applicable
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Analysis 1.39. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 39 Childhood
weight (kg).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 39 Childhood weight (kg)
Study or subgroup Lifestyle intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Crowther 2005 94 19.1 (2.9) 105 19.4 (4.2) 100.0 % -0.30 [ -1.29, 0.69 ]
Total (95% CI) 94 105 100.0 % -0.30 [ -1.29, 0.69 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.59 (P = 0.55)
Test for subgroup differences: Not applicable
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Analysis 1.40. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 40 Childhood height
(cm).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 40 Childhood height (cm)
Study or subgroup Lifestyle intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Crowther 2005 94 107.9 (4.6) 105 108.5 (5.8) 100.0 % -0.60 [ -2.05, 0.85 ]
Total (95% CI) 94 105 100.0 % -0.60 [ -2.05, 0.85 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 1.41. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 41 Adiposity
(Childhood BMI > 85th percentile).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 41 Adiposity (Childhood BMI > 85th percentile)
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Crowther 2005 31/94 29/105 20.5 % 1.19 [ 0.78, 1.82 ]
Garner 1997 11/43 8/25 7.6 % 0.80 [ 0.37, 1.72 ]
Landon 2009 86/264 91/236 71.9 % 0.84 [ 0.67, 1.07 ]
Total (95% CI) 401 366 100.0 % 0.91 [ 0.75, 1.11 ]
Total events: 128 (Lifestyle intervention), 128 (Usual care)
Heterogeneity: Chi2 = 2.07, df = 2 (P = 0.35); I2 =4%
Test for overall effect: Z = 0.90 (P = 0.37)
Test for subgroup differences: Not applicable
0.2 0.5 1 2 5
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Analysis 1.42. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 42 Adiposity (BMI Z
score childhood).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 42 Adiposity (BMI Z score childhood)
Study or subgroup Lifestyle intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Crowther 2005 (1) 94 0.49 (1.2) 105 0.41 (1.4) 100.0 % 0.08 [ -0.28, 0.44 ]
Total (95% CI) 94 105 100.0 % 0.08 [ -0.28, 0.44 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.43 (P = 0.66)
Test for subgroup differences: Not applicable
-0.2 -0.1 0 0.1 0.2
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(1) Age 4 to 5 years
Analysis 1.43. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 43 Childhood
glycaemic control (mmol/L).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 43 Childhood glycaemic control (mmol/L)
Study or subgroup Lifestyle intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Fasting blood glucose
Garner 1997 43 5 (0.4) 25 4.9 (0.4) 100.0 % 0.10 [ -0.10, 0.30 ]
Subtotal (95% CI) 43 25 100.0 % 0.10 [ -0.10, 0.30 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.99 (P = 0.32)
2 Two-hour postprandial blood glucose
Garner 1997 43 5.9 (1.2) 25 5.9 (0.83) 100.0 % 0.0 [ -0.48, 0.48 ]
Subtotal (95% CI) 43 25 100.0 % 0.0 [ -0.48, 0.48 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.0 (P = 1.0)
Test for subgroup differences: Chi2 = 0.14, df = 1 (P = 0.71), I2 =0.0%
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Analysis 1.44. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 44 Dyslipidaemia or
metabolic syndrome (Childhood cholesterol (mg/dL)).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 44 Dyslipidaemia or metabolic syndrome (Childhood cholesterol (mg/dL))
Study or subgroup Lifestyle intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Total cholesterol
Garner 1997 43 4.2 (0.5) 25 4.4 (0.8) 100.0 % -0.20 [ -0.55, 0.15 ]
Subtotal (95% CI) 43 25 100.0 % -0.20 [ -0.55, 0.15 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.13 (P = 0.26)
2 LDL cholesterol
Garner 1997 43 2.4 (0.5) 25 2.52 (0.9) 100.0 % -0.12 [ -0.50, 0.26 ]
Subtotal (95% CI) 43 25 100.0 % -0.12 [ -0.50, 0.26 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.61 (P = 0.54)
3 HDL cholesterol
Garner 1997 43 1.4 (0.3) 25 1.3 (0.3) 100.0 % 0.10 [ -0.05, 0.25 ]
Subtotal (95% CI) 43 25 100.0 % 0.10 [ -0.05, 0.25 ]
Heterogeneity: not applicable
Test for overall effect: Z = 1.33 (P = 0.19)
Test for subgroup differences: Chi2 = 3.13, df = 2 (P = 0.21), I2 =36%
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Analysis 1.45. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 45 Number of
antenatal visits or admissions.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 45 Number of antenatal visits or admissions
Study or subgroup Specific treatment Routine ANC Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Crowther 2005 141/490 139/510 100.0 % 1.06 [ 0.87, 1.29 ]
Total (95% CI) 490 510 100.0 % 1.06 [ 0.87, 1.29 ]
Total events: 141 (Specific treatment), 139 (Routine ANC)
Heterogeneity: not applicable
Test for overall effect: Z = 0.54 (P = 0.59)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
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Analysis 1.46. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 46 Number of
hospital or health professional visits (including midwife, obstetrician, physician, dietician, diabetic nurse).
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 46 Number of hospital or health professional visits (including midwife, obstetrician, physician, dietician, diabetic nurse)
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
1 Dietitian
Crowther 2005 453/490 51/510 100.0 % 9.24 [ 7.12, 12.01 ]
Subtotal (95% CI) 490 510 100.0 % 9.24 [ 7.12, 12.01 ]
Total events: 453 (Lifestyle intervention), 51 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 16.66 (P < 0.00001)
2 Diabetes educator
Crowther 2005 460/490 56/510 100.0 % 8.55 [ 6.67, 10.96 ]
Subtotal (95% CI) 490 510 100.0 % 8.55 [ 6.67, 10.96 ]
Total events: 460 (Lifestyle intervention), 56 (Usual care)
Heterogeneity: not applicable
Test for overall effect: Z = 16.95 (P < 0.00001)
Test for subgroup differences: Chi2 = 0.18, df = 1 (P = 0.67), I2 =0.0%
0.01 0.1 1 10 100
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Analysis 1.47. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 47 Number of
hospital or health professional visits (including midwife, obstetrician, physician, dietician, diabetic nurse)l.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 47 Number of hospital or health professional visits (including midwife, obstetrician, physician, dietician, diabetic nurse)l
Study or subgroup Lifestyle intervention Usual care
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
1 Obstetrician
Yang 2014 339 7.8 (3) 361 7.6 (2.5) 100.0 % 0.20 [ -0.21, 0.61 ]
Subtotal (95% CI) 339 361 100.0 % 0.20 [ -0.21, 0.61 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
2 Healthcare provider (not specified)
Ferrara 2011 96 11.1 (5.9) 101 11 (6.1) 100.0 % 0.10 [ -1.58, 1.78 ]
Subtotal (95% CI) 96 101 100.0 % 0.10 [ -1.58, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.12 (P = 0.91)
Test for subgroup differences: Chi2 = 0.01, df = 1 (P = 0.91), I2 =0.0%
-1 -0.5 0 0.5 1
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Analysis 1.48. Comparison 1 Lifestyle intervention versus usual care/control, Outcome 48 Admission to
neonatal intensive care unit/nursery.
Review: Lifestyle interventions for the treatment of women with gestational diabetes
Comparison: 1 Lifestyle intervention versus usual care/control
Outcome: 48 Admission to neonatal intensive care unit/nursery
Study or subgroup Lifestyle intervention Usual care Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bancroft 2000 2/32 6/36 6.9 % 0.38 [ 0.08, 1.73 ]
Crowther 2005 357/506 321/524 54.4 % 1.15 [ 1.05, 1.26 ]
Landon 2009 43/477 53/455 38.7 % 0.77 [ 0.53, 1.13 ]
Total (95% CI) 1015 1015 100.0 % 0.91 [ 0.59, 1.40 ]
Total events: 402 (Lifestyle intervention), 380 (Usual care)
Heterogeneity: Tau2 = 0.09; Chi2 = 6.61, df = 2 (P = 0.04); I2 =70%
Test for overall effect: Z = 0.41 (P = 0.68)
Test for subgroup differences: Not applicable
0.5 0.7 1 1.5 2
Lifestyle intervention Usual care
A D D I T I O N A L T A B L E S
Table 1. Examples of diagnostic criteria for gestational diabetes mellitus
Organisation/
professional
body
Screening crite-
ria
Diagnostic criteria
1-
hour oral glucose
challenge test
Oral glucose tol-
erance test
Fasting One hour Two hour Three hour
ADA 2015b*,
IADPSG 2010*,
ADIPS 2014* (
Nankervis 2014)
;
- 75 g ≥ 5.1 mmol/L
(≥ 92 mg/dL)
≥ 10mmol/L (≥
180 mg/dL)
≥ 8.5 mmol/L
(≥ 153 mg/dL)
-
WHO 2013* 75 g 5.1-6.9 mmol/L
(92 -125 mg/dl)
≥ 10mmol/L (≥
180 mg/dL)
8.5-11.0 mmol/
L (153 -199 mg/
dl)
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Table 1. Examples of diagnostic criteria for gestational diabetes mellitus (Continued)
ADA 2015b 50 g
(≥ 7.8 mmol/L;
≥ 140 mg/dL)
75 g ≥ 5.1 mmol/L
(≥ 92 mg/dL)
≥ 10mmol/L (≥
180 mg/dL)
≥ 8.5 mmol/L
(≥ 153 mg/dL)
-
ACOG 2013
Carpenter and
Coustanˆ
Na-
tional Diabetes
Data Groupˆ
50 g
(> 7.2 mmol/L;
> 130 mg/dL)
100 g ≥ 5.3 mmol/L
(95 mg/dL)
≥ 10 mmol/L
(180 mg/dL)
≥ 8.6 mmol/L
(155 mg/dL)
≥ 7.8 mmol/L
(140 mg/dL)
50 g
(> 7.8mmol/L; >
140 mg/dL)
100 g ≥ 5.8 mmol/L
(105 mg/dL)
≥ 10.6 mmol/L
(190 mg/dL)
≥ 9.2 mmol/L
(165 mg/dL)
≥ 8.0 mmol/L
(145 mg/dL)
ADIPS 1998 (
Hoffman 1998)
75 g ≥ 5.5 mmol/L
(≥ 99 mg/dL)
≥ 8.0 mmol/L
(≥ 144 mg/dL)
WHO 1999* 75 g ≥ 7.0 mmol/L
(≥ 126 mg/dL)
- ≥ 7.8 mmol/L
(140 mg/dL)
NICE 2015 - 75 g ≥ 5.6 mmol/L
(≥ 101 mg/dL)
- ≥ 7.8 mmol/L
(140 mg/dL)
-
New Zealand
Ministry of
Health 2014*
50 g if HbA1c <
41 mmol/mol
(≥ 7.8 mmol/L;
≥ 140 mg/dL)
75 g ≥ 5.5 mmol/L
(≥ 99 mg/dL)
- ≥ 9.0 mmol/L
(≥ 162 mg/dL)
-
ADA American Diabetes Association (recommends either the one step or two step strategy)
IADPSG International Association of the Diabetes and Pregnancy Study Groups
ADIPS Australasian Diabetes in Pregnancy Society
ACOG American College of Obstetrics and Gynecology
NICE National Institute for Health and Care Excellence
*1 abnormal result required for diagnosis
ˆ2 or more abnormal results required for diagnosis
Table 2. Maternal age (years)
Study ID Lifestyle intervention Usual care or diet alone
Bancroft 2000 Not stated Not stated
Bo 2014 Exercise 35.9 ± 4.8 (n = 51)
Behaviour 35.1 ± 4.4 (n = 49)
Behaviour/exercise/diet 35.5 ± 4.4 (n = 50)
Diet 33.9 ± 5.3 (n = 50)
Crowther 2005 30.9 ± 5.4 (n = 490) 30.1 ± 5.5 (n = 510)
Elnour 2008 31.1 (95% CI 30.2 to 32.1) 30.7 (95% CI 29.4 to 32)
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Table 2. Maternal age (years) (Continued)
Ferrara 2011 Not stated Not stated
Garner 1997 30.7 ± 4.8 (n = 149) 30.7 ± 4.6 (n = 150)
Gillen 2004 Not stated Not stated
Jovanovic-Peterson 1989 31.1 ± 2.8 (n = 9) 29.5 ± 2.5 (n = 10)
Kaviani 2014 Not stated Not stated
Landon 2009 29.2 ± 5.7 (n = 485) 28.9 ± 5.6 (n = 473)
Mendelson 2008 30.6 ± 5.6 (n = 49) 31.5 ± 5.2 (n = 51)
Rahimikian 2014 30.9 ± 5.7 (n = 42) face to face
30.4 ± 5.5 (n = 42) booklet
30.1 ± 5.8 (n = 42)
Yang 2003 Not stated Not stated
Yang 2014 29.9 ± 3.5 (n = 339) 29.73 ± 3.2 (n = 361)
Youngwanichsetha 2014 32.58 ± 5.01 (n = 85) 31.24 ± 4.54 (n = 85)
Bo 2014; Jovanovic-Peterson 1989 compared a lifestyle intervention with diet alone
Table 3. Maternal BMI at trial entry (kg/m2)
Study ID Lifestyle intervention Usual care or diet alone
Bancroft 2000 31.2 ± 6.7 (n = 32) 27.5 ± 6.1 (n = 36)
Bo 2014 Exercise 27.7 ± 4.3 (n = 49)
Behaviour 27.5 ± 4.4 (n = 49)
Behaviour/exercise/diet 27.5 ± 3.9 (n = 50)
Diet 27.5 ± 4.5 (n = 50)
Crowther 2005 Median 26 (IQR 23.3 to 31.2) (n = 490) Median 26 (IQR 22.9 to 30.9) (n = 510)
Elnour 2008 Not stated Not stated
Ferrara 2011 Not stated but 57% had BMI > 30 Not stated but 53% had BMI > 30
Garner 1997 Not stated Not stated
Gillen 2004 Not stated Not stated
Jovanovic-Peterson 1989 Not stated Not stated
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Table 3. Maternal BMI at trial entry (kg/m2) (Continued)
Kaviani 2014 Not stated Not stated
Landon 2009 30.1 ± 5.0 (n = 485) 30.2 ± 5.1 (n = 473)
Mendelson 2008 Not stated Not stated
Rahimikian 2014 Not stated Not stated
Yang 2003 Not stated Not stated
Yang 2014 22.9 ± 3.6 (n = 339) 23.4 ± 3.9 (n = 361)
Youngwanichsetha 2014 27.09 ± 3.56 (n = 85) 27.05 ± 4.06 (n = 85)
Bo 2014; Jovanovic-Peterson 1989 compared a lifestyle intervention with diet alone
Table 4. Ethnicity/Race
Study ID Ethnicity/Race
Bancroft 2000 31% of women were Asian and 69% were Caucasian
Bo 2014 Not stated
Crowther 2005 76% were Caucasian and 17% were Asian
Elnour 2008 UAE national
Ferrara 2011 52% were Asian or Pacific Islander; 19% were non-Hispanic Caucasian and 19% were Hispanic
Garner 1997 Not stated
Gillen 2004 Not stated
Jovanovic-Peterson 1989 Not stated
Kaviani 2014 Persian
Landon 2009 11.5% Black, 25% Caucasian, 5% Asian, 56.5% Hispanic
Mendelson 2008 Mexican
Rahimikian 2014 Not stated
Yang 2003 Not stated - probably Chinese
Yang 2014 97% Chinese Han
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Table 4. Ethnicity/Race (Continued)
Youngwanichsetha 2014 Thai
Bo 2014; Jovanovic-Peterson 1989 compared a lifestyle intervention with diet alone
Table 5. Gestation at trial entry (weeks)
Study ID Lifestyle intervention Usual care or diet alone
Bancroft 2000 31 (range 24 to 38) (n = 32) 32 (range 15 to 37) (n = 36)
Bo 2014 Not stated Not stated
Crowther 2005 Median 29.1 (IQR 28.2 to 30.0) (n = 490) Median 29.2 (IQR 28.2 to 30.0) (n = 510)
Elnour 2008 < 20 weeks’ < 20 weeks’
Ferrara 2011 31 ± 5.6 (n = 96) 31.0 ± (n = 6.1)
Garner 1997 Not stated Not stated
Gillen 2004 Not stated Not stated
Jovanovic-Peterson 1989 Not stated Not stated
Kaviani 2014 Not stated Not stated
Landon 2009 28.8 ± 1.6 (n = 485) 28.9 ± 1.5 (n = 473)
Mendelson 2008 Not stated Not stated
Rahimikian 2014 Not stated Not stated
Yang 2003 Not stated Not stated
Yang 2014 Not stated Not stated
Youngwanichsetha 2014 Not stated Not stated
Bo 2014; Jovanovic-Peterson 1989 compared a lifestyle intervention with diet alone
123Lifestyle interventions for the treatment of women with gestational diabetes (Review)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 6. Treatment target
Study ID Treatment target
Bancroft 2000 Insulin was introduced if 5 or more capillary measurements > 7.0 mmol/L (126 mg/dL) in 1 week
Bo 2014 Treatment glycaemic targets were not detailed but insulin was started in the presence of fetal abdominal
ultrasound > 70th percentile and or maternal hyperglycaemia (no details)
Crowther 2005 Fasting glucose levels 3.5 mmol/L (63 mg/dL) to 5.5 mmol/L (99 mg/dL), pre-prandial levels of no more
than 5.5 mmol/L (99 mg/dL), and levels 2 hours post-prandially that were no more than 7.0 mmol/L
(126 mg/dL)
Elnour 2008 Not stated
Ferrara 2011 Not stated
Garner 1997 Fasting glucose levels < 4.4 mmol/L (80 mg/dL); 1-hour post-prandial < 7.8 mmol/L (140 mg/dL)
Gillen 2004 Not stated
Jovanovic-Peterson 1989 Fasting plasma glucose ≤ 5.8 mmol/L or 105 mg/dL and/or 1-hour post-prandial plasma glucose was ≤
7.8 mmol/L (140 mg/dL)
Kaviani 2014 Not stated
Landon 2009 Fasting glucose levels < 5.3 mmol/L, 2-hour post-prandial glucose < 6.7 mmol/L
Mendelson 2008 Not stated
Rahimikian 2014 Not stated
Yang 2003 < 5.5 mmol/L (99 mg/dL) fasting; < 7.0 mmol/L (126 mg/dL) 1.5 hours postprandial
Yang 2014 ≥ 3.5 to ≤ 5.1 mmol/L for fasting capillary glucose and ≤ 7.0 mmol/L (126 mg/dL) for 2-hour post-
prandial capillary glucose up to 36 weeks’ gestation and ≤ 8.0 mmol/L from 36 weeks’ onwards
Youngwanichsetha 2014 Not stated
Bo 2014; Jovanovic-Peterson 1989 compared a lifestyle intervention with diet alone
Table 7. Details of diagnosis
Study ID Timing Screening Diagnosis
Bancroft 2000 Not stated Not stated 75 g OGTT: fasting ≥ 7.0
mmol/L; 2 hour 7.8 to 11.
0 mmol/L
WHO 1999
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Table 7. Details of diagnosis (Continued)
Bo 2014 24 to 26 weeks’ Not stated 75 g OGTT no further de-
tails
No details
Crowther 2005 24 to 34 weeks’ 50 g 1-hour glucose chal-
lenge at least 7.8 mmol/L
(140 mg/dL)
75 g OGTT plasma glu-
cose level was less than 7.8
mmol/L and 2-hour value
was 7.8 to 11.0 mmol/L
(198 mg/dL)
WHO 1999
Elnour 2008 24 and 28 weeks’ 50 g 1-hour glucose chal-
lenge, serum value > 7.2
mmol/L or plasma value >
7.8 mmol/L or risk factors
present
100 g OGTT diagnosis if
2 or more values are ab-
normal from fasting ≥ 5.
3 mmol/L, 1-hour value
≥ 10.0 mmol/L, 2-hour
value ≥ 8.7 mmol/L, 3-
hour value ≥ 7.8 mmol/L
Carpenter and Coustan
criteria
Ferrara 2011 Not stated 50 g 1-hour glucose chal-
lenge
100 g OGTT; 3-hour ADA (2000) criteria
Garner 1997 24 to 32 weeks’ 75 g 1-hour > 8 mmol/L 75 g OGTT > 7.5 mmol/
L (2nd trimester) and > 9.
6 mmol/L (3rd trimester)
Hatem 1988
Gillen 2004 28 weeks’ 50 g 1-hour venous plasma
glucose level ≥ 7.8 mmol/
L or
75 g hour venous plasma
glucose level ≥ 8.0 mmol/
L
75 g OGTT plasma glu-
cose level at fasting of≥ 5.5
mmol/L and/or at 2 hours
of ≥ 8.0 mmol/L
ADIPS 1998
Jovanovic-Peterson 1989 Not stated 50 g 1-hour glucose chal-
lenge
Fasting and 1-hour toler-
ance test but no other de-
tails provided
No details
Kaviani 2014 Not stated Not stated Not stated Not stated
Landon 2009 24 to 30 weeks’ 50 g 1-hour glucose chal-
lenge 5.3 to 11 mmol/L
100 g OGTT; 2 or more
of results was abnormal in
addition to the abnormal
challenge test (fasting < 5.
3 mmol/L, 1-hour > 10.
0 mmol/L, 2-hours > 8.
6 mmol/L, 3-hours > 7.8
mmol/L
Carpenter and Coustan
criteria
Mendelson 2008 Not stated Not stated Not stated Not stated
Rahimikian 2014 Not stated Not stated Not stated Not stated
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Table 7. Details of diagnosis (Continued)
Yang 2003 26 to 30 weeks’ 50 g, 1-hour glucose chal-
lenge, ≥ 7.8 mmol/L
75 g, 2-hour OGTT; fast-
ing ≥ 7.0 mmol/L, or 2-
hour glucose ≥ 7.8 and ≤
11.1 mmol/L
WHO criteria
Yang 2014 24 to 28 weeks’ 50 g, 1-hour glucose chal-
lenge, ≥ 7.8 mmol/L
75 g, 2-hour OGTT; fast-
ing ≥ 5.1 mmol/L, or
1-hour glucose ≥ 10.0
mmol/L or 2-hour glucose
≥ 8.5 mmol/L
IADPSG criteria
Youngwanichsetha 2014 24 to 30 weeks’ Not stated Not stated Not stated
OGTT: oral glucose tolerance test
Table 8. Other maternal outcomes
Study ID Outcome Lifestyle Usual care
Bancroft 2000 Postnatal fasting glucose (mmol/L) Median 4.5 (range 2.7 - 5.9) n = 28 Median 4.4 (range 2.4 -8.8) n = 28
Postnatal post prandial 2-hour
(mmol/L)
Median 5.1 (range 2.1-8.5) n = 28 Median 5.5 (range 3.0-13.7) n = 28
Landon 2009 Maternal BMI (kg/m2) at follow-up Mean 29.4 (95% CI 28.6 to 30.3) n
= 243
Mean 29.1 (95% CI 28.2 to 30.0) n
= 214
Garner 1997 Maternal BMI (kg/m2) at follow-up BMI median 27.3 (range 19.4 to 50.
5)
BMI median 29.6 (21.3 to 49.1)
Garner 1997 Maternal fasting glucose at follow-up Fasting glucose median 5.4 (range 4.
4 to 7.8) mmol/L
Fasting glucose median 5.5 (range 4.
8 to 17.6) mmol/L
Table 9. Neonatal outcomes
Study ID Outcome Lifestyle intervention Ususal care or diet alone
Crowther 2005 Gestational age at birth Median 39 weeks (IQR 38.1 -40.0) (n
= 490)
Median 39.3 (IQR 38.3 -40.4) (n =
510)
Jovanovic-Peterson 1989 Gestational age at birth Range 39.5 to 40.5 weeks Range 39.4 to 40.0 weeks
Jovanovic-Peterson 1989 compared a lifestyle intervention with diet alone
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Table 10. Health service use
Study ID Type of health service use Lifestyle intervention Usual care
Bancroft 2000 Number of capillary blood tests Median 118 (range 0-520); n = 32 Median 0 (range 0); n = 36
Bancroft 2000 Number of antenatal visits Median 17 (range 2-28); n = 32 Median 14 (range 6-33); n = 36
Crowther 2005 Number of antenatal clinic visits af-
ter enrolment
Median 5.0 (IQR 1-7) n = 490 Median 5.2 (IQR 3-7) n = 510
Crowther 2005 Number of physician clinic visits af-
ter enrolment
Median 3 (IQR 1-7) n = 490 Median 0 (IQR 0-2) n = 510
Bancroft 2000 Number of hospital admissions Median 1 (range 0-6); n = 32 Median 0 (range 0-8); n = 36
Crowther 2005 Duration of stay in neonatal nursery Median 1 day (IQR 1-2) n = 506 Median 1 day (IQR 1-3) n = 524
Crowther 2005 Length of postnatal stay (mother) Median 4 days (IQR 3-5) n = 490 Median 4 days (IQR 3-5) n = 510
Mendelson 2008 Hospitalisation (days) (mother) Mean 3.3, no SD provided 3.3, no SD provided
Mendelson 2008 Hospitalisation (days) (infant) Mean 3.4, no SD provided 3.3, no SD provided
IQR: interquartile range
Table 11. Cost
Crowther 2005 Lifestyle intervention Usual care
Package of treatment for mild GDM versus usual care Package of treatment
Direct costs per 100 women with a single-
ton pregnancy - including antenatal clinic
visits, specialist clinics, dietician, diabetes
educator, insulin therapy
AUD67,432 AUD33,681
In-patient costs - hospital costs AUD545,125 AUD524,891
Total direct health service costs AUD612,557 AUD558,572
Patient/family costs AUD36,749 AUD30,229
These data are in the publication by Moss (2007)
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A P P E N D I C E S
Appendix 1. Clinical trial registry search strategy
gestational diabetes OR GDM
diabetes AND pregnancy
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• Liggins Institute, New Zealand.
Support for infrastructure to support the preparation of this protocol is from the Liggins Institute, University of Auckland, New
Zealand.
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External sources
• Australian Satellite of the Cochrane Pregnancy and Childbirth Review Group, Australia.
Support for infrastructure from the Australian Satellite of the Cochrane Pregnancy and Childbirth
• National Institute for Health Research (NIHR), UKNIHR Cochrane Programme Grant Project: 13/89/05 - Pregnancy and
childbirth systematic reviews to support clinical guidelines, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
There are some differences between our published protocol (Brown 2015) and the full review, these are listed below.
Background - portions of the background have been amended for clarity following feedback from the authors of this review.
Objectives - this section has been edited to reflect that the intervention is about ’combined’ lifestyle interventions which could be with
or without pharmacotherapy.
N O T E S
The original review (Alwan 2009) has been split into three new reviews due to the complexity of the included interventions. The
following new review protocols have been published.
Lifestyle interventions for the treatment of women with gestational diabetes (this review)
Oral anti-diabetic pharmacological therapies for the treatment of women with gestational diabetes
Insulin for the treatment of women with gestational diabetes
There will be similarities in the background, methods and outcomes between these three systematic reviews.
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